Nothing Special   »   [go: up one dir, main page]

CA2559021A1 - Novel alkyne compounds with an mch-antagonistic action and medicaments containing said compounds - Google Patents

Novel alkyne compounds with an mch-antagonistic action and medicaments containing said compounds Download PDF

Info

Publication number
CA2559021A1
CA2559021A1 CA002559021A CA2559021A CA2559021A1 CA 2559021 A1 CA2559021 A1 CA 2559021A1 CA 002559021 A CA002559021 A CA 002559021A CA 2559021 A CA2559021 A CA 2559021A CA 2559021 A1 CA2559021 A1 CA 2559021A1
Authority
CA
Canada
Prior art keywords
alkyl
group
phenyl
hydroxy
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002559021A
Other languages
French (fr)
Inventor
Dirk Stenkamp
Stephan Georg Mueller
Philipp Lustenberger
Thorsten Lehmann-Lintz
Leo Thomas
Marcus Schindler
Gerald Juergen Roth
Klaus Rudolf
Ralf R. H. Lotz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34982358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2559021(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2559021A1 publication Critical patent/CA2559021A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

The invention relates to alkyne compounds of general formula (I), in which the groups and radicals A, B, W, X, Y, Z, R1 and R2 are defined as cited in claim 1. The invention also relates to medicaments containing at least one inventive alkyne. As a result of the antagonistic action against the MCH-receptor, the inventive medicaments are suitable for treating metabolic disorders and/or eating disorders, in particular adiposity and diabetes.

Description

WO 2005/10301 ' 1 PCT/EP2005/003683 86981 pct Novel alkyne compounds with an MCH-antagonistic action and medicaments containing said compounds The present invention relates to new alkyne compounds, the physiologically acceptable salts thereof as well as their use as MCH antagonists and their use in preparing a pharmaceutical preparation which is suitable for the prevention and/or treatment of symptoms and/or diseases caused by MCH or causally connected with MCH in some other way. The invention also relates to the use of a compound according to the invention for influencing eating behaviour and for reducing body weight and/or for preventing any increase in body weight in a mammal. It further relates to compositions and medicaments containing a compound according to the invention and processes for preparing them. Other aspects of this invention relate to processes for preparing the compounds according to the invention.
Background to the Invention The intake of food and its conversion in the body is an essential part of life for all living creatures. Therefore, deviations in the intake and conversion of food generally lead to problems and also illness. The changes in the lifestyle and nutrition of humans, particularly in 2o industrialised countries, have promoted morbid overweight (also known as corpulence or obesity) in recent decades. In affected people, obesity leads directly to restricted mobility and a reduction in the quality of life. There is the additional factor that obesity often leads to other diseases such as, for example, diabetes, dyslipidaemia, high blood pressure, arteriosclerosis and coronary heart disease. Moreover, high body weight alone puts an increased strain on the support and mobility apparatus, which can lead to chronic pain and diseases such as arthritis or osteoarthritis. Thus, obesity is a serious health problem for society.
The term obesity means an excess of adipose tissue in the body. In this connection, obesity is fundamentally to be seen as the increased level of fatness which leads to a health risk.
There is no sharp distinction between normal individuals and those suffering from obesity, but the health risk accompanying obesity is presumed to rise continuously as the level of fatness increases. For simplicity's sake, in the present invention, individuals with a Body Mass Index (BMI), which is defined as the body weight measured in kilograms divided by the height (in metres) squared, above a value of 25 and more particularly above 30, are preferably regarded as suffering from obesity.
Apart from physical activity and a change in nutrition, there is currently no convincing treatment option for effectively reducing body weight. However, as obesity is a major risk factor in the development of serious and even life-threatening diseases, it is all the more important to have access to pharmaceutical active substances for the prevention and/or treatment of obesity. One approach which has been proposed very recently is the therapeutic use of MCH antagonists (cf. inter alia WO 01/21577, WO 01/82925).
Melanin-concentrating hormone (MCH) is a cyclic neuropeptide consisting of 19 amino acids.
It is synthesised predominantly in the hypothalamus in mammals and from there travels to other parts of the brain by the projections of hypothalamic neurones. Its biological activity is mediated in humans through two different G-protein-coupled receptors (GPCRs) from the family of rhodopsin-related GPCRs, namely the MCH receptors 1 and 2 (MCH-1 R, MCH-ZR).
Investigations into the function of MCH in animal models have provided good indications for a role of the peptide in regulating the energy balance, i.e. changing metabolic activity and food intake [1,2]. For example, after intraventricular administration of MCH in rats, food intake was increased compared with control animals. Additionally, transgenic rats which produce more MCH than control animals, when given a high-fat diet, responded by gaining significantly more weight than animals without an experimentally altered MCH level. It was also found that there is a positive correlation between phases of increased desire for food and the quantity of MCH mRNA in the hypothalamus of rats. However, experiments with MCH knock-out mice are particularly important in showing the function of MCH. Loss of the neuropeptide results in lean animals with a reduced fat mass, which take in significantly less food than control animals.
The anorectic effects of MCH are presumably mediated in rodents through the Gds-coupled MCH-1 R [3-6], as, unlike primates, ferrets and dogs, no second MCH receptor subtype has hitherto been found in rodents. After losing the MCH-1 R, knock-out mice have a lower tat mass, an increased energy conversion and, when fed on a high fat diet, do not put on weight, compared with control animals. Another indication of the importance of the MCH
system in regulating the energy balance results from experiments with a receptor antagonist (SNAP-7941 ) [3]. In long term trials the animals treated with the antagonist lose significant amounts of weight.
In addition to its anorectic effect, the MCH-1 R antagonist SNAP-7941 also achieves additional anxiolytic and antidepressant effects in behavioural experiments on rats [3]. Thus, there are clear indications that the MCH-MCH-1 R system is involved not only in regulating the energy balance but also in affectivity.
Literature:
s 1. Qu, D., et ai., A role for melanin-concentrating hormone in the central regulation of feeding behaviour. Nature, 1996. 380(6571 ): p. 243-7.
2. Shimada, M., et al., Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature, 1998. 396(6712): p. 670-4.
3. Borowsky, B., et al., Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nat Med, 2002. 8(8): p.
825-30.
4. Chen, Y., et al., Targeted disruption of the melanin-concentrating hormone receptor-1 results in hyperphagia and resistance to diet-induced obesity.
Endocrinology, 2002. 143(7): p. 2469-77.
15 5. Marsh, D.J., et al., Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism. Proc Natl Acad Sci U S A, 2002. 99(5): p. 3240-5.
6. Takekawa, S., et al., T-226296: A novel, orally active and selective melanin-concentrating hormone receptor antagonist. Eur J Pharmacol, 2002. 438(3): p.
129-35.
In the patent literature certain amine compounds are proposed as MCH
antagonists. Thus, WO 01/21577 (Takeda) describes compounds of formula Ar'-X-Ar-Y-N'R
. z R
wherein Ar' denotes a cyclic group, X denotes a spacer, Y denotes a bond or a spacer, Ar denotes an aromatic ring which may be fused with a non-aromatic ring, R' and independently of one another denote H or a hydrocarbon group, while R' and RZ
together with the adjacent N atom may form an N-containing hetero ring and R2 with Ar may also form a spirocyclic ring, R together with the adjacent N atom and Y may form an N-containing hetero ring, as MCH antagonists for the treatment of obesity.
Moreover WO 01/82925 (Takeda) also describes compounds of formula Ar1 X-Ar-Y-N'R
. 2 R

wherein Ar' denotes a cyclic group, X and Y represent spacer groups, Ar denotes an optionally substituted fused polycyclic aromatic ring, R' and R2 independently of one another represent H or a hydrocarbon group, while R' and R2 together with the adjacent N atom may form an N-containing heterocyclic ring and R2 together with the adjacent N
atom and Y may form an N-containing hetero ring, as MCH antagonists for the treatment of obesity, inter alia.
WO 2004/024702 proposes carboxylic acid amide compounds of formula I
O
i iX~ /Z\
R-N Y N A--~W-~B
R2 Rs wherein Y, A and B may represent cyclic groups and X, Z and W may denote bridges or bonds, as MCH-antagonists.
WO 04/039780 A1 describes alkyne compounds of formula I

R2~N-X-Y- Z W-A-B
wherein Y, A and B may denote cyclic groups and X, Z and W may denote bridges or bonds, as MCH-antagonists. The following substances are mentioned, inter alias (2-{4-(5-(4-chloro-phenyl)-pyridin-2-ylethynylJ-2-methyl-phenoxy}-ethyl)-methyl-prop-2-ynyl-amine, (2-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-indol-1-yl}-ethyl)-cyclopropylmethyl-prop-2-ynyl-amine, {4-[6-(4-chloro-phenyl)-quinolin-2-ylethynyl]-benzyl}-methyl-(tetrahydro-pyran-4-yl)-amine, allyl-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-cyclopropylmethyl-amine, allyl-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-cyclopropylmethyl-amine, allyl-(2-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-indol-1-yl}-ethyl)-cyclopropylmethyl-amine.
WO 04/039764 A1 describes amide compounds of formula I
R'\ a R2~N X Y Z N3 C W A--~B,b R
wherein Y, A and B may denote cyclic groups and X denotes an alkylene bridge, Z denotes a bridge or bond and W is selected from the group comprising -CR6aRsb-O-, _CR'a=CR'°-, -CR6aRsb-NR8-, -CR'aR'b-CR'°R'd- and -NR8-CR6aRsb-, as MCH-antagonists.
Aim of the invention The aim of the present invention is to identify new alkyne compounds, particularly those which are especially effective as MCH antagonists. The invention also sets out to provide new alkyne compounds which can be used to influence the eating habits of mammals and achieve a reduction in body weight, particularly in mammals, and/or prevent an increase in body weight.
The present invention further sets out to provide new pharmaceutical compositions which are suitable for the prevention and/or treatment of symptoms and/or diseases caused by MCH or otherwise causally connected to MCH. In particular, the aim of this invention is to provide pharmaceutical compositions for the treatment of metabolic disorders such as obesity and/or diabetes as well as diseases and/or disorders which are associated with obesity and diabetes. Other objectives of the present invention are concerned with demonstrating advantageous uses of the compounds according to the invention. The invention also sets out to provide a process for preparing the amide compounds according to the invention. Other aims of the present invention will be immediately apparent to the skilled man from the foregoing remarks and those that follow.
Object of the invention In a first aspect the present invention relates to alkyne compounds of general formula I

N-X-Y- Z W-A-B
3o R
wherein R' denotes C3~-alkenyl, C3_6-alkynyl, (hydroxy-C3_~-cycloalkyl)-C,_3-alkyl, oxa-C4_~-cycloalkyl, dihydroxy-C3_,-alkyl, while the groups mentioned may be mono- or polysubstituted substituted by substituents which are selected independently of one another from the group consisting of halogen, hydroxy, cyano, C,_4-alkyl, C3_7-cycloalkyl, C3.,-cycloaikyl-C,_3-alkyl, C,_4-aikoxy-C,_4-alkyl, C,_4-alkoxy, C,_4-alkenyl, C,_4-alkynyl, amino, C,_4-alkyl-amino and di-(C,.~-alkyl)-amino, while the alkyl, aikoxy, cylcoalkyl groups may comprise one or more identical or different substituents selected from halogen and hydroxy; and Rz independently of R' has one of the meanings given hereinbefore for R' or R2 has a meaning from the group consisting of H, C,_8-alkyl, C3_,-cycloalkyl or a phenyl or pyridinyl group optionally mono- or polysubstituted by identical or different groups R2° and/or monosubstituted by nitro, while the alkyl or cycloalkyl group may be mono- or polysubstituted by identical or different groups R", and a -CH2-group in position 3 or 4 of a 5-, 6- or 7-membered cycloalkyl group may be replaced by -O-, -S- or -NR'3-, or the groups R', R2 together with the N atom to which they are bound form a heterocyclic group which selected is from the meanings - dihydroxy-cyclo-CQ_,-alkylene-imino, - (hydroxy-C~_4-alkyl)-hydroxy-cyclo-C3_~-alkylene-imino, - (hydroxy-C,_3-alkyl)-cyclo-C3_,-alkylene-imino, while in the last definition the C,_3-alkyl group is substituted by one or more identical or different C~_3-alkyl groups which may be joined together to form a C3_,-cyloalkyl group;
while the above-mentioned heterocyclic groups may be mono- or polysubstituted by substituents which are selected independently of one another from the group consisting of halogen, hydroxy, cyano, C,_4-alkyl, C3_~-cycloalkyl, C3_~-cycloalkyl-C~_3-alkyl, C~_4-alkoxy-C~_4-alkyl, C~~,-alkoxy, C,_4-alkenyl, C,_4-alkynyl, amino, C,_4-alkyl-amino and di-(C,_4-alkyl)-amino, while alkyl, alkoxy, cylcoalkyl groups may comprise one or more identical or different substituents selected from halogen and hydroxy;
X denotes a C~~,-alkylene bridge, while in the definition Cz~-alkylene one or two C atoms may be monosubstituted by R'°, or a C3_4-alkylene bridge, wherein a -CH2-CH2- group not directly adjacent to the N atom of the R' RZN- group is replaced by -CH=CH-, -C---C-, -CH2-O--CH2-S- or -CH2-NR4-, while the meanings given for X hereinbefore may comprise a substituent selected from C2_6-alkenyl, C2_6-alkynyl, C3_,-cycloalkyl and C3_~-cycloalkyl-C,_3-alkyl as well as independently one, two or three identical or different C~~-alkyl substituents, while two alkyl groups may be joined together forming a 3 to 7-membered cyclic group or an alkyl and an alkenyl group may be joined together forming a 5 to 7-membered cyclic group, and W, Z independently of one another denote a single bond or a C~_2-alkylene bridge, while two adjacent C atoms may be joined together with an additional C,_4-alkylene bridge, and one or two C atoms independently of one another may be substituted by one or two identical or different C,_3-alkyl groups, while two alkyl groups may be joined together to form a carbocyclic ring, and Y, A are selected independently of one another from the group of the bivalent cyclic groups phenyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, naphthyl, tetrahydronaphthyl, indolyl, dihydroindolyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl, tetrahydro-isoquinolinyl, benzimidazolyl, benzoxazolyl, chromanyl, chromen-4-onyl, thienyl, furanyl, benzothienyl or benzofuranyl, while the above-mentioned cyclic groups may be mono- or polysubstituted at one or more C atoms by identical or different groups RZ°, and in the case of a phenyl ring may also additionally be monosubstituted by vitro, and/or one or more NH groups may be substituted by R2', B has one of the meanings given for Y, A or denotes C»-alkyl, C,~-alkenyl, C,~-alkynyl, C3_,-cycloalkyl, C~~-cycloalkenyl, C3_~-cycloalkyl-C,_3-alkyl, C3_,-cycloalkenyl-C,_3-alkyl, C3_,-cycloalkyl-C~_3-alkenyl or C3_,-cycloalkyl-C,_3-alkynyl, wherein one or more C atoms may be mono- or polysubstituted independently of one another by halogen and/ or monosubstituted by hydroxy or cyano and/ or cyclic groups may be mono- or polysubstituted by identical or different groups R2°, Cy denotes a carbo- or heterocyclic group selected from one of the following meanings - a saturated 3- to 7-membered carbocyclic group, - an unsaturated 4- to 7-membered carbocyclic group, - a phenyl group, - a saturated 4- to 7-membered or unsaturated 5- to 7-membered heterocyclic group with an N, O or S atom as heteroatom, - a saturated or unsaturated 5- to 7-membered heterocyclic group with two or more N atoms or with one or two N atoms and an O or S atom as heteroatoms, an aromatic heterocyclic 5- or 6-membered group with one or more identical or different heteroatoms selected from N, O and/or S, while the above-mentioned saturated 6- or 7-membered groups may also be present as bridged ring systems with an imino, (C,_4-alkyl)-imino, methylene, (C~_4-alkyl)-methylene or di-(C~_4-alkyl)-methylene bridge, and the above-mentioned cyclic groups may be mono- or polysubstituted at one or more C atoms by identical or different groups R2°, in the case of a phenyl group may also additionally be monosubstituted by vitro, and/or one or more NH groups may be substituted by R2', R4 denotes H, C~.~-alkyl, C3_~-cycloalkyl or C3_~-cycloalkyl-C~_3-alkyl, R'° denotes hydroxy, w-hydroxy-C,_3-alkyl, C»-alkoxy or C,~-alkoxy-C,_3-alkyl, R" denotes halogen, C,~-alkyl, C2~-alkenyl, C2~-alkynyl, R'S-O-, R'S-O-CO-, R'S-CO-O-, cyano, R'6R"N, R'8R'9N-CO- or Cy, while in the above-mentioned groups one or more C atoms may be mono- or polysubstituted independently of one another by substituents selected from halogen, OH, CN, CF3, C,_3-alkyl, hydroxy-C~_3-alkyl;
R'3 has one of the meanings given for R", R'S denotes H, C,_4-alkyl, C3_,-cycloalkyl, C3_,-cycloalkyl-C,_3-alkyl, phenyl, phenyl-C~_3-alkyl, pyridinyl or pyridinyl-C,_3-alkyl, R's denotes H, C,.~-alkyl, C3_~-cycloalkyl, C3_~-cycloalkyl-C,_3-alkyl, C4_,-cycloalkenyl, C4_~-cycloalkenyl-C,_3-alkyl, w-hydroxy-Cz_3-alkyl, c~-(C,_ 4-alkoxy)-C2_3-alkyl, amino-C2~-alkyl, C,_4-alkyl-amino-C2~-alkyl, di-(C,~-alkyl)-amino-C2_s-alkyl or cyclo-C3_s-alkyleneimino-CZ_s-alkyl, R" has one of the meanings given for R's or denotes phenyl, phenyl-C,_3-alkyl, pyridinyl, C,~-alkylcarbonyl, hydroxycarbonyl-C~_3-alkyl, C,_4-alkoxycarbonyl, C,_4-alkoxycarbonyl-C,_3-alkyl, C,~-alkylcarbonylamino-CZ_3-alkyl, N-(C,_4-alkylcarbonyl)-N-(C,~,-alkyl)-amino-CZ_3-alkyl, Cf.~-alkylsulphonyl, C~_4-alkylsulphonylamino-C2_3-alkyl or N-(C,~-alkylsulphonyl)-N(-C~_ 4-alkyl)-amino-C2_3-alkyl;
R'$, R'9 independently of one another denote H or C~_s-alkyl, Rz° denotes halogen, hydroxy, cyano, C,~-alkyl, C2~-alkenyl, C2~-alkynyl, C3_ ~-cycloalkyl, C3_~-cycloalkyl-C~_3-alkyl, hydroxy-C,_3-alkyl, R22-C,_3-alkyl or has one of the meanings given for R2z, R2' denotes C~_4-alkyl, w-hydroxy-C2.~-alkyl, c~-C,_4-alkoxy-Cz_s-alkyl, urC,_4-alkyl-amino-Cz~-alkyl, cu-di-(C~~,-alkyl)-amino-C2_s-alkyl, c~-cyclo-C3_s-alkyleneimino-C2_s-alkyl, phenyl, phenyl-C,_3-alkyl, C~~-alkyl-carbonyl, C~_4-alkoxy-carbonyl, C,_4-alkylsulphonyl, aminosulphonyl, C~_4-alkylaminosulphonyl, di-C,_4-alkylaminosulphonyl or cyclo-C3~-alkylene-imino-sulphonyl, Rz2 denotes pyridinyl, phenyl, phenyl-C,_3-alkoxy, cyclo-C3~-alkyleneimino-CZ_4-alkoxy, OHC-, HO-N=HC-, C,~-alkoxy-N=HC-, C,_4-alkoxy, C,_4-alkylthio, carboxy, C,_4-alkylcarbonyl, C,_4-alkoxycarbonyl, aminocarbonyl, C,_4-alkylaminocarbonyl, di-(C~_4-alkyl)-aminocarbonyl, cyclo-C3~-alkyl-amino-carbonyl, cyclo-C3_s-alkyleneimino-carbonyl, phenylaminocarbonyl, cyclo-C3_6-alkyleneimino-CZ_4-alkyl-aminocarbonyl, C,_4-alkyl-sulphonyl, C,_4-alkyl-sulphinyl, C,~-alkyl-sulphonylamino, amino, C,_4-alkylamino, di-(C,~-alkyl)-amino, C,~-alkyl-carbonyl-amino, cyclo-C3~-alkyleneimino, phenyl-C,_3-alkylamino, N-(C~_4-alkyl)-phenyl-C,_3-alkylamino, acetylamino, propionylamino, phenylcarbonyl, phenylcarbonylamino, phenylcarbonylmethylamino, hydroxy-C2_3-alkylaminocarbonyl, (4-morpholinyl)carbonyl, (1-pyrrolidinyl)carbonyl, (1-piperidinyl)carbonyl, (hexahydro-1-azepinyl)carbonyl, (4-methyl-1-piperazinyl)carbonyl, methylenedioxy, aminocarbonylamino or C~~-alkylaminocarbonylamino, while in the above-mentioned groups and radicals, particularly in W, X, Z, R4, R'°, R'3 and R'S to R22, in each case one or more C atoms may additionally be mono-or polysubstituted by F and/or in each case one or two C atoms independently of one another may additionally be monosubstituted by CI or Br and/or in each case one or more phenyl rings may additionally comprise independently of one another one, two or three substituents selected from the group F, CI, Br, I, cyano, C,.~-alkyl, C,_4-alkoxy, difluoromethyl, trifluoromethyl, hydroxy, amino, C,_3-Aalkylamino, di-(C~_3-alkyl)-amino, acetylamino, aminocarbonyl, difluoromethoxy, trifluoromethoxy, amino-C~_3-alkyl, C,_3-alkylamino-C,_3-alkyl- and di-(C,_3-alkyl)-amino-C~_3-alkyl and/or may be monosubstituted by nitro, and the H atom of any carboxy group present or an H atom bound to an N atom may in each case be replaced by a group which can be cleaved in vivo, the tautomers, the diastereomers, the enantiomers, the mixtures thereof and the salts thereof, while the following compounds are not included in the invention:
(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-methyl-prop-2-ynyl-amine, (2-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-indol-1-yl}-ethyl)-cyclopropylmethyl-prop-2-ynyl-amine, {4-[6-(4-chloro-phenyl)-quinolin-2-ylethynylJ-benzyl}-methyl-(tetrahydro-pyran-4-yl)-amine, allyl-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-cyclopropylmethyl-amine, allyl-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-cyclopropylmethyl-amine, allyl-(2-{5-[5-(4-chloro-phenyl)-pyrid in-2-ylethynyl]-indol-1-yl}-ethyl)-cyclopropylmethyl-amine.
The compounds according to the present invention, including the physiologically acceptable salts, are especially effective, compared with known, structurally similar compounds, as antagonists of the MCH receptor, particularly the MCH-1 receptor, and exhibit very good affinity in MCH receptor binding studies. In addition, the compounds according to the invention have a high to very high selectivity with regard to the MCH
receptor. Generally the compounds according to the invention have low toxicity, they are well absorbed by oral route and have good intracerebral transitivity, particularly brain accessibility.
The invention also relates to the compounds in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates, in the form of the tautomers and in the form of the free bases or corresponding acid addition salts with pharmacologically acceptable acids. The subject of the invention also includes the compounds according to the invention, including their salts, wherein one or more hydrogen atoms are replaced by deuterium.
This invention also includes the physiologically acceptable salts of the alkyne compounds according to the invention as described above and hereinafter.
Also covered by this invention are compositions containing at least one alkyne compound according to the invention and/ or a salt according to the invention optionally together with one or more physiologically acceptable excipients.
Also covered by this invention are pharmaceutical compositions containing at least one alkyne compound according to the invention and/ or a salt according to the invention optionally together with one or more inert carriers and/or diluents.
This invention also relates to the use of at least one alkyne compound according to the invention and/or a salt according to the invention for influencing the eating behaviour of a mammal.
The invention further relates to the use of at least one alkyne compound according to the invention and/or a salt according to the invention for reducing the body weight and/ or for preventing an increase in the body weight of a mammal.

The invention also relates to the use of at least one alkyne compound according to the invention and/or a salt according to the invention for preparing a pharmaceutical composition with an MCH receptor-antagonistic activity, particularly with an MCH-1 receptor-antagonistic activity.
This invention also relates to the use of at least one alkyne compound according to the invention and/or a salt according to the invention for preparing a pharmaceutical composition which is suitable for the prevention and/or treatment of symptoms and/or diseases which are caused by MCH or are otherwise causally connected with MCH.
A further object of this invention is the use of at least one alkyne compound according to the invention and/or a salt according to the invention for preparing a pharmaceutical composition which is suitable for the prevention and/or treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, bulimia nervosa, cachexia, anorexia, anorexia nervosa and hyperphagia.
The invention also relates to the use of at least one alkyne compound according to the invention and/or a salt according to the invention for preparing a pharmaceutical composition which is suitable for the prevention and/or treatment of diseases and/or disorders associated with obesity, particularly diabetes, especially type II diabetes, complications of diabetes including diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, insulin resistance, pathological glucose tolerance, encephalorrhagia, cardiac insufficiency, cardiovascular diseases, particularly arteriosclerosis and high blood pressure, arthritis and gonitis.
In addition the present invention relates to the use of at least one alkyne compound according to the invention and/or a salt according to the invention for preparing a pharmaceutical composition which is suitable for the prevention and/or treatment of hyperlipidaemia, cellulitis, fat accumulation, malignant mastocytosis, systemic mastocytosis, emotional disorders, affective disorders, depression, anxiety, sleep disorders, reproductive disorders, sexual disorders, memory disorders, epilepsy, forms of dementia and hormonal disorders.
The invention also relates to the use of at least one alkyne compound according to the invention and/or a salt according to the invention for preparing a pharmaceutical composition which is suitable for the prevention and/or treatment of urinary problems, such as for example urinary incontinence, overactive bladder, urgency, nycturia and enuresis.
The invention further relates to the use of at least one alkyne compound according to the invention and/ or a salt according to the invention for preparing a pharmaceutical composition which is suitable for the prevention and/or treatment of dependencies and/or withdrawal symptoms.
The invention further relates to processes for preparing for preparing a pharmaceutical composition according to the invention, characterised in that at least one alkyne compound according to the invention and/ or a salt according to the invention is incorporated in one or more inert carriers and/or diluents by a non-chemical method.
The invention also relates to a pharmaceutical composition containing a first active substance which is selected from the alkyne compounds according to the invention and/or the corresponding salts as well as a second active substance which is selected from the group consisting of active substances for the treatment of diabetes, active substances for the treatment of diabetic complications, active substances for the treatment of obesity, preferably other than MCH antagonists, active substances for the treatment of high blood pressure, active substances for the treatment of dyslipidaemia or hyperlipidaemia, including arteriosclerosis, active substances for the treatment of arthritis, active substances for the treatment of anxiety states and active substances for the treatment of depression, optionally together with one or more inert carriers and/or diluents.
Moreover, in one aspect, the invention relates to a process for preparing alkyne compounds of formula A.5 R'RZN-X-Y-C=C-W-A-B (A.5) while in formulae A.1, A.2, A.3, A.4 and A.5 R', R2, X, Y, W, A and B have one of the meanings given hereinbefore and hereinafter, wherein a halogen compound of formula A.1 HO-X-Y-Hal (A.1 ) wherein Hal denotes chlorine, bromine or iodine, preferably bromine or iodine, is reacted with an alkyne compound of formula A.2 H-C=C-W-A-B (A.2) in the presence of a suitable palladium catalyst, a suitable base and copper(I)iodide in a suitable solvent, and the compound of formula A.3 obtained HO-X-Y-C=C-W-A-B (A.3) is reacted with methanesulphonic acid chloride (MsCI) to produce the methanesulphonate derivative A.4, Ms0-X-Y-C=C-W-A-B (A.4) which is further reacted with an amine of formula H-NR'R2 to form the end product A.S.
This invention further relates to a process for preparing alkyne compounds of formula B.5 R'R2N-X-Y-Z-C=C-A-B (B.5) while in formulae B.1, B.2, B.3, B.4 and B.5 R', R2, X, Y, Z, A and B have one of the meanings given hereinbefore and hereinafter, wherein a halogen compound of formula B.1 Hal-A-B (B.1 ) wherein Hal denotes chlorine, bromine or iodine, preferably bromine or iodine, is reacted with an alkyne compound of formula B.2 HO-X-Y-Z-C'--C-H (B.2) in the presence of a suitable palladium catalyst, a suitable base and copper(I)iodide in a suitable solvent, and the resulting compound of formula B.3 HO-X-Y-Z-C=C-A-B (B.3) is reacted with methanesulphonic acid chloride (MsCI) to form the methanesulphonate derivative B.4, Ms0-X-Y-Z-C=C-A-B (B.4) which is reacted further with an amine of formula H-NR'RZ to form the end product B.S.
In addition, the invention relates to a process for preparing alkyne compounds of formula C.3 R'RZN-X-Y-C=C-W-A-B (C.3) while in formulae C.1, C.2 and C.3 R', R2, X, Y, W, A and B have one of the meanings given hereinbefore and hereinafter, wherein a halogen compound of formula C.1 R'R2N-X-Y-Hal (C.1) wherein Hal denotes chlorine, bromine or iodine, preferably bromine or iodine, is further reacted with an alkyne compound of formula C.2 H-C=C-W-A-B ( C.2 ) in the presence of a suitable palladium catalyst, a suitable base and copper(I)iodide in a suitable solvent to yield the end product C.3.
In another aspect the invention relates to a process for preparing alkyne compounds of formula D.3 R'R2N-X-Y-Z-C=C-A-B (D.3) while in formulae D.1, D.2 and D.3 R', R2, X, Y, Z, A and B have one of the meanings given hereinbefore and hereinafter, wherein a halogen compound of formula D.2 Hal-A-B (D.2) wherein Hal denotes chlorine, bromine or iodine, preferably bromine or iodine, is reacted with an alkyne compound of formula D.1 R'R2N-X-Y-Z-C=C-H (D.1) in the presence of a suitable palladium catalyst, a suitable base and copper(I)iodide in a suitable solvent to form the end product D.3.
The starting materials and intermediate products used in the synthesis according to the invention are also a subject of this invention.
~5 Detailed description of the invention Unless otherwise specified, the groups, residues and substituents, particularly A, B, W, X, Y, Z, Cy, R', R2, R4, R'°, R", R'3 and R'S to R~2, have the meanings given hereinbefore.
If groups, residues and/or substituents occur more than once in a compound, they may have the same or different meanings in each case.
According to a first embodiment the group R' is selected from among the definitions C3~-alkenyi, C3_6-alkynyl, (hydroxy-C3_~-cycloalkyl)-C,_3-alkyl, oxa-C5_,-cycloalkyl, dihydroxy-C3_m alkyl, while the groups mentioned may be mono- or polysubstituted by substituents which are selected independently of one another from the group consisting of halogen, hydroxy, cyano, C,_4-alkyl, C3_,-cycioalkyl, C3_~-cycloalkyl-C~_3-alkyl, C,_4-alkoxy-C,_4-alkyl, C~_4-alkoxy, C~_4-alkenyl, C~_4-alkynyl, amino, C,~-alkyl-amino and di-(C~~-alkyl)-amino, while any alkyl, alkoxy, cylcoalkyl groups present in the above-mentioned substituents may independently of one another comprise one or more identical or different substituents selected from halogen, particularly fluorine or chlorine, and hydroxy.
According to this embodiment preferred meanings of the group R' are C3_5-alk-2-enyl, C3_5-alk-2-inyl, (1-hydroxy-C3_6-cycloalkyl)-C,_3-alkyl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, dihydroxy-C3_5-alkyl, while the groups mentioned may be mono- or polysubstituted as specified hereinbefore.
According to this first embodiment preferred substituents, independently of one another, are fluorine, chlorine, bromine, hydroxy, cyano, CF3, C,_4-alkyl, C3_~-cycloalkyl, C3_,-cycloalkyl-C,_3-alkyl, C~_4-alkoxy-C~~,-alkyl, C,_4-alkoxy, amino, C,_4-alkyl-amino and di-(C,_4-alkyl)-amino, while the alkyl, cylcoalkyl groups may comprise one or more identical or different substituents selected from fluorine and hydroxy.
Particularly preferred substituents, independently of one another, are fluorine, chlorine, hydroxy, cyano, CF3, hydroxymethyl, hydroxyethyl, C,_3-alkyl, C3~-cycloalkyl, C3~-cycloalkyl-methyl, C,_3-alkoxy-C~_3-alkyl, C,_3-alkoxy, amino, C~_3-alkyl-amino and di-(C~_3-alkyl)-amino.
According to this embodiment particularly preferred meanings of the group R' are prop-2-enyl, but-2-enyl, prop-2-ynyl, but-2-inyl, (1-hydroxy-C3_6-cycloalkyl)-methyl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, 2,3-dihydroxy-C3_5-alkyl. Most particularly preferred meanings are prop-2-enyl, prop-2-ynyl, (1-hydroxy-cyclopropyl)methyl, tetrahydropyran-4-yl, 2,3-dihydroxypropyl, 2-hydroxy-1-(hydroxymethyl)-ethyl, 1,1-di(hydroxymethyl)-ethyl.
According to this first embodiment RZ independently of R' has one of the meanings given hereinbefore for R' or R2 has a meaning selected from the group consisting of H, C~$-alkyl, C3_~-cycloalkyl or a phenyl or pyridinyl group optionally mono- or polysubstituted by the group Rz° and/or monosubstituted by vitro, while the alkyl or cycloalkyl group may be mono- or polysubstituted independently of one another by identical or different groups R", and a -CH2-group in position 3 or 4 of a 5-, 6- or 7-membered cycloalkyl group may be replaced by -O-, -S- or -NR'3-Preferred meanings of the group R" are F, CI, Br, C~_6-alkyl, CZ~-alkenyl, CZ~-alkynyl, R'S-O-, cyano, R'sR"N, C3_~-cycloalkyl, cyclo-C3_6-alkyleneimino, pyrrolidinyl, N-(C,_4-alkyl)-pyrrolidinyl, piperidinyl, N-(C~_4-alkyl)-piperidinyl, phenyl and pyridyl, while in the above-mentioned groups and radicals one or more C atoms may independently of one another be mono- or polysubstituted by F, C,_3-alkyl or hydroxy-C,_3-alkyl, and/or one or two C atoms independently of one another may be monosubstituted by CI, Br, OH, CF3 or CN, and the above-mentioned cyclic groups may be mono- or polysubstituted at one or more C
atoms by identical or different groups Rz°, and in the case of a phenyl group may also additionally be monosubstituted by vitro, and/or one or more NH groups may be substituted by R2'. If R" has one of the meanings R'S-O-, cyano, R'6R"N-or cyclo-C3~-alkyleneimino, the C
atom of the alkyl or cycloalky! group substituted by R" is not directly attached to a heteroatom, such as for example the group -N-X-.
Preferably the group R2 denotes H, C»-alkyl, C3_5-alkenyl, C3_5-alkynyl, C3_~-cycloalkyl, hydroxy-C3_,-cycloalkyl, C3_,-cycloalkyl-C,_3-alkyl, (hydroxy-C3_,-cycloalkyl)-C,_3-alkyl, hydroxy-C2_4-alkyl, c~-NC-C2_3-alkyl, C,~-alkoxy-C2_4-alkyl, hydroxy-C,_4-alkoxy-C2_4-alkyl, C,_4-alkoxy-carbonyl-C~_4-alkyl, carboxyl-C,_4-alkyl, amino-C2_4-alkyl, C,_4-alkyl-amino-C2~-alkyl, di-(C,~-alkyl)-amino-C2~-alkyl, cyclo-C3~-alkyleneimino-C2.~-alkyl, pyrrolidin-3-yl, N-(C,~-alkyl)-pyrrolidin-3-yl, pyrrolidinyl-C,_3-alkyl, N-(C,_4-alkyl)-pyrrolidiny!-C,_3-alkyl, piperidin-3-y!, piperidln-4-yl, N-(C~~-alkyl)-piperidin-3-yl, N-(C~_4-alkyl)-piperidin-4-yl, piperidinyl-C,_3-alkyl, N-(C~_4-alkyl)-piperidinyl-C~_3-alkyl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, phenyl, phenyl-C,_3-alkyl, pyridyl or pyridyl-C,_3-alkyl, while in the above-mentioned groups and radicals one or more C atoms may independently of one another be mono- or polysubstituted by F, C,_3-alkyl or hydroxy-C,_3-alkyl, and/or one or two C atoms may independently of one another be monosubstituted by CI, Br, OH, CF3 or CN, and the phenyl or pyridyl group may be mono- or polysubstituted by identical or different groups R2° and/or monosubstituted by vitro. Preferred substituents of the above-mentioned phenyl or pyridyl groups are selected from the group F, CI, Br, l, cyano, C,_4-alkyl, C~~,-alkoxy, difluoromethyl, trifluoromethyl, hydroxy, amino, C,_3-alkylamino, di-(C,_3-alkyl)-amino, acetylamino, aminocarbonyl, difluoromethoxy, trifiuoromethoxy, amino-C,_3-alkyl, C,_3-alkylamino-C~_3-alkyl- and di-(C~_3-alkyl)-amino-C,_3-alkyl, while a phenyl group may also be monosubstituted by vitro.
Particularly preferred meanings of the group R2 are selected from the group consisting of H, C,_4-alkyl, C3_5-alkenyi, C3_5-alkynyl, C3_,-cycloalkyl, C3_,-cycloalkyl-C,_3-alkyl, ar(C,~,-alkoxy)-CZ_3-alkyl, pyridyl and benzyl, while in the above-mentioned groups (with the exception of H) one or more C atoms may be mono- or polysubstituted independently of one another by F, C,_3-alkyl or hydroxy-C~_3-alkyl, and/or one or two C atoms may be monosubstituted independently of one another by CI, Br, OH, CF3 or CN.
Most particularly preferred groups Rz are selected from among H, methyl, ethyl, n-propyl, i-propyl, prop-2-enyl, prop-2-ynyl, 2-methoxyethyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopentylmethyl, (1-hydroxy-cyclopropyl)-methyl, 2-hydroxyethyl, 3-hydroxypropyl, benzyl and pyridyl.
According to a second embodiment the groups R', RZ together with the N atom to which they are bound form a heterocyclic group which is selected from the meanings dihydroxy-(cyclo-C4_,-alkylene-imino), ( hyd roxy-C, _4-alkyl )-hyd roxy-cyclo-C3_,-alkylene-i m ino, (hydroxy-C~_3-alkyl)-cyclo-C3_,-alkylene-imino, while in the last definition the C~_3-alkyl group may be substituted by one or more identical or different C~_3-alkyl groups, of which 2 alkyl groups may be joined together to form a C3_~-cyloalkyl group;
while the above-mentioned heterocyclic groups may be mono- or polysubstituted by substituents which are selected independently of one another from the group consisting of halogen, hydroxy, cyano, C,~-alkyl, C3_,-cycloalkyl, C3_,-cycloalkyl-C,_3-alkyl, C,_4-alkoxy-C~_a-alkyl, C»-alkoxy, C2_4-alkenyl, C2_4-alkynyl, amino, C~.~-alkyl-amino and di-(C,_4-alkyl)-amino, while in the alkyl, alkoxy or cycloalkyl groups contained in the above-mentioned substituents one or more C atoms may be mono- or polysubstituted by fluorine, and in the alkyl, alkoxy or cycloalkyl groups contained in the above-mentioned substituents one or more C
atoms may be monosubstituted by chlorine, bromine or hydroxy.
According to this second embodiment preferred heterocyclic groups are 3,4-dihydroxypyrrolidinyl, 3,4-dihydroxypiperidinyl, 3,5-dihydroxypiperidinyl, (hydroxy-C,_3-alkyl)-hydroxypyrrolidinyl, (hydroxy-C~_3-alkyl)-hydroxy-piperidinyl, (hydroxy-C3_6-cycloalkyl)-hydroxypyrrolidinyl, (hydroxy-C3_6-cycloalkyl)-hydroxy-piperidinyl, (C~_3-alkyl-hydroxy-methyl)-pyrrolidinyl, (C,_3-alkyl-hydroxy-methyl)-piperidinyl, (di-C,_3-alkyl-hydroxy-methyl)-pyrrolidinyl, (di-C,_3-alkyl-hydroxy-methyl)-piperidinyl, (1-hydroxy-C3_6-cycloalkyl)-pyrrolidinyl, (1-hydroxy-C3_6-cycloalkyl)-piperidinyl, while the above-mentioned groups may be substituted as specified hereinbefore.
In the above-mentioned heterocyclic groups in one or two hydroxy groups the H
atom may also be replaced by a methyl group.
Preferred substituents of the above-mentioned heterocyclic groups are fluorine, chlorine, hydroxy, CF3, C~_3-alkyl and hydroxy-C~_3-alkyl, particularly methyl, ethyl and CF3.
According to this second embodiment particularly preferred heterocyclic groups are 3,4-dihydroxypyrrolidinyl, 3,4-dihydroxypiperidinyl, 3,5-dihydroxypiperidinyl, (hydroxymethyl)-hydroxy-pyrrolidinyl, (hydroxymethyl)-hydroxy-piperidinyl, (1-hydroxyethyl)-hydroxy-pyrrolidinyl, (1-hydroxyethyl)-hydroxy-piperidinyl, (1-hydroxy-1-methylethyl)-hydroxy-pyrrolidinyl, (1-hydroxy-1-methylethyl)-hydroxy-piperidinyl, (1-hydroxycyclopropyl)-hydroxy-pyrrolidinyl, (1-hydroxycyclopropyl)-hydroxy-piperidinyl, (1-hydroxy-cyclopropyl)-pyrrolidinyl, (1-hydroxy-cyclopropyl)-piperidinyl, (1-hydroxyethyl)-pyrrolidinyl, (1-hydroxyethyl)-piperidinyl, (1-hydroxy-1-methylethyl)-pyrrolidinyl, (1-hydroxy-1-methylethyl)-piperidinyl, while the groups specified do not have any other substituents or have one or two substituents selected independently of one another from fluorine, hydroxy, C~_3-alkyl, hydroxy-C,_3-alkyl and CF3.
N~X~, ~2 Most particularly preferred definitions of the heterocyclic groups R are HO HO HO
v N-X-~ , \ . . N-X
' HO N-X
HO ' HO
HO HO HO
HO N-X
HO N-X~- ~ HO ~N-X
F3C \-/
HO HO HO
v . v N-X . N-X-~ , v . .
HO N-X
HO HO
HO HO HO , v . ~ ~ N-X
N-X . , N-X , . , ' HO
HO HO~
, , N-X-; , N-X . , N-X
HO HO HO~
, \ , N-X . N-X . N-X
, , ~ , HO HO \ HO
wherein X is defined as hereinbefore and particularly hereinafter, and wherein the heterocyclic groups R'R2N- specified are not further substituted, or wherein methyl or ethyl groups may be mono-, di- or trisubstituted by fluorine, and wherein one or more H atoms of the heterocycle formed by the group R'RZN- which are bound to carbon are substituted independently of one another by fluorine, chlorine, CN, CF3, C,_3-alkyl, hydroxy-C~_3-alkyl, particularly C~_3-alkyl or CF3, preferably methyl, ethyl, CF3.
According to a first embodiment the group X is preferably a C2~-alkylene bridge, particularly preferably ethylene or propylene, while one or two C atoms may be monosubstituted by hydroxy, hydroxy-C~_3-alkyl or C,_3-alkoxy, particularly hydroxy, and the alkylene bridge may be monosubstituted by C2_6-alkenyl, C2_6-alkynyl, C3_6-cycloalkyl or C3_6-cycloalkyl-C,_3-alkyl and/or independently may be mono-, di- or trisubstituted by identical or different C~_3-alkyl groups, and two alkyl groups may be joined together forming a 3- to 7-membered cycloalkyl group, or an alkyl group and an alkenyl group may be joined together forming a 5 to 7-membered cycloalkenyl group. In the group X one or more C atoms may be mono-or polysubstituted by F and/or CI, preferably F.
According to a second embodiment the group X is preferably a C3_4-alkylene bridge, wherein a -CH2-CH2- group not directly adjacent to the N atom of the R'R2N- group is replaced by -CH=CH-, -C=C-, -CHz-O-, -CHz-S- or -CH2-NR4-, particularly preferably a -CH2-CH=CH-, -CH2-C---C-, -CH2-CH2-O-, -CHZ-CH2-S- or -CH2-CHZ-NR4- bridge, while the meanings given for X hereinbefore may comprise a substituent selected from CZ~-alkenyl, C2~-alkynyl, C3_~-cycloalkyl and C3_,-cycloalkyl-C,_3-alkyl and/or one, two or three identical or different C,_4-alkyl substituents, while two alkyl groups may be joined together forming a 3 to 7-membered cyclic group, or an alkyl and an alkenyl group may be joined together forming a 5 to 7-membered cyclic group. In the group X one or more C atoms may be mono- or polysubstituted by F
and/or CI, preferably F.
Particularly preferred meanings of X are therefore ethylene, propylene, -CH2-CH=CH-, -CH2-C---C-, -CH2-CHZ-O-, -CHz-CH2-S- or -CH2-CH2-NR4-.
A particularly preferred meaning of X is unsubstituted ethylene or propylene or C~_4-alkylene, particularly ethylene or propylene, which comprises one or two identical or different substituents selected independently of one another from fluorine, chlorine, hydroxy and C,_3-alkyl and/or a C2~-alkenyl or cyclopropyl substituent, while two alkyl substituents may be joined together forming a C3_6-cycloalkyl group or an alkyl and an alkenyl group may be joined together forming a CS.~-cycloalkenyl group. Particularly preferably, the alkylene bridge is mono- or disubstituted by identical or different groups selected from methyl, ethyl and i-propyl, while two alkyl groups may be joined together as specified, forming a cyclic group.
In the definition substituted propylene particularly preferred meanings are selected from the group consisting of ,, Other particularly preferred meanings for X are -CH2-CH=CH-, -CHz-C=C-, -CHz-CHZ-O-, -CHZ-CHZ-S- or -CH2-CHZ-NR4-, particularly -CHZ-CH=CH-, -CHZ-CHZ-O- or -CH2-CHz-NR4, wherein R4 denotes H or C,_4-alkyl, while the meanings specified for X are unsubstituted or comprise one or two identical or different substituents selected independently of one another from fluorine and C,_3-alkyl and/or a cyclopropyl substituent, while two alkyl groups may be joined together forming a C3_6-cycloalkyl group or if an alkyl group denotes the group R4, may be joined together forming a pyrrolidine or piperidine group. Particularly preferably, the meanings given for X hereinbefore may be mono- or disubstituted by identical or different groups selected from methyl, ethyl and i-propyl, while two alkyl groups as specified may be joined together forming a cyclic group.
A particularly preferred meaning of X is unsubstituted -CH2-CH2-O- or substituted -CHZ-CHz-O- selected from the group consisting of O
,y\'~0~.,, , O
,, ~y\~O
~,, .
O
~,, Another particularly preferred meaning of X is -CHZ-CH2-NH- or -CH2-CH2-NCH3-or substituted -CH2-CH2-NCH3- selected from the group consisting of i , N~,, N
~,, , Another particularly preferred meaning of X is -CH2-CH=CH- or substituted -CH2-CH=CH-selected from the group consisting of /
, ' /
' ' /
, , ', / , / , For X representing substituted alkenylene, only one of the two possible E/Z
configurations is given above. Obviously, the other of the two E/Z configurations is also included according to the invention.
The position of the imino group within the alkylene bridge X is selected such that no aminal function is formed together with the amino group NR'R2 or another adjacent amino group, or two N atoms are not adjacent to one another.
Preferred meanings of the group R'° are -OH, methoxy and hydroxymethyl, particularly -OH.
According to a third embodiment the group X is a -CH2- bridge, which is unsubstituted or substituted by one or two identical or different C,_3-alkyl substituents and/or a substituent selected from C2_6-alkenyl, C2_6-alkynyl, C3_6-cycloalkyl or C3_6-cycloalkyl-C~_3-alkyl, while two alkyl substituents may be joined together forming a 3- to 6-membered carbocyclic ring system. According to this embodiment X denoting -CHz- is preferably unsubstituted or mono-or disubstituted by methyl, while two methyl substituents may be joined together forming a cyclopropyl group. This third embodiment regarding X is particularly preferred if Y is a bicyclic group, while the first ring of the bicyclic group is linked to X and the second ring is linked to Z.
The bridge W preferably denotes a single bond or ethylene, particularly preferably a single bond.
The bridge Z preferably denotes a single bond or ethylene which may comprise one or two methyl substituents, which may be joined together, forming a cyclopropyl group. Particularly preferably Z denotes a single bond.
The group Y preferably has a meaning selected from among the bivalent cyclic groups phenyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, naphthyl, tetrahydronaphthyl, indolyl, dihydroindolyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl, tetrahydro-isoquinolinyl, benzimidazolyl, benzoxazolyl, chromanyl, chromen-4-onyl, benzothienyl, or benzofuranyl, particularly preferably phenyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl, while the above-mentioned cyclic groups may be mono-or polysubstituted at one or more C atoms by identical or different groups R2°, and in the case of a phenyl ring may also additionally be monosubstituted by nitro, and/or substituted by Rz' at one or more N atoms.
If the group Y is a 6-membered cyclic or heterocyclic group, the bridges X and Z are preferably attached to the group Y in the para position.
Particularly preferably, the definition of the group Y is selected from among the bivalent cyclic groups , N-N
N- -N
, , N N
N ' N
' N ~ ~ ' ' /~N ~ ~ ' N
,~
N ~ ~ . , , N
N ~
/ ,, , ~ / , ;-~i ~
o /
N
' \ . ~
S ' ' S
\ , .
O ' \ , , , ,, O /
O
\ ' ,, O /
and particularly Y has one of the following meanings - N '.
' . \ , ' O /
O
\ ', , O
most particularly preferably, Y has one of the following meanings while the above-mentioned cyclic groups may be mono- or polysubstituted at one or more C
atoms by identical or different groups R2°, and in the case of a phenyl ring may also additionally be monosubstituted by nitro, and/or one or more NH groups may be substituted by Rzi.
If the group Y is selected from among the bivalent bicyclic groups ' ' . N
/ , , . / ~ , \ ' N \ ' / ' O /
~N
, \ , ,, \ , , ' /
S / ' O
~ , ' ' O /
O
, O
particularly if Y has one of the following meanings ' / ~ . N ~ ~ , and . ' ,, \ ~ \
/
/ , ~ O / ' N , O
, O
while the above-mentioned bicyclic groups may be mono- or polysubstituted at one or more C
atoms by identical or different groups R2°, and in the case of a phenyl ring may also additionally be monosubstituted by vitro, and/or one or more NH groups may be substituted by R2', the bridge X preferably denotes a -CH2- group which may be substituted according to the third embodiment described hereinbefore in respect of X.
The group Y is preferably unsubstituted or mono- or disubstituted.
Particularly preferred substituents R2° of the group Y are selected from the group consisting of fluorine, chlorine, bromine, cyano, vitro, C~_4-alkyl, C2_6-alkenyl, hydroxy, cu-hydroxy-C~_3-alkyl, C~_4-alkoxy, trifluoromethyl, trifluoromethoxy, C2~,-alkynyl, C,_4-alkoxy-carbonyl, w-(C,_4-alkoxy)-C,_3-alkyl, C,_4-alkoxy-carbonylamino, amino, C,_4-alkyl-amino, di-(C»-alkyl)-amino, aminocarbonyl, C,_4-alkyl-amino-carbonyl- and di-(C~~,-alkyl)-amino-carbonyl.
Most particularly preferred substituents RZ° of the group Y are selected from among fluorine, chlorine, bromine, cyano, C,_3-alkyl, C,_3-alkoxy, C~_4-alkoxycarbonyl, trifluoromethyl, trifluoromethoxy, and in the case of a phenyl ring vitro as well.
Most particularly preferably the group Y denotes substituted phenylene of the partial formula L~
wherein L' has one of the meanings given hereinbefore for R2°, preferably F, CI, Br, I, methyl, ethyl, ethenyl, ethynyl, CF3, OCH3, OCF3, -CO-CH3, -COOCH3, CN or N02, or denotes H.
Most particularly preferred meanings of the substituent L' are H, F, CI, Br, methyl, ethyl, ethenyl, acetyl or methoxy, particularly H or methyl.
Preferably the group A is selected from among the bivalent cyclic groups phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, which may be mono- or polysubstituted at one or more C
atoms by identical or different groups R2°, and in the case of a phenyl ring may also additionally be monosubstituted by vitro.
Most particularly preferably, A is one of the groups listed hereinafter ' /
' ' -N , N- ' ~\
N
-N N-' ' ' ' ~ / ' / ' . . ~ ' ' N N
' , \ / . , N-N
N . . -N . ' ' particularly ; / ~ , , ;~ , or . \ / ;
N N-N
most rarticularly rreferably ; ' while the groups listed may be substituted as specified hereinbefore.
Particularly preferred substituents R2° of the group A are, independently of one another, fluorine, chlorine, bromine, CF3, amino, methoxy and C,_3-alkyl.
Preferably the group A is unsubstituted or monosubstituted by Rz°, as specified.
Preferred definitions of the group B according to a first preferred embodiment are selected from the group consisting of phenyl, pyridyl, thienyl and furanyl.
Particularly preferably the group B denotes phenyl. The group B in the meanings specified may be mono- or polysubstituted by identical or different groups R2°, a phenyl group may additionally also be monosubstituted by nitro. Preferably the group B is unsubstituted or mono-, di-or trisubstituted, particularly unsubstituted or mono- or disubstituted. In the event of monosubstitution the substituent is preferably in the para position to the group A.
Preferred substituents R2° of the group B are selected from the group consisting of fluorine, chlorine, bromine, cyano, vitro, C~_4-alkyl, hydroxy, CHFz, CHF2-O-, hydroxy-C~_3-alkyl, C,_4-alkoxy, trifluoromethyl, trifluoromethoxy, C2_4-alkynyl, carboxy, C,_4-alkoxycarbonyl, w-(C,_ 4-alkoxy)-C,_3-alkyl, C~_4-alkoxy-carbonylamino, amino, C,_4-alkyl-amino, di-(C,~-alkyl)-amino, cyclo-C3_6-alkyleneimino, aminocarbonyl, C,~-alkyl-amino-carbonyl and di-(C,~-alkyl)-amino-carbonyl.
Particularly preferred substituents Rz° of the group B are selected from the group consisting of fluorine, chlorine, bromine, cyano, CF3, C,_3-alkyl, C,~-alkoxy and trifluoromethoxy.
Most particularly preferred substituents R2° of the group B are selected from the group consisting of chlorine, bromine and methoxy.
According to a second embodiment the meaning of the group B is preferably selected from C,_s-alkyl, C2~-alkenyl, C2~-alkynyl, C3_~-cycloalkyl, C5_~-cycloalkenyl, C3_~-cycloalkyl-C~_3-alkyl, C3_,-cycloalkenyl-C~_3-alkyl, C3_~-cycloalkyl-C,_3-alkenyl, C3_,-cycloalkyl-C~_3-alkynyl, while one or more C atoms in the groups mentioned hereinbefore for B may be mono- or polysubstituted by fluorine. In the cyclic groups according to the above-mentioned embodiment one or more C atoms may be substituted by identical or different R2°.
Particularly preferred according to this embodiment are the groups C3_6-alkyl, C3_6-alkenyl, C3_ 6-alkynyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclopentyl-C,_3-alkyl, cyclopentenyl-C,_3-alkyl, cyclohexyl-C,_3-alkyl, cyclohexenyl-C~_3-alkyl, cycloheptyl-C,_3-alkyl, cycloheptenyl-C,_3-alkyl, while one or more C atoms in the groups mentioned hereinbefore for B may be mono- or polysubstituted by fluorine, and in cyclic groups one or more C atoms may be substituted by identical or different R2°
Most particularly preferably according to this second embodiment, B denotes cyclohexenyl, which is unsubstituted or comprises 1, 2 or 3 identical or different substituents R2°, particularly methyl.
The following are preferred definitions of other substituents according to the invention:
R4 preferably denotes H, C,~,-alkyl, C3_6-cycloalkyl and C3.~-cycloalkyl-methyl, particularly H, methyl, ethyl, propyl, i-propyl, n-propyl, cylcopropyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopentylmethyl, cyclohexymethyl. Most particularly preferably R4 denotes H or methyl.
Preferably the substituent R'3 has one of the meanings given for R'6.
Particularly preferably R'3 denotes H, C~_4-alkyl, C3_~-cycloalkyl, C3_,-cycloalkyl-C~_3-alkyl, c~-hydroxy-Cz_3-alkyl, ur(C,_ 4-alkoxy)-Cz_3-alkyl-. Most particularly preferably R'3 denotes H or C~~,-alkyl. The alkyl groups specified hereinbefore may be monosubstituted by CI or mono- or polysubstituted by F.
Preferred meanings of the substituent R'S are H, C,_4-alkyl, C3_~-cycloalkyl, C3_~-cycloalkyl-C~_3-alkyl, while, as hereinbefore defined, in each case one or more C atoms may additionally be mono- or polysubstituted by F and/or in each case one or two C atoms independently of one another may additionally be monosubstituted by CI or Br. Particularly preferably R'S
denotes H, CF3, methyl, ethyl, propyi or butyl.
The substituent R's preferably denotes H, C»-alkyl, C3_~-cycloalkyl, C3_,-cycloalkyl-C~_3-alkyl, c~-hydroxy-C2_3-alkyl or w-(C,_4-alkoxy)-C2_3-alkyl, while, as hereinbefore defined, in each case one or more C atoms may additionally be mono- or polysubstituted by F and/or in each case one or two C atoms independently of one another may additionally be monosubstituted by CI
or Br. Particularly preferably R'6 denotes H, CF3, Cy_3-alkyl, C3_6-cycloalkyl or C3_6-cycloalkyl-C,_3-alkyl.
Preferably the substituent R" has one of the meanings given for R'6 which are specified as preferred or denotes phenyl, phenyl-C~_3-alkyl, pyridinyl or C,_4-alkylcarbonyl. Particularly preferably R" has one of the meanings given for R'6 which are specified as preferred.
Preferably one or both of the substituents R'8 and R'9 independently of one another denote hydrogen or C,_4-alkyl, particularly hydrogen.
The substituent R2° preferably denotes halogen, hydroxy, cyano, C~.~-alkyl, C2_4-alkenyl, CZ_4 alkynyl, C3_~-cycloalkyl, C3_~-cycloalkyl- C~_3-alkyl, hydroxy-C~_4-alkyl, R22-C,_3-alkyl or has one of the meanings given for R22 which are specified as preferred, while, as hereinbefore defined, in each case one or more C atoms may additionally be mono- or polysubstituted by F
and/or in each case one or two C atoms independently of one another may additionally be monosubstituted by CI or Br.
Particularly preferred definitions of the group R2° are halogen, hydroxy, cyano, C,_4-alkyl, C3_~-cycloalkyl, C~_3-alkylcarbonyl and C~_4-alkoxy, while, as hereinbefore defined, in each case one or more C atoms may additionally be mono- or polysubstituted by F and/or in each case one or two C atoms independently of one another may additionally be monosubstituted by CI
or Br. Most particularly preferably R2° denotes F, CI, Br, I, OH, cyano, methyl, difluoromethyl, trifluoromethyl, ethyl, n-propyl, acetyl, iso-propyl, methoxy, difluoromethoxy, trifluoromethoxy, ethoxy, n-propoxy or iso-propoxy.
The substituent R22 preferably denotes C»-alkoxy, C~_4-alkylthio, carboxy, C,_4-alkylcarbonyl, C,_4-alkoxycarbonyl, aminocarbonyl, C,_4-alkylaminocarbonyl, di-(C~_4-alkyl)-aminocarbonyl, C,_4-alkyl-sulphonyl, C,_4-alkyl-sulphinyl, C,_4-alkyl-sulphonylamino, amino, C,_4-alkylamino, di-(C~_4-alkyl)-amino, C,_4-alkyl-carbonyl-amino, hydroxy-C~_3-alkylaminocarbonyl, aminocarbonylamino or C,_4-alkylaminocarbonyl-amino, while, as hereinbefore defined, in each case one or more C atoms may additionally be mono- or polysubstituted by F and/or in each case one or two C atoms independently of one another may additionally be monosubstituted by CI or Br. Most particularly preferred meanings of Rz2 are C~_4-alkoxy, C~_3-alkylcarbonyl, amino, C,_4-alkylamino, di-(C,_4-alkyl)-amino, wherein one or more H atoms may be replaced by fluorine.
Preferred definitions of the group R2' are C~~,-alkyl, C~_4-alkylcarbonyl, C,_4-alkylsulphonyl, -SO2-NH2, -S02-NH-C,_3-alkyl, -S02-N(C,_3-alkyl)z and cyclo-C3~-alkyleneimino-sulphonyl, while, as hereinbefore defined, in each case one or more C atoms may additionally be mono-or polysubstituted by F and/or in each case one or two C atoms independently of one another may additionally be monosubstituted by CI or Br. Most particularly preferably R2' denotes C~_4-alkyl or CF3.
Cy preferably denotes a C3_~-cycloalkyl, particularly a C3~-cycloalkyl group, a C5_~-cycloalkenyl group, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, aryl or heteroaryl, and the above-mentioned cyclic groups may be mono- or polysubstituted at one or more C atoms by identical or different groups R2°, or in the case of a phenyl group may also additionally be monosubstituted by nitro, and/or one or more NH groups may be substituted by R2'. Most particularly preferred definitions of the group Cy are C3_6-cycloalkyl, pyrrolidinyl and piperidinyl, which may be substituted as specified.
The term aryl preferably denotes phenyl or naphthyl, particularly phenyl.
The term heteroaryl preferably includes pyridyl, indolyl, quinolinyl and benzoxazolyl.
Preferred compounds according to the invention are those wherein one or more of the groups, radicals, substituents and/or indices have one of the meanings specified hereinbefore as being preferred.
Particularly preferred compounds according to the invention may be described by one of the general formulae Ila, Ilb, Ilc, Ild, Ile, Ilf, Ilg, Ilh, particularly Ila, Ilb, Ile and Ilf, \L1)m \L2)n l 1 \L3)P
R~ / ~ Ila RziN X
~L )m ~L )n 3 1 ~ L )P
R ~ / \ ~-- - I I b RziN X N~ Z
1L1)m ~Lz)n ( 1 \L3)P
R ~ / ~ --1- I Ic RziN X
\L1)m ~Lz)n R\ - / \ ( )P Ild Rz~N X Z
N N
\L1)m \Lz)n \L3) R~ ~ ~ N P Ile RziN X
~Ll~m ~L2y 1 N ~L3~P
R2 N-X ~ ~ Z ~ Ilf R N N
~~'1~m ~L2~n R\N-X ~ \ Z N 119 L1 ~m ~ L2~n 1 N ~ L3 ~P
R2 N-X ~ ~ Z ~ Ilh R N N ~ \
wherein R', R2, X and Z have one of the preferred meanings given above and L', L2, L3, independently of one another have one of the meanings given for R2°, and m, n, p independently of one another represent the values 0, 1 or 2, and p may also denote 3.
In particular, in formulae Ila, Ilb, Ilc, !Id, Ile, Ilf, Ilg and Ilh, Z denotes a single bond, L' denotes fluorine, chlorine, bromine, cyano, C~_3-alkyl, C,_3-alkoxy, C,~-alkoxycarbonyl, trifluoromethyl, trifluoromethoxy, nitro, m denotes 0 or 1, L2 denotes fluorine, chlorine, bromine, CN, amino, CF3, methoxy and C~_3-alkyl, n denotes 0 or 1, L3 independently of one another have a meaning selected from among fluorine, chlorine, bromine, cyano, nitro, C,~,-alkyl, hydroxy, c~-hydroxy-C,_3-alkyl, C,_4-alkoxy, trifluoromethyl, trifluoromethoxy, Cz_4-alkynyl, carboxy, C»-alkoxycarbonyl, cu-(C,_4-alkoxy)-C,_3-alkyl, C,_ 4-alkoxy-carbonylamino, amino, C,~-alkyl-amino, di-(C~.~-alkyl)-amino, cyclo-C3~-alkyleneimino, aminocarbonyl, C~_4-alkyl-amino-carbonyl or di-(C~~-alkyl)-amino-carbonyl, particularly preferably fluorine, chlorine, bromine, cyano, CF3, C,_3-alkyl, C,~-alkoxy and trifluoromethoxy, with the proviso that a phenyl ring may only be monosubstituted by nitro, and p denotes 0, 1, 2 or 3, particularly 1 or 2.
Most particularly preferably in formulae Ila, Ilb, Ilc, Ild, Ile, Ilf, Ilg and Ilh R' denotes prop-2-enyl, but-2-enyl, prop-2-ynyl, but-2-ynyl, (1-hydroxy-C3_s-cycloalkyl)-methyl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, 2,3-dihydroxy-C3_5-alkyl, and R2 denotes H, C,~-alkyl, C3_5-alkenyl, C3_5-alkynyl, C3_,-cycloalkyl, C3_,-cycloalkyl-C~_3-alkyl, cu-(C,_4-alkoxy)-C2_3-alkyl, pyridyl and benzyl, while in the above-mentioned groups (with the exception of H) one or more C atoms independently of one another may be mono- or polysubstituted by F, C~_3-alkyl or hydroxy-C,_3-alkyl, and/or one or two C atoms independently of one another may be monosubstituted by CI, Br, OH, CF3 or CN, or R', R2 are joined together and form, together with the N atom to which they are bound, a heterocyclic group which is selected from 3,4-dihydroxypyrrolidinyl, 3,4 dihydroxypiperidinyl, 3,5-dihydroxypiperidinyl, (hydroxymethyl)-hydroxy-pyrrolidinyl, (hydroxymethyl)-hydroxy-piperidinyl, (1-hydroxyethyl)-hydroxy-pyrrolidinyl, (1-hydroxyethyl)-hydroxy-piperidinyl, (1-hydroxy-1-methylethyl)-hydroxy-pyrrolidinyl, (1-hydroxy-1-methylethyl)-hydroxy-piperidinyl, (1-hydroxycyclopropyl)-hydroxy-pyrrolidinyl, (1-hydroxycyclopropyl)-hydroxy-piperidinyl, (1-hydroxy-cyclopropyl)-pyrrolidinyl, (1-hydroxy-cyclopropyl)-piperidinyl, (1-hydroxyethyl)-pyrrolidinyl, (1-hydroxyethyl)-piperidinyl, (1-hydroxy-1-methylethyl)-pyrrolidinyl, (1-hydroxy-1-methylethyl)-piperidinyl, while the specified groups have no other substituents or have one or two substituents selected independently of one another from fluorine, hydroxy, C~_3-alkyl, hydroxy-C~_3-alkyl, CF3, X denotes ethylene or propylene, which is unsubstituted or has one or two identical or different substituents selected independently of one another from fluorine, chlorine, hydroxy and C,_3-alkyl and/or a C2_s-alkenyl or cyclopropyl substituent, while two alkyl substituents may be joined together, forming a C3~-cycloalkyl 1 o group, or an alkyl and an alkenyl group may be joined together, forming a C5_s-cycloalkenyl group, or -GH2-CH=CH-, -CH2-C--_C-, -CH2-CH2-O- or -CH2-CH2-NR4-, which are unsubstituted or comprise one or two identical or different substituents selected independently of one another from fluorine and C~_3-alkyl and/or a cyclopropyf substituent, while two alkyl groups may be joined together forming a C3~-cycioalkyl group or, if an alkyl group denotes the group R4, they may be joined together forming a pyrrolidine or piperidine group.
The compounds listed in the experimental section, including the tautomers, the diastereomers, the enantiomers, the mixtures thereof and the salts thereof, are preferred according to the invention.
Some expressions used hereinbefore and below to describe the compounds according to the invention will now be defined more fully.
The term halogen denotes an atom selected from among F, CI, Br and I, particularly F, CI and Br.
The term C,_"alkyl, where n has a value of 3 to 8, denotes a saturated, branched or unbranched hydrocarbon group with 1 to n C atoms. Examples of such groups include methyl, ethyl, n-propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, neo-pentyl, tert-pentyl, n-hexyl, iso-hexyl, etc.
The term C~_~ alkylene, where n may have a value of 1 to 8, denotes a saturated, branched or unbranched hydrocarbon bridge with 1 to n C atoms. Examples of such groups include methyiene (-CH2-), ethylene (-CH2-CH2-), 1-methyl-ethylene (-CH(CH3)-CH2-), 1,1-dimethyl-ethylene (-C(CH3)2-CH2-), n-prop-1,3-ylene (-CHZ-CH2-CHZ-), 1-methylprop-1,3-ylene (-CH(CH3)-CHZ-CHZ-), 2-methylprop-1,3-ylene (-CH2-CH(CH3)-CH2-), etc., as well as the corresponding mirror-symmetrical forms.
The term C2_~ alkenyl, where n has a value of 3 to 6, denotes a branched or unbranched hydrocarbon group with 2 to n C atoms and at least one C=C-double bond.
Examples of such groups include vinyl, 1-propenyi, 2-propenyi, iso-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl-1-propenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 3-methyl-2-butenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl etc.
The term C2_~ alkynyl, where n has a value of 3 to 6, denotes a branched or unbranched hydrocarbon group with 2 to n C atoms and a C---C triple bond. Examples of such groups include ethynyl, 1-propynyl, 2-propynyl, iso-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 2-methyl-1-propynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 3-methyl-2-butynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl etc.
The term C~_~ alkoxy denotes a C,_~ alkyl-O- group, wherein C~_~-alkyl is defined as above.
Examples of such groups include methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, iso-pentoxy, neo-pentoxy, tert-pentoxy, n-hexoxy, iso-hexoxy etc.
The term C,_~ aikylthio denotes a C,_~ alkyl-S- group, wherein C,_~ alkyl is defined as above.
Examples of such groups include methylthio, ethylthio, n-propylthio, iso-propylthio, n-butylthio, iso-butylthio, sec-butylthio, tent-butylthio, n-pentylthio, iso-pentylthio, neo-pentylthio, tert-pentylthio, n-hexylthio, iso-hexylthio, etc.
The term C~_~ alkylcarbonyl denotes a C~_~-alkyl -C(=O)- group, wherein C,_~
alkyl is defined as above. Examples of such groups include methylcarbonyl, ethylcarbonyl, n-propylcarbonyl, iso-propylcarbonyi, n-butylcarbonyl, iso-butylcarbonyl, sec-butylcarbonyl, tert-butylcarbonyl, n-pentylcarbonyl, iso-pentylcarbonyl, neo-pentylcarbonyl, tert-pentylcarbonyl, n-hexylcarbonyl, iso-hexylcarbonyl, etc.
The term C3_"-cycloalkyl denotes a saturated mono-, bi-, tri- or spirocarbocyclic, preferably monocarbocyclic group with 3 to n C atoms. Examples of such groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclododecyl, bicyclo[3,2,1]octyl, spiro[4,5]decyl, norpinyl, norbonyl, norcaryl, adamantyl, etc.
The term C5_~-cycloalkenyl denotes a monounsaturated mono-, bi-, tri- or spirocarbocyclic, preferably monocarboxylic group with 5 to n C atoms. Examples of such groups include cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclononenyl, etc.
The term C3_~ cycloalkylcarbonyl denotes a C3_~ cycloalkyl-C(=O) group, wherein C3_~
cycloalkyl is as hereinbefore defined.
The term aryl denotes a carbocyclic, aromatic ring system, such as for example phenyl, biphenyl, naphthyl, anthracenyl, phenanthrenyl, fluorenyl, indenyl, pentalenyl, azulenyl, biphenylenyl, etc. A particularly preferred meaning of "aryl" is phenyl.
The term cyclo-C3~-alkyleneimino denotes a 4- to 7-membered ring which comprises 3 to 6 methylene units as well as an imino group, while the bond to the residue of the molecule is made via the imino group.
The term cyclo-C3~-alkyleneimino-carbonyl denotes a cyclo-C3_6-alkyleneimino ring as hereinbefore defined which is linked to a carbonyl group via the imino group.
The term heteroaryl used in this application denotes a heterocyclic, aromatic ring system which comprises in addition to at least one C atom one or more heteroatorns selected from N, O and/or S. Examples of such groups are furanyl, thiophenyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, isoxazolyl, isothiazolyl, 1,2,3-triazolyl, 1,3,5-triazolyl, pyranyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, tetrazolyl, thiadiazinyl, indolyl, isoindolyl, benzofuranyl, benzothiophenyl (thianaphthenyl), indazolyl, benzimidazolyl, benzthiazolyl, benzisothiazolyl, benzoxazolyl, benzisoxazolyl, purinyl, quinazolinyl, quinozilinyl, quinolinyl, isoquinolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, azepinyl, diazepinyl, acridinyl, etc. The term heteroaryl also comprises the partially hydrogenated heterocyclic, aromatic ring systems, particularly those listed above. Examples of such partially hydrogenated ring systems are 2,3-dihydrobenzofuranyl, pyrolinyl, pyrazolinyl, indolinyl, oxazolidinyl, oxazolinyl, oxazepinyl, etc.
Particularly preferably heteroaryl denotes a heteroaromatic mono- or bicyclic ring system.
Terms such as C3_,-cycloalkyl-C~_~ alkyl, heteroaryl-C,_~ alkyl, etc. refer to C,_~ alkyl, as defined above, which is substituted with a C3_~-cycloalkyl, aryl or heteroaryl group.
Many of the terms given above may be used repeatedly in the definition of a formula or group and in each case have one of the meanings given above, independently of one another.
Thus, for example, in the group di-C~_4-alkyl-amino, the two alkyl groups may have the same or different meanings.
The term "unsaturated", for example in "unsaturated carbocyclic group" or "unsaturated heterocyclic group", as used particularly in the definition of the group Cy, comprises in addition to the mono- or polyunsaturated groups, the corresponding, totally unsaturated groups, but particularly the mono- and diunsaturated groups.
The term "optionally substituted" used in this application indicates that the group thus designated is either unsubstituted or mono- or polysubstituted by the substituents specified. If the group in question is polysubstituted, the substituents may be identical or different.
The style used hereinbefore and hereinafter, according to which in a cyclic group a bond of a substituent is shown towards the centre of this cyclic group, indicates unless otherwise stated that this substituent may be bound to any free position of the cyclic group carrying an H atom.
R2ols Thus in the example the substituent R2° where s = 1 may be bound to any of the free positions of the phenyl ring;
where s = 2 selected substituents R2° may independently of one another be bound to different free positions of the phenyl ring.
The H atom of any carboxy group present or an H atom bound to an N atom (imino or amino group) may in each case be replaced by a group which can be cleaved in vivo.
By a group which can be cleaved in vivo from an N atom is meant, for example, a hydroxy group, an acyl group such as the benzoyl or pyridinoyl group or a C,_,s-alkanoyl group such as the formyl, acetyl, propionyl, butanoyl, pentanoyl or hexanoyl group, an allyloxycarbonyl group, a C,_,s-alkoxycarbonyl group such as the methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, tert.butoxycarbonyl, pentoxycarbonyl, hexyloxycarbonyl, octyloxycarbonyl, nonyloxycarbonyl, decyloxycarbonyl, undecyloxycarbonyl, dodecyloxycarbonyl or hexadecyloxycarbonyl group, a phenyl-C,_s-alkoxycarbonyl group such as the benzyloxycarbonyl, phenylethoxycarbonyl or phenylpropoxycarbonyl group, a C,_3-alkylsulphonyl-C2_4-alkoxycarbonyl, C,_3-alkoxy-C2_4-alkoxy-C2~-alkoxycarbonyl or ReCO-O-(RfCRg)-O-CO- group wherein Re denotes a C,_$-alkyl, C5_~-cycloalkyl, phenyl or phenyl- C,_3-alkyl group, Rf denotes a hydrogen atom, a C,_3-alkyl, C5_~-cycloalkyl or phenyl group and R9 denotes a hydrogen atom, a C,_3-alkyl or ReCO-O-(RfCRg)-O-group wherein Re to R9 are as hereinbefore defined, while the phthalimido group is an additional possibility for an amino group, and the above-mentioned ester groups may also be used as a group which can be converted in vivo into a carboxy group.
The residues and substituents described above may be mono- or polysubstituted by fluorine as described. Preferred fluorinated alkyl groups are fluoromethyl, difluoromethyl and trifluoromethyl. Preferred fluorinated alkoxy groups are fluoromethoxy, difluoromethoxy and trifluoromethoxy. Preferred fluorinated alkylsulphinyl and alkylsulphonyl groups are trifluoromethylsulphinyl and trifluoromethylsulphonyl.
The compounds of general formula I according to the invention may have acid groups, predominantly carboxyl groups, and/or basic groups such as e.g. amino functions.
Compounds of general formula I may therefore be present as internal salts, as salts with pharmaceutically useable inorganic acids such as hydrochloric acid, sulphuric acid, phosphoric acid, sulphonic acid or organic acids (such as for example malefic acid, fumaric acid, citric acid, tartaric acid or acetic acid) or as salts with pharmaceutically useable bases such as alkali or alkaline earth metal hydroxides or carbonates, zinc or ammonium hydroxides or organic amines such as e.g. diethylamine, triethylamine, triethanolamine inter alia.
The compounds according to the invention may be obtained using methods of synthesis which are known in principle. Preferably the compounds are obtained analogously to the methods of preparation explained more fully hereinafter.
The two reaction plans A and B that follow show the synthesis of the compounds A.5 and B.5 according to the invention, while R', R2, X, Y, Z, W, A and B have one of the meanings described hereinbefore. Hal denotes chlorine, bromine or iodine, particularly bromine or iodine, particularly preferably iodine.
According to reaction plan A the halogen compound A.1 is reacted with the alkyne compound A.2 in a molar ratio of about 1.5 : 1 to 1 : 1.5 under a protective has atmosphere in the presence of a suitable palladium catalyst, a suitable base and copper(I)iodide in a suitable solvent.
A preferred amount of copper(I)iodide is in the range from 1 to 15 mol%, particularly 5 to 10 mol% based on the educt A.1.
Suitable palladium catalysts are for example Pd(PPh3)4, Pd2(dba)3, Pd(OAc)2, Pd(PPh3)2CIz, Pd(CH3CN)2CI2, Pd(dppf)CIz. The palladium catalyst is preferably used in an amount from 1 to 15 mol%, particularly 5 to 10 mol% based on the educt A.1.
Suitable bases are particularly amines, such as for example triethylamine or ethyldiisopropylamine, as well as Cs2C03. The base is preferably used in an at least equimolar amount based on the educt A.1, in excess or as the solvent.
Moreover, suitable solvents are dimethylformamide or ether, such as for example tetrahydrofuran, including the mixtures thereof. The reaction takes place over a period of about 2 to 24 hours in a temperature range of about 20 to 90°C.
The alkyne compound A.3 obtained is reacted directly or after prior purification with methanesulphonic acid chloride to form the methanesulphonate derivative A.4.
The reaction conditions required are known to the skilled man as such. Advantageous solvents are halogenated hydrocarbons, such as for example dichloromethane. Suitable reaction temperatures are usually in the range from 0 to 30°C.
The reaction solution containing the methanesulphonate derivative A.4 or the purified methanesulphonate derivative A.4, dissolved in a suitable solvent, is reacted with an amine H-NR'R2 to yield the end product A.5 and then optionally purified. If the amine H-NR'RZ has another primary or secondary amino function, this is advantageously provided with a protective group beforehand, which can be cleaved again after the reaction has ended, using methods known from the literature. The product thus obtained may for example be converted into the salt form by reaction with a corresponding acid. A preferred molar ratio of the derivative A.4 to the amine compound is in the range from 1.5 : 1 to 1 : 1.5.
Suitable solvents are dimethylformamide or ether, such as for example tetrahydrofuran, including the mixtures thereof.
The reaction to form the product A.5 is advantageously carried out in a temperature range from about 20 to 90°C.
Reaction plan A:
HO-X-Y-Hal + H-C=C-W-A-B
(A.1 ) (A.2) Cul [Pd]
HO-X-Y-C=C-W-A-B (A.3) MsCI
Ms0-X-Y-C=C-W-A-B (A.4) HNR'R2 R' RzN- X-Y-C -C-W-A-B (A.5) According to reaction plan B the halogen compound B.2 is reacted with the alkyne compound B.1 in a molar ratio of about 1.5 : 1 to 1 : 1.5 under a protective gas atmosphere in the presence of a suitable palladium catalyst, a suitable base and copper(I)iodide in a suitable solvent. Information on suitable reaction conditions, including catalysts, bases and solvents, may be found in the explanations of reaction plan A.
The alkyne compound B.3 obtained is reacted directly, or after prior purification, with methanesulphonic acid chloride to form the methanesulphonate derivative B.4.
The reaction conditions to be respected can again be found in the remarks accompanying Diagram A.
The reaction solution containing the methanesulphonate derivative B.4 or the purified methanesulphonate derivative B.4, dissolved in a suitable solvent, is reacted with an amine H-NR'R2 to form the end product B.5 and then optionally purified. Here again, the remarks concerning Diagram A apply.
Reaction plan B:
HO-X-Y-Z- C=C-H + Hal-A-B
(B.1 ) (B.2) Cul [Pd]
HO-X-Y-Z- C=C-A-B (B.3) MsCI
Ms0-X-Y-Z-C=C-A-B (B.4) HNR~R2 R1R2N-X-Y-Z-C-C-A-B (B.5) According to the other reaction plan C the halogen compound C.1 is reacted with the alkyne compound C.2 in a molar ratio of about 1.5 : 1 to 1 : 1.5 under a protective gas atmosphere in the presence of a suitable palladium catalyst, a suitable base and copper(I)iodide in a suitable solvent to form the product C.3 directly. Information on suitable reaction conditions, including catalysts, bases and solvents, may be found in the explanatory remarks accompanying reaction plan A.
Reaction plan C:
R' R2N- X-Y-Hal + H-C=C-W-A-B
(C.1 ) (C.2) Cul [Pd]
R~R2N- X-Y-C-C-W-A-B (C.3) An alternative method of synthesis to this is shown in reaction plan D.
According to this, the halogen compound D.2 is reacted with the alkyne compound D.1 in a molar ratio of about 1.5 1 to 1 : 1.5 under a protective gas atmosphere in the presence of a suitable palladium catalyst, a suitable base and copper(I)iodide in a suitable solvent to form the product D.3 directly. Once again, information on suitable reaction conditions, including catalysts, bases and solvents, may be found in the explanatory remarks accompanying reaction plan A.
Reaction plan D:
R'R2N-X-Y-Z- C-C-H + Hal-A-B
(D.1 ) (D.2) Cul [Pd]
R~RZN-X-Y-Z- C-C-A-B (D.3) The reactions according to plans A, B, C and D are particularly advantageously carried out with the corresponding iodine compounds A.1, B.2, C.1 and D.2. In the event that Hal denotes bromine in compounds A.1, B.2, C.1 or D.2, it is advantageous to convert it into the corresponding iodine compound beforehand. One particularly advantageous method is the Aryl-Finkelstein reaction (Klapars, Artis; Buchwald, Stephen L.. Copper-Catalyzed Halogen Exchange in Aryl Halides: An Aromatic Finkelstein Reaction. Journal of the American Chemical Society (2002), 124(50), 14844-14845). Thus, for example, the halogen compound A.1, B.2, C.1 or D.2 may be reacted with sodium iodide in the presence of N, N'-dimethyl-ethylenediamine and copper(I)iodide in a suitable solvent to form the corresponding iodine compound. An advantageous molar ratio of the halogen compound to sodium iodide is 1 : 1.8 to 1 : 2.3. N, N'-dimethyl-ethylenediamine is advantageously used in a molar ratio of 10 to 30 mol% based on the halogen compound A.1, B.2, C.1 or D.2. Preferred amounts of copper(I)iodide are in the range from 5 to 20 mol% based on the halogen compound A.1, B.2, C.1 or D.2. A suitable solvent is for example 1,4-dioxane. Suitable reaction temperatures are in the range from about 20 to 110°C. The reaction is substantially complete after 2 to 72 hours.
The compounds according to the invention may be obtained using methods of synthesis which are known in principle. Preferably the compounds are obtained analogously to the methods of preparation explained more fully in the experimental section.
Stereoisomeric compounds of formula (I) may chiefly be separated by conventional methods.
The diastereomers are separated on the basis of their different physico-chemical properties, e.g. by fractional crystallisation from suitable solvents, by high pressure liquid or column chromatography, using chiral or preferably non-chiral stationary phases.
Racemates covered by general formula (I) may be separated for example by HPLC
on suitable chiral stationary phases (e.g. Chiral AGP, Chiralpak AD). Racemates which contain a basic or acidic function can also be separated via the diastereomeric, optically active salts which are produced on reacting with an optically active acid, for example (+) or (-)-tartaric acid, (+) or (-)-diacetyl tartaric acid, (+) or (-)-monomethyl tartrate or (+)-camphorsulphonic acid, or an optically active base, for example with (R)-(+)-1-phenylethylamine, (S)-(-)-1-phenylethylamine or (S)-brucine.
According to a conventional method of separating isomers, the racemate of a compound of formula (I) is reacted with one of the above-mentioned optically active acids or bases in equimolar amounts in a solvent and the resulting crystalline, diastereomeric, optically active salts thereof are separated using their different solubilities. This reaction may be carried out in any type of solvent provided that it is sufficiently different in terms of the solubility of the salts.
Preferably, methanol, ethanol or mixtures thereof, for example in a ratio by volume of 50:50, are used. Then each of the optically active salts is dissolved in water, carefully neutralised with a base such as sodium carbonate or potassium carbonate, or with a suitable acid, e.g.
with dilute hydrochloric acid or aqueous methanesulphonic acid and in this way the corresponding free compound is obtained in the (+) or (-) form.
The (R) or (S) enantiomer alone or a mixture of two optically active diastereomeric compounds of general formula (I) may also be obtained by performing the syntheses described above with a suitable reaction component in the (R) or (S) configuration.
As already mentioned, the compounds of formula (I) may be converted into the salts thereof, particularly for pharmaceutical use into the physiologically and pharmacologically acceptable salts thereof. These salts may be present on the one hand as physiologically and pharmacologically acceptable acid addition salts of the compounds of formula (I) with inorganic or organic acids. On the other hand, in the case of acidically bound hydrogen, the compound of formula (I) may also be converted by reaction with inorganic bases into physiologically and pharmacologically acceptable salts with alkali or alkaline earth metal cations as counter-ion. The acid addition salts may be prepared, for example, using hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, ethanesulphonic acid, toluenesulphonic acid, benzenesulphonic acid, acetic acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or malefic acid.
Moreover, mixtures of the above mentioned acids may be used. To prepare the alkali and alkaline earth metal salts of the compound of formula (I) with acidically bound hydrogen the alkali and alkaline earth metal hydroxides and hydrides are preferably used, while the hydroxides and hydrides of the alkali metals, particularly of sodium and potassium, are preferred and sodium and potassium hydroxide are most preferred.
The compounds according to the present invention, including the physiologically acceptable salts, are effective as antagonists of the MCH receptor, particularly the MCH-1 receptor, and exhibit good affinity in MCH receptor binding studies. Pharmacological test systems for MCH-antagonistic properties are described in the following experimental section.
As antagonists of the MCH receptor the compounds according to the invention are advantageously suitable as pharmaceutical active substances for the prevention and/or treatment of symptoms and/or diseases caused by MCH or causally connected with MCH in some other way. Generally the compounds according to the invention have low toxicity, they are well absorbed by oral route and have good intracerebral transitivity, particularly brain accessibility.
Therefore, MCH antagonists which contain at least one compound according to the invention are particularly suitable in mammals, such as for example rats, mice, guinea pigs, hares, dogs, cats, sheep, horses, pigs, cattle, monkeys and humans, for the treatment and/or prevention of symptoms and/or diseases which are caused by MCH or are otherwise causally connected with MCH.
Diseases caused by MCH or otherwise causally connected with MCH are particularly metabolic disorders, such as for example obesity, and eating disorders, such as for example bulimia, including bulimia nervosa. The indication obesity includes in particular exogenic obesity, hyperinsulinaemic obesity, hyperplasmic obesity, hyperphyseal adiposity, hypoplasmic obesity, hypothyroid obesity, hypothalamic obesity, symptomatic obesity, infantile obesity, upper body obesity, alimentary obesity, hypogonadal obesity, central obesity. This range of indications also includes cachexia, anorexia and hyperphagia.
Compounds according to the invention may be particularly suitable for reducing hunger, curbing appetite, controlling eating behaviour and/or inducing a feeling of satiation.
In addition, the diseases caused by MCH or otherwise causally connected with MCH also include hyperlipidaemia, cellulitis, fatty accumulation, malignant mastocytosis, systemic mastocytosis, emotional disorders, affectivity disorders, depression, anxiety states, reproductive disorders, sexual disorders, memory disorders, epilepsy, forms of dementia and hormonal disorders.
Compounds according to the invention are also suitable as active substances for the prevention and/or treatment of other illnesses and/or disorders, particularly those which accompany obesity, such as for example diabetes, diabetes mellitus, particularly type II
diabetes, hyperglycaemia, particularly chronic hyperglycaemia, complications of diabetes including diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, etc., insulin resistance, pathological glucose tolerance, encephalorrhagia, cardiac insufficiency, cardiovascular diseases, particularly arteriosclerosis and high blood pressure, arthritis and gonitis.
MCH antagonists and formulations according to the invention may advantageously be used in combination with a dietary therapy, such as for example a dietary diabetes treatment, and exercise.
Another range of indications for which the compounds according to the invention are advantageously suitable is the prevention and/or treatment of micturition disorders, such as for example urinary incontinence, hyperactive bladder, urgency, nycturia, enuresis, while the hyperactive bladder and urgency may or may not be connected with benign prostatic hyperplasia.
Generally speaking, the compounds according to the invention are potentially suitable for preventing and/or treating dependencies, such as for example alcohol and/or nicotine dependency, and/or withdrawal symptoms, such as for example weight gain in smokers coming off nicotine. By "dependency" is generally meant here an irresistible urge to take an addictive substance and/or to perform certain actions, particularly in order to either achieve a feeling of well-being or to eliminate negative emotions. In particular, the term "dependency" is used here to denote a dependency on an addictive substance. By "withdrawal symptoms" are meant here, in general, symptoms which occur or may occur when addictive substances are withdrawn from patients dependent on one or more such substances. The compounds according to the invention are potentially suitable particularly as active substances for reducing or ending tobacco consumption, for the treatment or prevention of a nicotine dependency and/or for the treatment or prevention of nicotine withdrawal symptoms, for reducing the craving for tobacco and/or nicotine and generally as an anti-smoking agent. The compounds according to the invention may also be useful for preventing or at least reducing the weight gain typically seen when smokers are coming oft nicotine. The substances may also be suitable as active substances which prevent or at least reduce the craving for and/or relapse into a dependency on addictive substances. The term addictive substances refers particularly but not exclusively to substances with a psycho-motor activity, such as narcotics or drugs, particularly alcohol, nicotine, cocaine, amphetamine, opiates, benzodiazepines and barbiturates.
The dosage required to achieve such an effect is conveniently, by intravenous or sub-cutaneous route, 0.001 to 30 mg/kg of body weight, preferably 0.01 to 5 mg/kg of body weight, and by oral or nasal route or by inhalation, 0.01 to 50 mg/kg of body weight, preferably 0.1 to 30 mg/kg of body weight, in each case 1 to 3 x daily.
For this purpose, the compounds prepared according to the invention may be formulated, optionally in conjunction with other active substances as described hereinafter, together with one or more inert conventional carriers and/or diluents, e.g. with corn starch, lactose, glucose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethylene glycol, propylene glycol, cetylstearyl alcohol, carboxymethylcellulose or fatty substances such as hard fat or suitable mixtures thereof, to produce conventional galenic preparations such as plain or coated tablets, capsules, lozenges, powders, granules, solutions, emulsions, syrups, aerosols for inhalation, ointments or suppositories.
In addition to pharmaceutical compositions the invention also includes compositions containing at least one alkyne compound according to the invention and/ or a salt according to the invention optionally together with one or more physiologically acceptable excipients.
Such compositions may also be for example foodstuffs which may be solid or liquid, in which the compound according to the invention is incorporated.
For the above mentioned combinations it is possible to use as additional active substances particularly those which for example potentiate the therapeutic effect of an MCH antagonist according to the invention in terms of one of the indications mentioned above and/or which make it possible to reduce the dosage of an MCH antagonist according to the invention.
Preferably one or more additional active substances are selected from among - active substances for the treatment of diabetes, - active substances for the treatment of diabetic complications, active substances for the treatment of obesity, preferably other than MCH
antagonists, - active substances for the treatment of high blood pressure, - active substances for the treatment of hyperlipidaemia, including arteriosclerosis, active substances for the treatment of dyslipidaemia, including arteriosclerosis, - active substances for the treatment of arthritis, - active substances for the treatment of anxiety states, - active substances for the treatment of depression.
The above mentioned categories of active substances will now be explained in more detail by means of examples.
Examples of active substances for the treatment of diabetes are insulin sensitisers, insulin secretion accelerators, biguanides, insulins, a-glucosidase inhibitors, (33 adreno-receptor agonists.
Insulin sensitisers include glitazones, particularly pioglitazone and its salts (preferably hydrochloride), troglitazone, rosiglitazone and its salts (preferably maleate), JTT-501, GI-262570, MCC-555, YM-440, DRF-2593, BM-13-1258, KRP-297, R-119702 and GW-1929.
Insulin secretion accelerators include sulphonylureas, such as for example tolbutamide, chloropropamide, tolazamide, acetohexamide, glyclopyramide and its ammonium salts, glibenclamide, gliclazide, glimepiride. Further examples of insulin secretion accelerators are repaglinide, nateglinide, mitiglinide (KAD-1229) and JTT-608.
Biguanides include metformin, buformin and phenformin.
3o Insulins include those obtained from animals, particularly cattle or pigs, semisynthetic human insulins which are synthesised enzymatically from insulin obtained from animals, human insulin obtained by genetic engineering, e.g. from Escherichi coli or yeasts.
Moreover, the term insulin also includes insulin-zinc (containing 0.45 to 0.9 percent by weight of zinc) and protamine-insulin-zinc obtainable from zinc chloride, protamine sulphate and insulin. Insulin may also be obtained from insulin fragments or derivatives (for example INS-1, etc.).
Insulin may also include different kinds, e.g. with regard to the onset time and duration of effect ("ultra immediate action type", "immediate action type", "two phase type", "intermediate type", "prolonged action type", etc.), which are selected depending on the pathological condition of the patient.
a-Glucosidase inhibitors include acarbose, voglibose, miglitol, emiglitate.
X33 Adreno receptor agonists include AJ-9677, BMS-196085, SB-226552, AZ40140.
Active substances for the treatment of diabetes other than those mentioned above include ergoset, pramlintide, leptin, BAY-27-9955 as well as glycogen phosphorylase inhibitors, sorbitol dehydrogenase inhibitors, protein tyrosine phosphatase 1 B inhibitors, dipeptidyl protease inhibitors, glipazide, glyburide.
Active substances for the treatment of diabetic complications include for example aldose reductase inhibitors, glycation inhibitors and protein kinase C inhibitors, DPPIV blockers, GLP-1 or GLP-2 analogues and SGLT-2 inhibitors.
Aldose reductase inhibitors are for example tolrestat, epalrestat, imirestat, zenarestat, SNK-860, zopolrestat, ARI-50i, AS-3201.
An example of a glycation inhibitor is pimagedine.
Protein Kinase C inhibitors are for example NGF, LY-333531.
DPPIV blockers are for example LAF237 (Novartis), MK431 (Merck) as well as 815541, 823093 and 825964 (all GIaxoSmithkline).
GLP-1 analogues are for example Liraglutide (NN2211 ) (NovoNordisk), CJC1131 (Conjuchem), Exenatide (Amylin).
SGLT-2 inhibitors are for example AVE-2268 (Aventis) and T-1095 (Tanabe, Johnson&Johnson).
Active substances other than those mentioned above for the treatment of diabetic complications include alprostadil, thiapride hydrochloride, cilostazol, mexiletine hydrochloride, ethyl eicosapentate, memantine, pimagedine (ALT-711 ).
Active substances for the treatment of obesity, preferably other than MCH
antagonists, include lipase inhibitors and anorectics.
A preferred example of a lipase inhibitor is orlistat.
Examples of preferred anorectics are phentermine, mazindol, dexfenfluramine, fluoxetine, sibutramine, baiamine, (S)-sibutramine, SR-141716, NGD-95-1.
Active substances other than those mentioned above for the treatment of obesity include lipstatin.
Moreover, for the purposes of this application, the active substance group of anti-obesity active substances also includes the anorectics, of which the (33 agonists, thyromimetic active substances and NPY antagonists should be emphasised. The range of substances which may be considered as preferred anti-obesity or anorectic active substances is indicated by the following additional list, by way of example:
phenylpropanolamine, ephedrine, pseudoephedrine, phentermine, a cholecystokinin-A
(hereinafter referred to as CCK-A) agonist, a monoamine reuptake inhibitor (such as for example sibutramine), a sympathomimetic active substance, a serotonergic active substance (such as for example dexfenfluramine, fenfluramine, a 5-HT2C agonist such as BVT.933 or APD356, or duloxetine), a dopamine antagonist (such as for example bromocriptine or pramipexol), a melanocyte-stimulating hormone receptor agonist or mimetic, an analogue of melanocyte-stimulating hormone, a cannabinoid receptor antagonist (Rimonabant, ACOMPLIA TM), an MCH antagonist, the OB protein (hereinafter referred to as leptin), a leptin analogue, a fatty acid synthase (FAS) antagonist, a leptin receptor agonist, a galanine antagonist, a GI lipase inhibitor or reducer (such as for example orlistat). Other anorectics include bombesin agonists, dehydroepiandrosterone or its analogues, glucocorticoid receptor agonists and antagonists, orexin receptor antagonists, urocortin binding protein antagonists, agonists of the Glucagon-like Peptide-1 receptor, such as for example exendin, AC 2993, CJC-1131, ZP10 or GRT0203Y, DPPIV inhibitors and ciliary neurotrophic factors, such as for example axokines. In this context mention should also be made of the forms of therapy which produce weight loss by increasing the fatty acid oxidation in the peripheral tissue, such as for example inhibitors of acetyl-CoA carboxylase.
Active substances for the treatment of high blood pressure include inhibitors of angiotensin converting enzyme, calcium antagonists, potassium channel openers and angiotensin II
antagonists.
Inhibitors of angiotensin converting enzyme include captopril, enalapril, alacepril, delapril (hydrochloride), lisinopril, imidapril, benazepril, cilazapril, temocapril, trandolapril, manidipine (hydrochloride).
Examples of calcium antagonists are nifedipine, amlodipine, efonidipine, nicardipine.
Potassium channel openers include levcromakalim, L-27152, AL0671, NIP-121.
Angiotensin II antagonists include telmisartan, losartan, candesartan cilexetil, valsartan, irbesartan, CS-866, E4177.
Active substances for the treatment of hyperlipidaemia, including arteriosclerosis, include HMG-CoA reductase inhibitors, fibrate compounds.
HMG-CoA reductase inhibitors include pravastatin, simvastatin, lovastatin, atorvastatin, fluvastatin, lipantil, cerivastatin, itavastatin, ZD-4522 and their salts.
Fibrate compounds include bezafibrate, clinofibrate, clofibrate and simfibrate.
Active substances for the treatment of dyslipidaemia, including arteriosclerosis, include e.g.
medicaments which raise the HDL level, such as e.g. nicotinic acid and derivatives and preparations thereof, such as e.g. niaspan, as well as agonists of the nicotinic acid receptor.
Active substances for the treatment of arthritis include NSAIDs (non-steroidal antiinflammatory drugs), particularly COX2 inhibitors, such as for example meloxicam or ibuprofen.
Active substances for the treatment of anxiety states include chlordiazepoxide, diazepam, oxozolam, medazepam, cloxazolam, bromazepam, lorazepam, alprazolam, fludiazepam.
Active substances for the treatment of depression include fluoxetine, fluvoxamine, imipramine, paroxetine, sertraline.
The dosage for these active substances is conveniently 1/5 of the lowest normal recommended dose up to 1/1 of the normal recommended dose.
In another embodiment the invention also relates to the use of at least one alkyne compound according to the invention and/ or a salt according to the invention for influencing the eating behaviour of a mammal. This use is particularly based on the fact that compounds according to the invention may be suitable for reducing hunger, curbing appetite, controlling eating behaviour and/or inducing a feeling of satiety. The eating behaviour is advantageously influenced so as to reduce food intake. Therefore, the compounds according to the invention are advantageously used for reducing body weight. Another use according to the invention is the prevention of increases in body weight, for example in people who had previously taken steps to lose weight and are interested in maintaining their lower body weight. According to this embodiment it is preferably a non-therapeutic use. Such a non-therapeutic use might be a cosmetic use, for example to alter the external appearance, or an application to improve general health. The compounds according to the invention are preferably used non-therapeutically for mammals, particularly humans, not suffering from any diagnosed eating disorders, no diagnosed obesity, bulimia, diabetes and/or no diagnosed micturition disorders, particularly urinary incontinence. Preferably, the compounds according to the invention are suitable for non-therapeutic use in people whose BMI (body mass index), defined as their body weight in kilograms divided by their height (in metres) squared, is below a level of 30, particularly below 25.
The Examples that follow are intended to illustrate the invention:
Preliminary remarks As a rule, IR, 1 H-NMR and/or mass spectra have been obtained for the compounds prepared.
Unless otherwise stated the Rf values were determined using ready-made silica gel 60 TLC
plates F254 (E. Merck, Darmstadt, Item no. 1.05714) without chamber saturation. The Rf values obtained under the heading Alox were determined using ready-made aluminium oxide 60 TLC plates F254 (E. Merck, Darmstadt, Item no. 1.05713) without chamber saturation.
For chromatographic purification, silica gel made by Messrs Millipore (MATREXTM, 35-70 my) or Alox (E. Merck, Darmstadt, standardised aluminium oxide 90, 63-200 Nm, Item No.:
1.01097.9050) is used. The ratios specified for the eluants are based on units by volume of the solvents in question.
The specified units by volume of NH3 solutions relate to a concentrated solution of NH3 in water. Unless otherwise stated the acid, base and salt solutions used for working up the reaction solutions are aqueous systems of the concentrations specified.
In the asymmetric dihydroxylations the "AD-Mix Alpha" (item number: 39,275-8) and "AD-Mix-Beta" (item number: 39,276-6) sold by Messrs Aldrich are used.
The HPLC data specified were measured under the parameters indicated below:
Analytical columns: Zorbax column (Agilent Technologies), SB (Stable Bond) C18; 3.5 pm;
4.6 x 75 mm; column temperature: 30°C; flow: 0.8 mL / min; injection volume: 5 NL; detection at 254 nm (methods A, B, C and D).
Method A:
time (min) percent by volume of percent by volume of acetonitrile water (with 0.1 % formic acid) (with 0.1 % formic acid) Method B:
time (min) percent by volume of percent by volume of acetonitrile water (with 0.1 % formic acid) (with 0.1 % formic acid) 10_ 10 90 Method C:
time (min) percent by volume of percent by volume of acetonitrile water (with 0.1 % formic acid) (with 0.1 % formic acid) Method D:
time (min) percent by volume of waterpercent by volume of acetonitrile (with 0.1% formic acid) (with 0.1% formic acid) Analytical columns: Zorbax column (Agilent Technologies), Bonus RP C14; 3.5 Nm; 4.6 x 75 mm; column temperature: 30°C; flow: 0.8 mL / min; injection volume: 5 NL; detection at 254 nm (method E) Method E:
time (min) percent by volume of waterpercent by volume of acetonitrile (with 0.1% formic acid) (with 0.1% formic acid) Preparative column: Zorbax column (Agilent Technologies), SB (Stable Bond) -C18; 3.5 Nm;
10 30 x 100 mm; column temperature: ambient temperature; flow: 30 mL / min;
detection at 254 nm.
In preparative HPLC purification, as a rule the same gradients are used which were used when obtaining the analytical HPLC data.
The products are collected under mass control, the fractions containing the product are combined and freeze-dried.
Temperatures are given in degrees Celsius (°C) ; times are generally given in minutes (min), hours (h) or days (d). If there is no specific information as to the configuration, it is not clear whether there are pure enantiomers or whether partial or even total racemisation has taken place.
The following abbreviations are used above and hereinafter:
abs. absolute CDI carbonyldiimidazole Cyc cyciohexane DCM dichloromethane DIPE diisopropylether DMF dimethylformamide dppf 1,1 '-bis(diphenyiphosphino)ferrocene EtOAc ethyl acetate EtOH ethanol i. vac. in vacuo MeOH methanol MTBE methyl-tert-butylether PE petroleum ether RT ambient temperature (approx. 20°C) TBAF tetrabutylammonium fluoride hydrate THF tetrahydrofuran dil. dilute -a* denotes the bonding site of a group Amine A1 (3S,4R)-4-trifluoromethyl-piperidine-3,4-diol OH
HO
CF3' N~H
A1a 1-benzyl-4-trifluoromethyl-pyridinium chloride A solution of 7.59 mL (65.94 mmol) benzyl chloride in 10 mL acetonitrile is added to a solution of 10.0 g (65.94 mmol) 4-trifluoromethyl-pyridine in 40 mL acetonitrile and the mixture is stirred for 2 h at 80 °C. Another 1.5 mL of benzyl chloride are added and the mixture is stirred for 22 h at 80 °C. The reaction mixture is cooled to RT and combined with MTBE. The precipitate is filtered off, washed with MTBE, dried i. vac. and stored in the desiccator.
Yield: 14.48 g (80% of theoretical) C~3H~~F3N * CI (M= 273.681) Calc.: molpeak (M+H)+: 238 Found: molpeak (M+H)+: 238 A1 b 1-benzyl-4-trifluoromethyl-1,2,3,6-tetrahydro-pyridine 3.0 g (79.36 mmol) NaBHa is added batchwise at 0 °C, with vigorous cooling, to a solution of 14.48 g (52.91 mmol) 1-benzyl-4-trifluoromethyl-pyridinium chloride in 100 mL
EtOH, then the cooling is removed and the reaction mixture is stirred for 1.5 h at 14 °C. While cooling, 50 mL
water and then 50 mL EtOH are added within 30 min. The reaction mixture is stirred for a further 30 min, the suspension formed is filtered and the filtrate is evaporated down i. vac..
Yield: 11.72 g (92% of theoretical) C~3H~4F3N (M= 241.252) Calc.: molpeak (M+H)': 242 Found: molpeak (M+H)+: 242 HPLC-MS: 3.60 min (method B) A1c (3S,4R)-1-benzyl-4-trifluoromethyl-piperidine-3,4-diol 43.80 g AD-Mix-Beta are placed in 3 L tert-butanol/water (1:1 ) and stirred for 20 min at RT.
The mixture is cooled to 0 °C, 2.97 g (31.25 mmol) methanesulphonamide and 7.54 g (31.25 mmol) 1-benzyl-4-trifluoromethyl-1,2,3,6-tetrahydro-pyridine are added, the cooling bath is removed and the mixture is stirred for 8 d at RT. Another 22 g AD-Mix-Beta and 1.5 g methanesulphonamide are added and the mixture is again stirred for 7 d at RT.
11.2 g sodium sulphite are added and the mixture is stirred for 1 h. 200 mL
semisaturated NaHC03 solution are added and the aqueous phase is exhaustively extracted with DCM.
The combined organic phases are dried over Na2S04 and evaporated down i. vac.. The crude product is purified by MPLC-MS (Grom-Sil 120 ODS 4, 10 Nm, gradient 0.15%
formic acid in water / acetonitrile 90:10 --> 10:90 in 10 min.). The eluates are combined, evaporated down i.
vac. and neutralised with 100 mL semisaturated NaHC03 solution. The aqueous phase is extracted with EtOAc, the combined organic phases are dried over Na2S04 and evaporated down i. vac..
Yield: 1.51 g (17% of theoretical) C~3H~6F3N02 (M= 275.267) Calc.: molpeak (M+H)+: 276 Found: molpeak (M+H)+: 276 Rf value: 0.40 (silica gel, Cyc/EtOAc 2:1 ) A1 d (3S,4R)-4-trifluoromethyl-piperidine-3,4-diol A mixture of 1.50 g (5.45 mmol) (3S,4R)-1-benzyl-4-trifluoromethyl-piperidine-3,4-diol and 170 mg Pd/C (10%) in 17 mL MeOH is hydrogenated at RT and 3 bar hydrogen pressure for 5 h. The catalyst is filtered off and the filtrate is evaporated down i. vac..
Yield: 910 mg (90% of theoretical) C6H,oF3N02 (M= 185.144) Calc.: molpeak (M+H)+: 186 Found: molpeak (M+H)+: 186 Rf value: 0.35 (silica gel, EtOAc/MeOH/NH3 7:3:0.3) Amine A2 (3R,4S)-4-trifluoromethyl-piperidine-3,4-diol OH
HO,,, N~H
A2a (3R,4S)-1-benzyl-4-trifluoromethyl-piperidine-3,4-diol The product is obtained analogously to A1 c starting from 5.8 g (24.04 mmol) 1-benzyl-4-trifluoromethyl-1,2,3,6-tetrahydro-pyridine and AD-Mix-Alpha. The crude product is purified by HPLC-MS.
Yield: 1.09 g ( 16% of theoretical) C13H16F3N~2 (M= 275.267) Calc.: molpeak (M+H)+: 276 Found: molpeak (M+H)+: 276 HPLC-MS: 3.70 min (method A) A2b (3R,4S)-4-trifluoromethyl-piperidine-3,4-diol The product is obtained analogously to A1d starting from 1.09 g (3.96 mmol) (3R,4S)-1-benzyl-4-trifluoromethyl-piperidine-3,4-diol, Yield: 665 mg (91 % of theoretical) C6H~oF3N02 (M= 185.144) Calc.: molpeak (M+H)+: 186 Found: molpeak (M+H)+: 186 Rf value: 0.35 (silica gel, EtOAc/MeOH/NH3 7:3:0.3) Amine A3 (3R,4S)-4-methyl-piperidine-3,4-diol OH
HO,,, ~N~H
A3a 1-benzyl-4-methyl-1,2,3,6-tetrahydro-pyridine The product is obtained analogously to A1 b starting from 10.0 g (45.5 mmol) 1-benzyl-4-methyl-pyridinium chloride.
Yield: 7.15 g (84% of theoretical) C~3H"N (M= 187.281 ) Calc.: molpeak (M+H)+: 188 Found: molpeak (M+H)+: 188 Rf value: 0.95 (silica gel, EtOAc/MeOH/NH3 9:1:0.1 ) A3b (3R,4S)-1-benzyl-4-methyl-piperidine-3,4-diol Under a nitrogen atmosphere 14 g AD-Mix-Alpha in 50 mL water and 50 mL tert-butanol are taken and the mixture is stirred for 20 min at RT. Subsequently it is cooled to 0°C, 0.95 g (10.0 mmol) methanesulphonic acid amide and 1.87 g (10.0 mmol) 1-benzyl-4-methyl-1,2,3,6-tetrahydro-pyridine are added, the cooling bath is removed and the reaction mixture is stirred for 24 h at RT. 3.5 g sodium sulphite are added to the reaction mixture and it is stirred for 1 h.
200 mL DCM and 200 mL saturated NaHC03 solution are added, the organic phase is separated off and extracted with 100 mL KHS04 solution. The aqueous phase is made alkaline with saturated K2C03 solution, extracted with 200 mL EtOAc and the organic phase is dried over Na2S04. After the desiccant and solvent have been eliminated the crude product is purified by chromatography (silica gel, EtOAc/MeOH/NH3 19:1:0.1 ).
Yield: 1.23 g (56% of theoretical) C~3H~9N02 (M= 221.296) Calc.: molpeak (M+H)+: 222 Found: molpeak (M+H)+: 222 Rf value: 0.56 (silica gel, EtOAc/MeOH/NH3 19:1:0.1 ) A3c (3R,4S)-4-methyl-piperidine-3,4-diol The product is obtained analogously to A1d starting from 1.23 g (5.57 mmol) (3R,4S)-1-benzyl-4-methyl-piperidine-3,4-diol.
Yield: 730 mg (quant. yield) C6H~3N02 (M= 931.173) Calc.: molpeak (M+H)+: 132 Found: molpeak (M+H)': 132 HPLC-MS: 0.93 min (method C) Amine A4 (3S,4R)-4-methyl-piperidine-3,4-diol OH
HO
NCH
A4a (3S,4R)-1-benzyl-4-methyl-piperidine-3,4-diol The product is obtained analogously to A3b starting from 5.0 g (26.7 mmol) 1-benzyl-4-methyl-1,2,3,6-tetrahydro-pyridine and AD-Mix-Beta.
Yield: 4.68 g (79% of theoretical) C~3H~9N02 (M= 221.296) Calc.: molpeak (M+H)': 222 Found: molpeak (M+H)': 222 Rf value: 0.54 (silica gel, EtOAc/MeOH/NH3 9:1:0.1 ) A4b (3S,4R)-4-methyl-piperidine-3,4-diol The product is obtained analogously to A1d starting from 4.68 g (21.14 mmol) (3S,4R)-1-benzyl-4-methyl-piperidine-3,4-diol.
Yield: 2.33 g (84% of theoretical) C6H~3N02 (M= 131.173) Calc.: molpeak (M+H)+: 132 Found: molpeak (M+H)+: 132 Rf value: 0.05 (silica gel, EtOAc/MeOH/NH3 9:1:0.1 ) Amine A5 (3R,4S)-3-methyl-piperidine-3,4-diol HO
HO,, N
H
A5a 1-benzyl-3-methyl-pyridinium chloride The product is obtained analogously to A1 a starting from 41.8 mL (430 mmol) of 3-methylpyridine.
Yield: 73.8 g (78% of theoretical) C,3H~4N * CI (M= 219.710) Calc.: molpeak (M)+: 184 Found: molpeak (M)+: 184 A5b 1-benzyl-5-methyl-1,2,3,6-tetrahydro-pyridine The product is obtained analogously to A1b starting from 40.0 g (182 mmol) 1-benzyl-3-methyl-pyridinium chloride.
Yield: 14.9 g (44% of theoretical) C,3H»N (M= 187.281 ) Calc.: molpeak (M+H)+: 188 Found: molpeak (M+H)+: 188 Rf value: 0.32 (silica gel, Cyc/EtOAc 4:1 ) A5c (3R,4S)-1-benzyl-3-methyl-piperidine-3,4-diol The product is obtained analogously to A3b starting from 7.5 g (40.0 mmol) 1-benzyl-5-methyl-1,2,3,6-tetrahydro-pyridine and AD-Mix-Alpha.
Yield: 5.73 g (65% of theoretical) C~3H~9N02 (M= 221.296) Calc.: molpeak (M+H)+: 222 Found: molpeak (M+H)+: 222 Rf value: 0.63 (silica gel, EtOAc/MeOH/NH3 9:1:0.1 ) A5d (3R,4S)-3-methyl-piperidine-3,4-diol The product is obtained analogously to A1d starting from 5.73 g (25.9 mmol) (3R,4S)-1-benzyl-3-methyl-piperidine-3,4-diol.
Yield: 3.4 g (quant. yield) C6H~3N02 (M= 131.173) Calc.: molpeak (M+H)+: 132 Found: molpeak (M+H)+: 132 Rf value: 0.05 (silica gel, EtOAc/MeOH/NH3 9:1:0.1 ) Amine A6 (3S,4R)-3-methyl-piperidine-3,4-diol HO
HO
NCH
A6a (3S,4R)-1-benzyl-3-methyl-piperidine-3,4-diol The product is obtained analogously to A3b starting from 7.5 g (40.0 mmol) 1-benzyl-5-methyl-1,2,3,6-tetrahydro-pyridine and AD-Mix-Beta.
Yield: 7.42 g (84% of theoretical) C,3H,9N02 (M= 221.296) Calc.: molpeak (M+H)+: 222 Found: molpeak (M+H)+: 222 Rf value: 0.63 (silica gel, EtOAc/MeOH/NH3 9:1:0.1 ) A6b (3S,4R)-3-methyl-piperidine-3,4-diol The product is obtained analogously to A1d starting from 8.86 g (40.0 mmol) (3S,4R)-1-benzyl-3-methyl-piperidine-3,4-diol.
Yield: 5.03 g (96% of theoretical) C6H~3N02 (M= 131.173) Calc.: molpeak (M+H)+: 132 Found: molpeak (M+H)+: 132 R, value: 0.17 (silica gel, EtOAc/MeOH/NH3 5:5:0.5) Amine A7 (3S,4R)-4-ethyl-piperidine-3,4-diol OH
HO
H
A7a 1-benzyl-4-ethyl-pyridinium chloride The product is obtained analogously to A1a starting from 100 mL (933 mmol) 4-ethylpyridine.
Yield: 143 g (66% of theoretical) C~4H~6N * CI (M= 233.736) Calc.: molpeak (M+H)+: 198 Found: molpeak (M+H)': 198 Rf value: 0.12 (silica gel, EtOAc/MeOH/NH3 9:1:0.1 ) A7b 1-benzyl-4-ethyl-1,2,3,6-tetrahydro-pyridine The product is obtained analogously to A1 b starting from 143 g (614 mmol) 1-benzyl-4-ethyl-pyridinium chloride.
Yield: 99 g (80% of theoretical) C~4H~9N (M= 201.307) Galc.: molpeak (M+H)+: 202 Found: molpeak (M+H)+: 202 Rf value: 0.91 (silica gel, EtOAc/MeOH/NH3 9:1:0.1 ) A7c (3S,4R)-1-benzyl-4-ethyl-piperidine-3,4-diol The product is obtained analogously to A3b starting from 14.37 g (71.4 mmol) 1-benzyl-4-ethyl-1,2,3,6-tetrahydro-pyridine and AD-Mix-Beta.
Yield: 11.46 g (68% of theoretical) C~4H2~NO2 (M= 235.322) Calc.: molpeak (M+H)': 236 Found: molpeak (M+H)+: 236 Rf value: 0.58 (silica gel, EtOAc/MeOH/NH3 95:5:0.5) A7d (3S,4R)-4-ethyl-piperidine-3,4-diol The product may be obtained analogously to A1d starting from (3S,4R)-1-benzyl-4-ethyl-piperidine-3,4-diol.
The enantiomer (3R,4S)-4-ethyl-piperidine-3,4-diol may be obtained analogously to the sequence described.
Amine A8 cis-pyrrolidine-3,4-diol OH
HO~
L,N
H
A8a 1-benzyl-2,5-dihydro-1H pyrrole 14.6 mL (127 mmol) benzyl chloride are added dropwise to a solution of 10 mL
(127 mmol) 2,5-dihydro-1 H-pyrrol in 100 mL acetonitrile, while the reaction mixture heats up to 45°C.
After 1.5 h 300 mL MTBE is added to the suspension, the precipitate is suction filtered and the filtrate is evaporated down. The residue is purified by chromatography (silica gei, EtOAc/MeOH/NH3 19:1:0.1 ).
Yield: 4.0 g (20% of theoretical) C~~H~3N (M= 159.228) Calc.: molpeak (M+H)+: 160 Found: molpeak (M+H)+: 160 Rf value: 0.60 (silica gel, EtOAc/MeOH/NH3 19:1:0.1 ) A8b cis-1-benzyl-pyrrolidine-3,4-diol The product is obtained analogously to A3b starting from 4.0 g (25.1 mmol) 1-benzyl-2,5-dihydro-1 H-pyrrol and AD-Mix-Beta.
Yield: 0.97 g (20% of theoretical) C~,H,SNOz (M= 193.242) Calc.: molpeak (M+H)+: 194 Found: molpeak (M+H)+: 194 R, value: 0.15 (silica gel, EtOAc/MeOH/NH3 9:1:0.1 ) A8c cis-pyrrolidine-3,4-diol The product is obtained analogously to A1d starting from 0.97 g (5.04 mmol) cis-1-benzyl-pyrroiidine-3,4-dioi.
Yield: 0.52 g (quant. yield) C4H9NOz (M= 103.120) Calc.: molpeak (M+H)+: 104 Found: molpeak (M+H)+: 104 Rf value: 0.05 (silica gel, EtOAc/MeOH/NH3 5:5:0.5) Amine A9 (3R,4S)-piperidine-3,4-diol OH
,,OH
., I
H
A9a (3R,4S)-1-benzyl-piperidine-3,4-diol The product is obtained analogously to A3b starting from 8.0 g (46.17 mmol) 1-benzyl-1,2,3,6-tetrahydro-pyridine and AD-Mix-Alpha.
Yield: 6.40 g (67% of theoretical) C,2H~,NOZ (M= 207.269) Calc.: molpeak (M+H)+: 208 Found: molpeak (M+H)+: 208 Rf value: 0.24 (silica gel, EtOAc/MeOH/NH3 9:1:0.1 ) A9b (3R,4S)-piperidine-3,4-diol The product is obtained analogously to A1 d starting from 6.4 g (30.86 mmol) (3R,4S)-1-benzyl-piperidine-3,4-diol.
Yield: 3.83 g (quant. yield) C5H»N02 (M= 117.146) Calc.: molpeak (M+H)': 118 Found: molpeak (M+H)+: 118 Rf value: 0.13 (silica gel, EtOAc/MeOH/NH3 5:5:0.5) Amine A10 (3S,4R)-piperidine-3,4-diol OH
OH
N
i H
A10a (3S,4R)-1-benzyl-piperidine-3,4-diol The product is obtained analogously to A3b starting from 8.0 g (46.17 mmol) 1-benzyl-1,2,3,6-tetrahydro-pyridine and AD-Mix-Beta.
Yield: 6.13 g (64% of theoretical) C~2H»N02 (M= 207.269) Calc.: molpeak (M+H)+: 208 Found: molpeak (M+H)+: 208 Rf value: 0.35 (silica gel, EtOAc/MeOH/NH3 9.1:0.1 ) AlOb (3S,4R)-piperidine-3,4-diol The product is obtained analogously to A1d starting from 6.13 g (29.56 mmol) (3S,4R)-1-benzyi-piperidine-3,4-diol.
Yield: 3.75 g (quant. yield) C5H»N02 (M= 117.146) Calc.: molpeak (M+H);: 118 Found: molpeak (M+H)+: 118 Rf value: 0.12 (silica gel, EtOAc/MeOH/NH3 5:5:0.5) Amine A11 4-hydroxymethyl-piperidin-4-of HO
--~~N-H
Ho A11a 1-benzyl-4-hydroxymethyl-piperidin-4-of The product is obtained analogously to A3b starting from 3.15 g (16.83 mmol) 1-benzyl-4-methylene-piperidine and AD-Mix-Alpha.
Yield: 2.92 g (79% of theoretical) C~3H~9N02 (M= 221.296) Calc.: molpeak (M+H)': 222 Found: molpeak (M+H)+: 222 Rf value: 0.12 (silica gel, EtOAc/MeOH/NH3 9:1:0.1 ) A11 b 4-hydroxymethyl-piperidin-4-of The product is obtained analogously to A1d starting from 2.92 g (13.21 mmol) 1-benzyl-4-hydroxymethyl-piperidin-4-ol.
Yield: 1.88 g (quant. yield) C6H~3N02 (M= 131.173) Calc.: molpeaK (M+H)+: 132 Found: molpeak (M+H)+: 132 Rf value: 0.06 (silica gel, EtOAc/MeOH/NH3 5:5:0.5) Amine A12 (S)-1-pyrrolidin-2-yl-cyclopropanol ~N_H
HO
A12a 1-((S)-1-benzyl-pyrrolidin-2-yl)-cyclopropanol First 6.91 mL (23.57 mmol) titanium(IV)-isopropoxide and then 14.3 mL (42. 9 mmol, 3 M in diethyl ether) ethylmagnesium bromide are slowly added dropwise to a solution of 5.0 g (21.43 mmol) N-benzyl-L-prolinethylester in 80 mL dry diethyl ether cooled to -15°C and the reaction mixture is stirred for 30 min at this temperature. Subsequently 5.4 mL (42.9 mmol) boron trifluoride-diethyl ether complex are added at approx 10°C and the mixture is stirred for a further 75 h at RT. While cooling the mixture is combined with 50 mL of 1 M
NaOH, stirred for 1 h at RT, combined with 100 mL diethyl ether, the organic phase is separated off and dried over NazS04. After the desiccant and solvent have been eliminated the residue is purified by chromatography (silica gel, EtOAc).
Yield: 0.745 g (16% of theoretical) C~aH~sNO (M= 217.307) Calc.: molpeak (M+H)+: 218 Found: molpeak (M+H)+: 218 Rf value: 0.17 (silica gel, EtOAc) A12b (S)-1-pyrrolidin-2-yl-cyclopropanol The product is obtained analogously to A1d starting from 745 mg (3.43 mmol) 1-((S)-1-benzyl-pyrrolidin-2-yl)-cyclopropanol.
Yield: 350 mg (80% of theoretical) C~H~3N0 (M= 127.184) Calc.: molpeak (M+H)+: 128 Found: molpeak (M+H)+: 128 R, value: 0.10 (silica gel, EtOAc/MeOH/NH3 5:5:0.5) Amine A13 (2S,4R~2-hydroxymethyl-pyrrolidine-4-of HO' ~l~'N-H
HO
A13a tert-butyl (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine-1-carboxylate 54 mL (54.0 mmol) borane-THF complex are added dropwise to a solution, cooled to 0°C, of 5.0 g (21.62 mmol) 1-tert-butyl (2S,4R)-4-hydroxy-pyrrolidine-1,2-dicarboxylate in 25 mL dry THF, the reaction mixture is stirred for a further 15 min at 0°C and then for 4 h at RT. While cooling with ice 60 mL MeOH are added, the mixture is stirred for a further 62 h at RT and then evaporated down i. vac.. The residue obtained is purified by chromatography (silica gel, EtOAc/MeOH 19:1 ).
Yield: 4.53 g (96% of theoretical) C~oH~9N04 (M= 217.262) Calc.: molpeak (M+H)+: 218 Found: molpeak (M+H)+: 218 Rf value: 0.50 (silica gel, EtOAc/MeOH 19:1 ) A13b (2S,4R)-2-hydroxymethyl-pyrrolidin-4-of 16.0 mL TFA are added to a solution cooled to 0°C of 4.53 g (20.85 mmol) tert-butyl (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine-1-carboxylate in 200 mL DCM and the reaction mixture is stirred overnight at RT. It is evaporated down i. vac. and the product is freeze-dried. The product is obtained as the trifluoroacetate salt.
Yield: 4.73 g (96% of theoretical) C5H"NOZ''CzHF302 (M= 231.170) Calc.: molpeak (M+H)+: 118 Found: molpeak (M+H)+: 118 Rf value: 0.68 (silica gel, EtOAc/MeOH 9:1 ) Example 1 (3S,4R)-1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-4-trifluoromethyl-piperidine-3,4-diol / c~
off ~ J
HO / N
F "", \
F
F N~ ~ /
O
1a 2-(4-iodo-2-methyl-phenoxy)-ethanol Under an N2 atmosphere 2.34 g (10 mmol) 4-iodo-2-methyl-phenol are added batchwise to a suspension of 0.48 g (11 mmol) NaH in 50 mL THF cooled to 0°C and tmis stirred for a further 30 min at this temperature. Then 0.85 mL (12 mmol) 2-bromoethanol, dissolved in 5 mL THF, are added dropwise and the mixture is stirred for 18 h at RT. 5 mL of DMF are added and the reaction mixture is heated to 70°C for 8 h. It is evaporated down i.
vac., the residue is taken up in water, extracted exhaustively with EtOAc and dried through Na2S04. After the desiccant and solvent have been eliminated the residue is purified by chromatography (silica gel, Cyc/EtOAc 7:3).
Yield: 0.39 g (14% of theoretical) C9H~,lOZ (M= 278.091) Calc.: molpeak (M+H)+: 279 Found: molpeak (M+H)': 279 Rf value: 0.28 (silica gel, Cyc/EtOAc 2:1 ) 1 b 2-(2-methyl-4-trimethylsilanylethynyl-phenoxy)-ethanol ?0 31 mg (0.160 mmol) Cul are added under argon to a degassed solution of 2.23 g (8.00 mmol) 2-(4-iodo-2-methyl-phenoxy)-ethanol, 1.22 mL (8.80 mmol) trimethylsilylacetylene, 185 mg (0.160 mmol) tetrakis-triphenylphosphane-palladium and 2.38 mL (24.00 mmol) piperidine in 50 mL THF and the mixture is stirred for 1 h at RT. The reaction mixture is diluted with water and the aqueous phase is exhaustively extracted with EtOAc. The combined organic phases are washed with saturated NaCI solution and dried over Na2S04. After the desiccant and solvent have been eliminated the residue is purified by chromatography (silica gel, Cyc/EtOAc 2:1 ).
Yield: 1.70 g (86% of theoretical) C,4H2o02Si (M= 248.393) Calc.: molpeak (M+H)+: 249 Found: molpeak (M+H)+: 249 Rf value: 0.24 (silica gel, Cyc/EtOAc 2:1 ) 1 c 2-(4-ethynyl-2-methyl-phenoxy)-ethanol 20.8 g (74.4 mmol) TBAF is added at RT to a solution of 16.8 g (67.6 mmoi) 2-(2-methyl-4-trimethylsilanylethynyl-phenoxy)-ethanol in 500 mL THF and the mixture is stirred for 3 h at RT. The reaction mixture is evaporated down i. vac. and the residue dissolved in EtOAc. The organic phase is washed with water and saturated NaCI solution and dried over Na2S04. After the desiccant and solvent have been eliminated the residue is reacted further without purification.
Yield: 12.0 g (quant. yield) C~~H~202 (M= 176.212) Calc.: molpeak (M)+: 176 Found: molpeak (M)+: 176 Rf value: 0.24 (silica gel, Cyc/EtOAc 2:1 ) 1d 2-[4-(5-bromo-pyridin-2-ylethynyl)-2-methyl-phenoxy]-ethanol 0.26 g (1.36 mmol) Cul are added to a degassed solution of 11.98 g (68.0 mmol) 2-(4-ethynyl-2-methyl-phenoxy)-ethanol, 16.11 g (68.0 mmol) 2,5-dibromopyridine, 0.96 g (1.36 mmol) bis-triphenylphosphane-palladium(II)-chloride and 19.22 mL (136.0 mmol) diisopropylamine in 500 mL THF and the mixture is stirred for 4 h at RT. The reaction mixture is evaporated down i. vac. and the residue is taken up in 800 mL EtOAc. The organic phase is washed with water and saturated NaCI solution and dried over Na2S04. After the desiccant and solvent have been eliminated the residue is purified by chromatography (silica gel, gradient DCM/ EtOAc 90:10 --~ 80:20).
Yield: 13.20 g (58% of theoretical) C~6H,4BrN02 (M= 332.192) Calc.: molpeak (M+H)+: 332/334 (Br) Found: molpeak (M+H)+: 332/334 (Br) Rf value: 0.39 (silica gel, Cyc/EtOAc 1:1 ) 1e 2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethanol 40 mL 2 N NaHC03 solution are added to a suspension of 13.20 g (39.74 mmol) 2-[4-(5-bromo-pyridin-2-ylethynyl)-2-methyl-phenoxyJ-ethanol, 9.32 g (59.60 mmol) 4-chlorophenylboric acid and 2.30 g (1.99 mmol) tetrakis-triphenylphosphane-palladium in 400 mL 1,4-dioxane and the mixture is refluxed for12 h. Another 4.66 g 4-chlorophenylboric acid and 1.14 g tetrakis-triphenylphosphane-palladium are added and the mixture is again refluxed for 8 h. The reaction mixture is evaporated down i. vac. and the residue is stirred with EtOAc and water. The precipitate is filtered off, washed with diethlyether and dried i. vac..
Yield: 10.70 g (74% of theoretical) C22H,8CIN02 (M= 363.837) Calc.: molpeak (M+H)': 364/366 (CI) Found: molpeak (M+H)+: 364/366 (CI) Rf value: 0.47 (silica gel, DCM/EtOAc 2:1 ) 1f 2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl methanesulphonate 2.74 mL (35.29 mmol) methanesulphonic acid chloride are added dropwise at 0 °C to a solution of 10.70 g (29.41 mmol) 2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethanol and 4.08 mL (29.41 mmol) triethylamine in 500 mL THF and the mixture is then stirred for 2 h at RT. The reaction mixture is filtered and the filtrate is evaporated down i.
vac.. The residue is stirred with diethyl ether and water, the precipitate is filtered off and dried i. vac..
Yield: 11.00 g (85% of theoretical) CZ3H2oC1NOaS (M= 441.928) Calc.: molpeak (M+H)+: 442/444 (CI) Found: molpeak (M+H)+: 442/444 (CI) Rf value: 0.73 (silica gel, DCM/EtOAc 1:1 ) 1 g (3S,4R)-1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-4-trifluoromethyl-piperidine-3,4-diol A mixture of 82.6 mg (0.187 mmoi) 2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl methanesulphonate, 69.2 mg (0.374 mmol) (3S,4R)-4-trifluoromethyi-piperidine-3,4-diol (amine A1 ) and 0.13 mL (0.748 mmol) N-ethyldiisopropylamine in 1.7 mL
DMF is shaken for 40 h at 60°C. After filtration through an injection filter the crude product is purified by HPLC. The fractions containing the product are evaporated down i.
vac., the residue is stirred with 20 mL EtOAc and 10 mL saturated NaHC03 solution, the organic phase is separated off and dried over Na2S04. After the desiccant and solvent have been eliminated the residue is stirred with DIPE, suction filtered and dried.
Yield: 39.2 mg (39% of theoretical) Cz8H26CIF3N203 (M= 530.966) Calc.: molpeak (M+H)+: 531/533 (CI) Found: molpeak (M+H)+: 531/533 (CI) HPLC-MS: 8.2 Min. (method A) The following Examples are prepared analogously starting from 2-{4-(5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl methanesulphonate (Example 1f) and the corresponding amines:
ci R~
(.
ExampleR Yield Empirical Mass HPLC retention (%) formula spectrum time in min (method) 1 " 15 CzaH2sCIF3N203531/533 8.3 (A) . "

F (M+H]+
~
~

F
~
N
F ~' .

1 - " 57 CZ8H29CINZ03 477/479 7.6 (A) . " (M+H]~

N~

1 " 54 C28Hz9CIN203 477/479 7.5 (A) . "

, ~ (M+HI+

N~

1 -, 66 C28H29CIN203 477/479 7.6 (A) 4 "

. "
, (M+H]+

N~

1 " 51 C28HZ9CIN203 477/479 7.6 (A) . "

(M+H]+

N~

1.6 " 43 C26H2sCIN203 449/451 7.5 (A) '~ (M+H]+

HO
N~ ~

1 ~" 18 C2~H2~CIN203 463/465 7.4 (A) . " (M+H]+
..
N~
1 " 35 C2,H27CIN203 463/465 7.4 (A) . "

[M+H]+

N~

1.9 " 66 C28H29CIN203 477/479 7.4 (A) HO
N [M+H]+

1.10 ~ 36 C29HZ9CIN202 473/475 0.58 * [M+H]+ (EtOAc/MeOH/N

"o~ H3 19:1:0.1) 1.11 ~ 20 CZ9H3~CIN202 475/477 0.20 * [M+H]+ (EtOAc/MeOH/N

"o~ H3 19:1:0.1) 1.12 " 8 C2~H2~CIN203 463/465 7.5 (A) N ~ * [M+H]+

HO~

1 " CzsHsiCIN203 . "
\\~N

1 " 31 C29H3~CIN203 491/493 4.7 (B) . "

w,..w 1 [M+H]+

N~

Example 1.15 (S)-3-[(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-cyclopropylmethyl-amino]-propane-1,2-diol c~
°"
N
OOH
~N~ i °
1.15a (2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-cyclopropylmethyl-amine A mixture of 1.00 g (2.26 mmol) 2-~4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl methanesulphonate, 0.99 mL (11.32 mmol) C-cyclopropyl-methylamine and 1.92 mL (11.32 mmol) ethyldiisopropylamine is stirred in 15 mL DMF for 72 h at 60°C. It is evaporated down i. vac. and the residue is purified by chromatography (silica gel, EtOAc/MeOH/NH3 19:1:0.1 ).
Yield: 0.27 g (29 % of theoretical) CzeHzsCIN20 (M= 416.942) Calc.: molpeak (M+H)+: 417/419 (CI) Found: molpeak (M+H)+: 417/419 (CI) Rf value: 0.39 (silica gel, DCM/MeOH/NH3 9:1:0.1 ) 1.15b (S)-3-[(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-cyclopropylmethyl-amino]-propane-1,2-diol A mixture of 70 mg (0.168 mmol) (2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-cyclopropylmethyl-amine, 56 NL (0.672 mmol) (R)-3-chloro-propane-1,2-diol and 0.12 mL (0.672 mmol) N-ethyldiisopropylamine in 1.7 mL DMF is shaken for 20 h at 80°C. Then another 100 NL (1.12 mmol) (R)-3-chloro-propane-1,2-diol are added and the reaction mixture is kept for a further 6 days at this temperature. It is evaporated down i. vac., the residue is distributed between 10 mL semisaturated NaHC03 solution and 20 mL EtOAc, the organic phase is separated off and dried over NazS04. After the desiccant and solvent have been eliminated the residue is purified by chromatography (silica gel, DCM/MeOH/NH3 98:2:0.2).
Yield: 10 mg (12 % of theoretical) CzgH3~CIN2O3 (M= 491.021) Calc.: molpeak (M+H)+: 491/493 (CI) Found: molpeak (M+H)+: 491/493 (CI) R, value: 0.30 (silica gel, DCM/MeOH/NH3 19:1:0.1 ) Exam~~le 1.16 (R)-3-[(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-cyclopropylmethyl-amino]-propane-1,2-diol c~
The product is prepared analogously to Example 1.15b starting from 70 mg (0.168 mmol) (2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-cyclopropylmethyl-amine and 0.28 mL (3.35 mmol) (S)-3-chloro-propane-1,2-diol.
Yield: 29.6 mg (36% of theoretical) C2gH3~CIN2O3 (M= 491.021 ) Calc.: molpeak (M+H)+: 4911493 (CI) Found: molpeak (M+H)+: 491/493 (CI) Rf value: 0.24 (silica gel, DCM/MeOH/NH3 19:1:0.1 ) Example 1.17 (2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynylJ-2-methyl-phenoxy}-ethyl)-cyclopropylmethyi-prop-2-ynyl-amine 39.8 mg K2C03 and 17 NL (0.16 mmol, 80% in toluene) 3-bromo-propyne are added to a solution of 60 mg (0.144 mmol) (2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl)-2-methyl-phenoxy}-ethyl)-cyclopropylmethyl-amine in 2 mL DMF and the reaction mixture is stirred for 2 h at RT. It is evaporated down i. vac., the residue is distributed between 20 mL water and 40 mL EtOAc, the organic phase is separated off and dried over Na2S04. After the desiccant and solvent have been eliminated the residue is purified by chromatography (Alox, Cyc/EtOAc 9:1 ).
Yield: 46.1 mg (70% of theoretical) C29Hz~CIN20 (M= 454.990) Calc.: molpeak (M+H)+: 455/457 (CI) Found: molpeak (M+H)+: 455/457 (CI) Rf value: 0.90 (Alox, Cyc/EtOAc 2:1 ) Example 1.18 Allyl-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-cyclopentyl-amine V

1.18a (2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-cyclopentyl-amine A mixture of 1.33 g (3.0 mmol) 2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl methanesulphonate, 1.49 mL (15.0 mmol) cyclopentylamine and 2.57 mL
(15.0 mmol) N-ethyldiisopropylamine in 30 mL DMF is stirred for 36 h at 60°C. It is evaporated down i. vac., the residue is stirred with water and EtOAc, suction filtered, the precipitate is dissolved in DCM, the organic phase is washed with semisaturated K2C03 solution and the organic phase is dried over Na2S04. After the desiccant and solvent have been eliminated the residue is stirred with diethyl ether, suction filtered and dried.
Yield: 0.82 g (63 % of theoretical) CZ~H2~CIN20 (M= 430.969) Calc.: molpeak (M+H)+: 431/433 (CI) Found: molpeak (M+H)+: 4311433 (CI) Rf value: 0.21 (silica gel, DCM/MeOH 9:1 ) 1.18b allyl-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-2o cyclopentyl-amine The product is prepared analogously to Example 1.17 starting from 86.2 mg (0.20 mmol) (2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-cyclopentyl-amine and 42 NL (0.48 mmol) 3-bromo-propene.
Yield: 5.1 mg (5% of theoretical) C3oH3,CIN20 (M= 471.033) Calc.: molpeak (M+H)+: 471/473 (CI) Found: molpeak (M+H)+: 471/473 (CI) HPLC-MS: 6.4 min (method B) Example 1.19 allyl-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-cyclopentylmethyl-amine N~
L
1.19a (2-{4-[5-(4-chioro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-cyclopentylmethyl-amine A mixture of 1.33 g (3.0 mmol) methanesulphonate 2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl, 595 mg (6.0 mmol) cyclopentyl-methylamine and 2.57 mL
(15.0 mmol) N-ethyldiisopropylamine in 30 mL DMF is stirred for 20 h at 60°C. It is evaporated down i. vac., the residue is taken up in semiconcentrated K2C03 solution, the organic phase is separated off and dried over Na2S04. After the desiccant and solvent have been eliminated the residue is purified by chromatography (silica gel, DCM/MeOH 95:5).
Yield: 0.57 g (42 % of theoretical) C28H29CIN20 (M= 444.995) Calc.: moipeak (M+H)+: 445/447 (CI) Found: molpeak (M+H)+: 445/447 (CI) Rf value: 0.21 (silica gel, DCM/MeOH 95:5) 1.19b allyl-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-cyclopentylmethyl-amine The product is prepared analogously to Example 1.17 starting from 89.0 mg (0.20 mmol) (2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-cyclopentylmethyl-amine and 21 NL (0.24 mmol) 3-bromo-propene.
Yield: 37.4 mg (39% of theoretical) Cg~Hg3CIN2O (M= 485.059) Calc.: molpeak (M+H)+: 485/487 (CI) Found: molpeak (M+H)+: 485/487 (CI) HPLC-MS: 6.6 min (method B) Example 1.20 allyl-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl)-2-methyl-phenoxy}-ethyl)-amine The product is prepared analogously to Example 1.19a starting from 400 mg (0.91 mmol) 2-{4-(5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl methanesulphonate and 0.2 mL (2.72 mmol) allylamine.
Yield: 228 mg (63% of theoretical) CzsHzsCIN20 (M= 402.916) Calc.: molpeak (M+H)+: 403/405 (CI) Found: molpeak (M+H)+: 403/405 (C1) HPLC-MS: 5.4 min (method B) Example 1.21 2-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethylamino)-propane-1,3-diol H H
A mixture of 100 mg (0.23 mmol) 2-{4-(5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl phenoxy}-ethyl methanesulphonate, 0.15 mL (0.91 mmol) ethyldiisopropylamine and 62 mg (0.68 mmol) 2-amino-propane-1,3-diol in 2.5 mL DMF are shaken for 48 h at 60°C, while after 8 h another 63 mg (0.69 mmol) 2-amino-propane-1,3-diol are added. When the reaction has ended the reaction mixture is purified by HPLC without working up. The fractions containing the product are combined and lyophilised.
Yield: 50 mg (51 % of theoretical) C25H25CIN2O3 (M= 436.930) Calc.: molpeak (M+H)+: 437/439 (CI) Found: molpeak (M+H)': 437/439 (CI) HPLC-MS: 6.9 min (method A) Example 1.22 (3R,4R)-1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-pyrrolidine-3,4-diol A mixture of 83 mg (0.19 mmol) 2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl methanesulphonate, 0.13 mL (0.75 mmol) ethyldiisopropylamine and 39 mg (0.37 mmol) (3R,4R)-pyrrolidine-3,4-diol in 1.7 mL DMF are shaken for 20 h at 60°C. After the end of the reaction the reaction mixture is purified by HPLC without working up. The fractions containing the product are combined, evaporated down to approx. 10 mL i. vac., made alkaline with 5% NaHC03 solution and extracted with 20 ml hot EtOAc. The organic phase is separated off and dried over Na2S04. After the desiccant and solvent have been eliminated the residue is triturated with a little DIPE and suction filtered.
Yield: 26 mg (31 % of theoretical) CzsH2sCINz03 (M= 448.941 ) Calc.: molpeak (M+H)+: 449/451 (CI) Found: molpeak (M+H)+: 449/451 (CI) HPLC-MS: 4.6 min (method B) Example 2 (3S,4R)-1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-4-trifluoromethyl-?0 piperidine-3,4-diol ci /
\ \
OH N
HO
F
F N~ ( /
O
2a 2-(4-iodo-phenoxy)-ethanol A suspension of 11 g (50 mmol) 4-iodophenol, 3.88 mL (55 mmol) 2-bromoethanol and 8.3 g (60 mmol) K2C03 in 60 mL acetone is refluxed for24 h. The solvent is removed i. vac., the residue is combined with water, exhaustively extracted with EtOAc and the organic phase is dried over NazS04. After the desiccant and solvent have been eliminated the residue is purified by chromatography (silica gel, Cyc/EtOAc 7:3).
Yield: 2.9 g (22 % of theoretical) C$H9102 (M= 264.064) Calc.: molpeak (M)+: 264 Found: molpeak (M)+: 264 Rf value: 0.24 (silica gel, Cyc/EtOAc 2:1 ) 2b 2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethanol Under an argon atmosphere 253 mg (0.22 mmol) tetrakis-triphenylphosphane-palladium and 42 mg (0.22 mmol) Cul are added to a solution of 2.9 g (11 mmol) 2-(4-iodo-phenoxy)-ethanol and 2.35 g (11 mmol) 5-(4-chloro-phenyl)-2-ethynyl-pyridine in 50 mL
piperidine and the reaction mixture is stirred for 30 min at RT. The solvent is eliminated i.
vac., the residue is combined with water and stirred with EtOAc. The precipitated product is suction filtered and dried.
Yield: 2.1 g (55 % of theoretical) C2,H~sCIN02 (M= 349.820) Calc.: molpeak (M+H)+: 350/352 (CI) Found: molpeak (M+H)+: 350/352 (CI) Rf value: 0.42 (silica gel, Cyc/EtOAc 1:1 ) 2c 2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy} ethyl methanesulphonate The product is obtained analogously to Example 1f starting from 4.40 g (12.58 mmol) 2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethanol.
Yield: 4.50 g (84% of theoretical) C22H~8CIN04S (M= 427.901 ) Calc.: molpeak (M+H)+: 428/430 (CI) Found: molpeak (M+H)+: 428/430 (CI) Rf value: 0.88 (silica gel, EtOAc) 2d (3S,4R)-1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-4-trifluoromethyl-piperidine-3,4-diol The product is prepared analogously to Example 1g starting from 80 mg (0.187 mmol) 2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl methanesulphonate and 69.2 mg (0.374 mmol) (3S,4R)-4-trifluoromethyl-piperidine-3,4-diol (amine A1 ).
Yield: 43.6 mg (45% of theoretical) C2~H24CIF3N203 (M= 516.939) Calc.: molpeak (M+H)+: 517/519 (CI) Found: molpeak (M+H)+: 517/519 (CI) HPLC-MS: 7.7 min (method A) The following Examples are prepared analogously starting from 2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl methanesulphonate (Example 2c):
R
O
ExampleR Yield Empirical formulaMass HPLC retention (%) spectrumtime in min ( method) 2.1 " " 22 C27H24CIF3N203517/519 7.9 (A) F [M+H]+
\
~

F
~
N
F

2.2 " " 60 C2~H2~CIN203 463/465 7.2 (A) [M+H]+

N~

2.3 " " 45 C2~Hz~CIN203 463/465 7.2 (A) 1 [M+Hl+

N~

2.4 " 50 CZ~H2~CIN203 463/465 7.3 (A) -.

, "

1 [M+H]+

N~

2.5 " 49 Cz~H2~CIN203 463/465 7.3 (A) "

[M+H]+

N~

2.6 " 24 C25H2sCINz03 435/437 7.2 (A) ~ [M+H]+

HO
N~ ~

2.7 " " 64 C26H2sCIN203 449/451 6.5 (A) .. [M+H]+
N~
2.8 "o " 49 C26H25CIN203 449/451 6.6 (A) [M+H]+

N~

2.9 " 24 C2~H2~CINz03 463/465 7.1 (A) "

N [M+H]+

2.10 ~ 18 C28H2~CIN202 459/461 8.0 (A) N

= [M+H]+
~

HO~

2.11 ~ 44 C28H29CIN202 461/463 5.3 (B) N

,- * [M+H]+

HO~

2.12 " " C28H29CIN203 \~N

2.13 " " 46 CZaH29CINz03 477/479 4.5 (B) w,..w ~ [M+H]+

N~

Example 2.14 (2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-cyclopropylmethyl-(tetrahydro-pyran-4-yl)-amine N
~O
2.14a (2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-cyclopropylmethyl-amine The product is prepared analogously to Example 1.19a starting from 1.71 g (4.0 mmol) 2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl methanesulphonate and 2.02 mL
(20.0 mmol) C-cyclopropyl-methylamine.
Yield: 0.70 g (43% of theoretical) CzsH2sCIN20 (M= 402.916) Calc.: molpeak (M+H)+: 403/405 (CI) Found: molpeak (M+H)+: 403/405 (CI) HPLC-MS: 5.1 min (method B) 2.14b (2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl) cyclopropylmethyl-(tetrahydro-pyran-4-yl)-amine 37 NL (0.4 mmol) tetrahydro-pyran-4-on and 1 drop of glacial acetic acid are added to a solution of 80.6 mg (0.2 mmol) (2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-cyclopropylmethyl-amine in 10 mL THF and the reaction mixture is stirred for 15 min at RT, before the addition of 170 mg (0.8 mmol) NaBH(OAc)3. The mixture is stirred for a further 16 h at RT, diluted with water, extracted exhaustively with EtOAc and dried over Na2S04. After the desiccant and solvent have been eliminated the residue is purified by chromatography (silica gel, DCM/MeOH 95:5).
Yield: 9 mg (9% of theoretical) C3oH3,CIN202 (M= 487.032) Calc.: molpeak (M+H)+: 487/489 (CI) Found: molpeak (M+H)+: 487/489 (CI) Rf value: 0.52 (silica gel, DCM/MeOH 95:5) Examole 2.15 1-[(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethylamino)-methyl]-cyclopropanol The product is prepared analogously to Example 1.19a starting from 1.71 g (4.0 mmol) 2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl methanesulphonate and 0.54 g (4.8 mmol) 1-aminomethyl-cyclopropanol.
Yield: 0.55 g (33% of theoretical) C2sHzsCIN202 (M= 418.915) Calc.: molpeak (M+H)+: 419/421 (CI) Found: molpeak (M+H)+: 419/421 (CI) Rf value: 0.18 (silica gel, EtOAc/MeOH/NH3 95:5:0.5) HPLC-MS: 4.9 min (method B) Example 2.16 1-{((2-{4-[5-(4-chloro-phenyl )-pyridin-2-ylethynyl]-phenoxy}-ethyl )-(tetra hyd ro-pyran-4-yl )-amino]-methyl}-cyclopropanol c~
\
° ~J
N
H \
~N~
O
The product is prepared analogously to Example 2.14b starting from 83.8 mg (0.2 mmol) 1-[(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethylamino)-methyl]-cyclopropanol and 37 NL (0.4 mmol) tetrahydro-pyran-4-one.
Yield: 2.1 mg (2% of theoretical) C30H31CINpO3 (M= 503.032) Calc.: molpeak (M+H)+: 503/505 (CI) Found: molpeak (M+H)': 503/505 (CI) Rf value: 0.47 (silica gel, DCM/MeOH 9:1 ) The following Examples are prepared analogously starting from 1-[(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethylamino)-methyl]-cyclopropanol (Example 2.15):
'! 5 Example R Yield Empirical Mass Rf value auf (%) formula silica spectrum gel (eluant) 2.17 ~ 22 C3~H33CIN202 501/503 0.70 [M+H]+ (DCM/MeOH
8:2) 2.18 ~ 63 CZ9H29CIN20z 473/475 0.84 [ [M+H]+ (EtOAc/MeOH/N

H3 95:5:0.5) 2.19 ~ 31 C3oH3~CINz02 487/489 0.57 [M+H]+ (DCM/MeOH
9:1 ) Example 2.20 1-{[(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-(3-hydroxy-propyl)-amino]-methyl}-cyclopropanol OH
N~
O
55.3 mg (0.4 mmol) K2C03 and 36 NL (0.4 mmol) 3-bromo-1-propanol are added to a solution of 83.8 mg (0.2 mmol) 1-[(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethylamino)-methyl]-cyclopropanol (Example 2.15) in 2 mL DMF and the reaction mixture is stirred for 24 h at RT. Another 36 NL (0.4 mmol) 3-bromo-1-propanol are added and the reaction mixture is heated to 50°C for 8 h. It is evaporated down i. vac., the residue is taken up in water, extracted exhaustively with DCM and the combined organic phases are dried over NazS04.
After the desiccant and solvent have been eliminated the residue is purified by chromatography (silica gel, EtOAc/MeOH/NH3 95:5:0.5).
Yield: 22 mg (23% of theoretical) CZ$Hz9CIN203 (M= 476.994) Calc.: molpeak (M+H)+: 478/480 (CI) Found: molpeak (M+H)+: 478/480 (CI) Rf value: 0.34 (silica gel, EtOAc/MeOH 4:1 ) Example 2.21 1-{[(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-propyl-amino]-methyl}-z0 cyclopropanol N~
O
The product is prepared analogously to Example 2.20 starting from 83.8 mg (0.2 mmol) 1-[(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethylamino)-methyl]-cyclopropanol (Example 2.15) and 23 NL (0.25 mmol) 1-bromo-propane.
Yield: 22 mg (24% of theoretical) C28H29CIN202 (M= 460.995) Calc.: molpeak (M+H)+: 461/463 (CI) Found: molpeak (M+H)+: 461/463 (CI) Rf value: 0.56 (silica gel, DCM/MeOH 95:5) Example 2.22 2-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethylamino)-propane-1,3-diol H H
~N~
H
The product is obtained analogously to Example 1.21 from 100 mg (0.23 mmol) 2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl methanesulphonate and 128 mg (1.40 mmol) 2-amino-propane-1,3-diol.
Yield: 48 mg (49% of theoretical) C24H23CINzO3 (M= 422.904) Calc.: molpeak (M+H)+: 423/425 (CI) Found: molpeak (M+H)+: 423/425 (CI) HPLC-MS: 6.6 min (method A) Example 2.23 (3R,4R)-1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-pyrrolidine-3,4-diol The product is obtained analogously to Example 1.22 from 80 mg (0.19 mmol) 2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl methanesulphonate and 39 mg (0.37 mmol) (3R,4R)-pyrrolidine-3,4-diol.
Yield: 34 mg (42% of theoretical) C25H23CIN2O3 (M= 434.915) Calc.: molpeak (M+H)+: 435/437 (CI) Found: molpeak (M+H)+: 435/437 (CI) HPLC-MS: 4.4 min (method B) Example 3 2-((E)-3-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenyl}-allylamino)-propane-1,3-diol 3a 5-bromo-2-[(tent-butyl-dimethyl-silanyl)-ethynyl]-pyridine Under an argon atmosphere 0.80 g (4.20 mmol) Cul and 2.90 g (4.13 mmol) bis-triphenylphosphane-palladium(//)-chloride is added to a solution of 49.90 g (201.0 mmol) 2,5-dibromopyridine and 43.0 mL (225.6 mmol) tert-butyl-ethynyl-dimethyl-silane in 500 mL dry THF and 120 mL triethylamine at -7 °C and the mixture is stirred for 30 min at 0 °C. The reaction mixture is stirred for a further 3.5 h at RT, then filtered and the filtrate is evaporated down i. vac.. The residue is dissolved in 1 L EtOAc, the organic phase is washed with water and saturated NaCI solution, dried over Na2S04 and evaporated down i. vac..
The crude product is reacted further without purification.
Yield: 59.5 g (quant. yield) C,3H,$BrNSi (M= 296.278) Calc.: molpeak (M+H)+: 296/298 (Br) Found: molpeak (M+H) : 296/298 (Br) Rf value: 0.75 (silica gel, Cyc/EtOAc 8:1 ) 3b 2-[(tert-butyl-dimethyl-silanyl)-ethynyl]-5-(4-chloro-phenyl)-pyridine 250 mL MeOH, 220 mL 2 N NaZC03 solution and 1.80 g (2.46 mmol) PdCl2(dppf) are added to a solution of 59.5 g (201.0 mmol) 5-bromo-2-[(tert-butyl-dimethyl-silanyl)-ethynyl]-pyridine and 36.5 g (233.4 mmol) 4-chlorophenylboric acid in 600 mL 1,4-dioxane and the mixture is refluxed for 1 h. The reaction mixture is evaporated down i. vac. and diluted with EtOAc. The organic phase is washed with water and semisaturated NaHC03 solution, dried over Na2S04 and evaporated down i. vac.. The residue is purified by column chromatography (silica gel, Cyc/EtOAc 9:1 ).
Yield: 38.5 g (58% of theoretical) C~9HzzCINSi (M= 327.923) Calc.: molpeak (M+H)+: 328/330 (CI) Found: molpeak (M+H) : 328/330 (CI) Rf value: 0.60 (silica gel, Cyc/EtOAc 8:1 ) 3c 5-(4-chloro-phenyl)-2-ethynyl-pyridine 43.66 g (156.0 mmol) TBAF are added at RT to a solution of 46.50 g (142.0 mmol) 2-[(tert-butyl-dimethyl-silanyl)-ethynyl]-5-(4-chloro-phenyl)-pyridine in 1 L DCM and the mixture is stirred for 2 h. The organic phase is washed with water, dried over NazS04 and evaporated down i. vac.. The residue is stirred with DIPE, the precipitate is filtered off and washed with PE.
Yield: 26.0 g (86% of theoretical) C,3H8CIN (M= 213.662) Calc.: molpeak (M+H)+: 214/216 (CI) Found: molpeak (M+H) : 214/216 (CI) Rf value: 0.30 (silica gel, Cyc/EtOAc 4:1 ) 3d (E)-3-(4-iodo-phenyl)-prop-2-en-1-of Under a nitrogen atmosphere 12.0 g (80.0 mmol) Nal and 0.85 mL (8.0 mmol) N,N~-dimethylethylendiamine are added to a solution of 4.26 g (20.0 mmol) (E)-3-(4-bromo-phenyl)-prop-2-en-1-of and 762 mg (4 mmol) Cul in 20 mL 1,4-dioxane and the reaction mixture is shaken for 17 h at 110°C. The reaction mixture is cooled to RT, combined with 200 mL EtOAc and 100 mL semiconcentrated NH3 solution, vigorously stirred, the organic phase is separated off and dried over Na2S04. After the desiccant and solvent have been eliminated the residue is reacted further without purification.
Yield: 4.69 g (90% of theoretical) C9H9102 (M= 260.072) Calc.: molpeak (M+H)+: 261 Found: molpeak (M+H) : 261 HPLC-MS: 7.9 min (method A) 3e (E)-3-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenyl}-prop-2-en-1-of A solution of 3.12 g (12.0 mmol) (E)-3-(4-iodo-phenyl)-prop-2-en-1-ol, 3.33 g (15.0 mmol) 5 (4-chloro-phenyl)-2-ethynyl-pyridine and 4.31 mL (24 mmol) diisopropylamine in 120 mL dry THF is evacuated three times and then gassed with argon. Then 45 mg (0.24 mmol) Cul and 196 mg (0.24 mmol) PdCl2(dppf) are added. The reaction mixture is stirred for 18 h at RT, the solvent is evaporated down i. vac., the residue is combined with 100 mL DCM
and 50 mL
semisaturated NaHC03 solution and vigorously stirred. The precipitate is separated off, washed with water and a little DCM, suspended in DIPE, suction filtered again and dried in the circulating air dryer at 50°C until the weight remains constant.
Yield: 4.23 g (quant. yield) CZZH~6CIN0 (M= 345.821 ) Calc.: molpeak (M+H)+: 346/348 (CI) Found: molpeak (M+H) : 346/348 (CI) Rf value: 0.24 (silica gel, Cyc/EtOAc 2:1 ) 3f 5-(4-chloro-phenyl)-2-[4-((E)-3-chloro-propenyl)-phenylethynylJ-pyridine A solution of 2.56 mL (35.28 mmol) thionyl chloride in 10 mL DCM is slowly added dropwise to a solution, cooled to 0°C, of 6.1 g (17.64 mmol) (E)-3-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenyl}-prop-2-en-1-of in 80 ml DCM and the reaction solution is stirred for a further 2 h at 0°C and 14 h at RT. It is again cooled to 0°C, 150 mL
semisaturated NaHC03 solution are carefully added dropwise thereto, the organic phase is separated off and dried over Na2S04. After the desiccant and solvent have been eliminated the residue is purified by chromatography (silica gel, Cyc/EtOAc 4:1 ).
Yield: 3.2 g (50% of theoretical) CZ2H~5CIZN (M= 364.267) Calc.: molpeak (M+H)+: 364/366/368 (2C1) Found: molpeak (M+H) : 364/366/368 (2C1) Rf value: 0.60 (silica gel, Cyc/EtOAc 2:1 ) 3g 2-((E)-3-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenyl}-allylamino)-propane-1,3-diol A solution of 70 mg (0.192 mmol) 5-(4-chloro-phenyl)-2-[4-((E)-3-chloro-propenyl)-phenylethynyl]-pyridine, 70 mg (0.768 mmol) 2-amino-1,3-propanediol and 0.13 mL (0.768 mmol) N-ethyldiisopropylamine in 1.7 mL DMF is shaken for 3.5 h at 60°C. The reaction mixture is filtered through an injection filter and purified directly by HPLC.
Yield: 37.6 mg (47% of theoretical) C25H2sCIN202 (M= 418.915) Calc.: molpeak (M+H)+: 419/421 (CI) Found: molpeak (M+H) : 419/421 (CI) HPLC-MS: 4.9 min (method B) Example 3.1 2-((E)-3-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenyl}-allylamino)-2-methyl-propane-1,3-diol H~
Prepared analogously to Example 3g from 70 mg (0.192 mmol) 5-(4-chloro-phenyl)-2-[4-((E)-3-chloro-propenyl)-phenylethynyl]-pyridine and 80.7 mg (0.768 mmol) 2-amino-2-methyl-1,3-propanediol.
Yield: 38.2 mg (46% of theoretical) CzsH25CIN202 (M= 432.942) Calc.: molpeak (M+H)+: 433/435 (CI) Found: molpeak (M+H) : 433/435 (CI) HPLC-MS: 4.9 min (method B) The following compounds are prepared according to the process described in Example 3g:
Exam Structure Yield Mass HPLC
-ple spectrum retention time (method) / c1 37% 459/461 4.6 min 3.2 \ \ I ~M+Hl+ (B) OH N
HO
~N \ /
c1 45% 459/461 4.6 min 3.3 \ \ I ~M+H~+ (B) OH N
HO
.,." \ /
CI
/I
3.4 I \ \
H N/
HO
".... \
N \ I /
/ CI
\ \
3.5 OH I N
HO
N \ I /
CI
/I
3.6 I \ \
OH N/
F HO
N \ I /
c~
/

3.7 OH

N
F HO

F
~

N \ /

The following compounds are prepared starting from Example 3 according to the process described in Example 2.14b:
Exam Structure YieldMass HPLC
-ple spectrumretention time (method) ~ ci gg% 473/475 4.9 min 3.8 \ \ I [M+H]+ (B) H H I
N

~N \ /

c~ 17% 487/489 7.6 min 3 \ I [M+Hl+ (A) . \

H H

N \ I /

Example 4 (3R,4S)-1-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-benzo[b]thiophen-2-ylmethyl}-4-methyl-piperidine-3,4-diol 4a methyl5-iodo-benzo[b]thiophene-2-carboxylate Under an argon atmosphere 0.35 g (1.84 mmol) Cul, 5.53 g (36.88 mmol) Nal and 0.39 mL
(3.67 mmol) N,N~-dimethylethylenediamine are added to a solution of 5.0 g (18.4 mmol) methyl 5-bromo-benzo(b]thiophene-2-carboxylate in 18 mL 1,4-dioxane and after flushing again with argon the reaction mixture is heated overnight to 110°C.
After cooling the reaction mixture is combined with 30% NH3 solution and water, exhaustively extracted with EtOAc, the combined organic phases are washed twice with water and dried over MgS04.
After the desiccant and solvent have been eliminated the residue is triturated with DIPE
and MTBE, suction filtered and dried in the air.
Yield: 3.4 g (58% of theoretical) C,oH~102S (M= 318.132) Calc.: molpeak (M)+: 318 Found: molpeak (M)+: 318 1o HPLC-MS: 6.4 min (method B) 4b methyl5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-benzo[b]thiophene-2-carboxylate Under an argon atmosphere 3.7 mL (26.72 mmol) triethylamine are added to a solution of 3.4 g (10.69 mmol) methyl 5-iodo-benzo[b]thiophene-2-carboxylate and 2.48 g (10.69 mmol) 5-(4-chloro-phenyl)-2-ethynyl-pyridine in 20 mL THF and the reaction mixture is evacuated three times and in each case gassed with argon. Then 195 mg (0.267 mmol) PdCl2(dppf)*DCM
complex and 51 mg (0.267 mmol) Cul are added and the reaction mixture is stirred for 70 h at RT. EtOAc is added, the precipitated product is suction filtered, washed with a little EtOAc and dried in the air.
Yield: 3.0 g (70% of theoretical) Cz3H~4CIN02S (M= 403.881 ) Calc.: molpeak (M+H)+: 404/406 (CI) Found: molpeak (M+H)+: 404/406 (CI) HPLC-MS: 7.3 min (method B) 4c 5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-benzo[b]thiophene-2-carboxylic acid 22.3 mL 1 N NaOH are added to a suspension of 3.0 g (7.43 mmol) methyl 5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-benzo[b]thiophene-2-carboxylate in 100 mL EtOH
and the reaction mixture is stirred overnight at RT. The reaction solution is cooled to 0°C and adjusted to pH 6 by dropwise addition of 1 N HCi. The precipitated product is suction filtered, washed with EtOH and dried in the air. As the product still contains educt the hydrolysis described above is repeated.
Yield: 2.7 g (93% of theoretical) C2ZH,2CINOZS (M= 389.855) Calc.: molpeak (M+H)+: 390/392 (CI) Found: molpeak (M+H)+: 390/392 (CI) R, value: 0.89 (silica gel, PE/EtOAc 1:1 ) 4d {5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-benzo[bJthiophen-2-yl}-methanol 2.37 g (14.62 mmol) CDI are added to a suspension of 1.9 g (4.87 mmol) 5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-benzo[b]thiophene-2-carboxylic acid in 40 mL DMF
and the reaction mixture is heated to 50°C overnight. After cooling to RT the reaction solution is added to a solution of 552 mg (14.62 mmol) NaBH4 in 5 mL water in such a way that the temperature does not exceed30°C. It is stirred for 2 h at RT, carefully combined with KHS04 solution until an acidic reaction is obtained, made basic with saturated Na2C03 solution, extracted exhaustively with DCM, the combined organic phases are washed twice with water and dried over MgS04. After the desiccant and solvent have been eliminated the residue is triturated with PE, suction filtered and dried in the air.
Yield: 1.1 g (60% of theoretical) CZZH~4CINOS (M= 375.871 ) Calc.: molpeak (M+H)+: 376/378 (CI) Found: molpeak (M+H) : 376/378 (CI) HPLC-MS: 6.2 min (method B) 4e 2-(2-chloromethyl-benzo[b]thiophen-5-ylethynyl)-5-(4-chloro-phenyl)-pyridine 1.07 mL (15 mmol) thionyl chloride are added to a solution, cooled to 0°C, of 1.1 g (2.93 mmol) {5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-benzo[b]thiophen-2-yl}-methanol in 20 mL
DCM and the reaction mixture is stirred for 70 h at RT. It is evaporated down i. vac., the residue is combined with semisaturated NaHC03 solution, extracted exhaustively with DCM, the combined organic phases are washed twice with water and dried over MgS04.
After the desiccant and solvent have been eliminated the residue is purified by chromatography (silica gel, PE/EtOAc 7:3).
Yield: 0.65 g (56% of theoretical) C22H~3CIZNS (M= 394.317) Calc.: molpeak (M+H)+: 394/396/398 (2C1) Found: molpeak (M+H) : 394/396/398 (2C1) HPLC-MS: 7.6 min (method B) 4f (3R,4S)-1-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-benzo[b]thiophen-2-ylmethyl}-4-methyl-piperidine-3,4-diol 39.9 mg (0.30 mmol) (3R,4S)-4-methyl-piperidine-3,4-diol (amine A3) are added to a solution of 60 mg (0.15 mmol) 2-(2-chloromethyl-benzo[b]thiophen-5-ylethynyl)-5-(4-chloro-phenyf)-pyridine in 2 mL DMF and the reaction mixture is stirred overnight at 70°C. After filtration through an injection filter the reaction mixture is purified by HPLC .
Yield: 30 mg (40% of theoretical) C28HZSCIN202S (M= 489.029) Calc.: molpeak (M+H)+: 489/491 (CI) Found: molpeak (M+H) : 489/491 (CI) HPLC-MS: 5.4 min (method A) The following compounds are prepared according to the process described in Example 4f:
Example Structure c1 4.1 H OH ~
N
N
S /
/ CI
4.2 ~, OH pH
N~ _ N
S ~ /
CI
/
4.3 °H off ~ w N ~ .N
S /
CI
/
F
4.4 F~,",, OH OH
N~
S /
/ CI
F
4.5 F OH pH
N~
S
/ CI
4.6 I w HO~ ~H
~N
N
HO
S
Example 5 (3R,4S)-1-(2-{4-[5-(4-chloro-phenyl)-3-fluoro-pyridin-2-ylethynyl]-phenoxy}-ethyl)-4-methyl-piperidine-3,4-diol OH
HO
~~N~
O
5a 2,5-dibromo-3-fluoro-pyridine A solution of 1.78 g (25.80 mmol) sodium nitrite in 3.5 mL water is added dropwise at -5°C to a solution of 6.50 g (25.80 mmol) 2,5-dibromo-pyridin-3-ylamine and 15 mL
concentrated HCI
(180.62 mmol) in 15 mL water and the mixture is stirred for 30 min. At 0°C 11.41 mL (77.41 mmol) hexafluorophosphorsaure (60% in water) are added and the mixture is stirred for 1 h at 0°C. The diazonium salt formed is filtered off, washed with cold water, isopropanol and diethyl ether and dried i. vac. in the desiccator. PE (100-140°C) is heated to 90 °C, the diazonium salt is added batchwise and the mixture is stirred until no further development of gas can be detected. The reaction mixture is cooled to RT, made alkaline with saturated NaZC03 solution and the aqueous phase is exhaustively extracted with MTBE. The combined organic phases are washed with saturated NazC03 solution and water, dried over MgS04 and evaporated down i. vac.. The residue is dissolved in DCM, filtered through silica gel and the filtrate is evaporated down i. vac..
'0 Yield: 3.30 (51 % of theoretical) CSHZBr2FN (M= 254.883) Calc.: molpeak (M+H)+: 253/255/257 (2Br) Found: molpeak (M+H) : 253/255/257 (2Br) Rf value: 0.63 (silica gel, PE/EtOAc 9:1 ) 5b 5-bromo-2-[(tert-butyl-dimethyl-silanyl)-ethynylJ-3-fluoro-pyridine Under an argon atmosphere 5.22 mL (37.67 mmol) triethylamine, 2.62 mL (13.81 mmol) tert-butyl-ethynyl-dimethyl-silane, 59.8 mg (0.31 mmol) Cul and 220.3 mg (0.31 mmol) bis-triphenylphosphane-palladium(II)-chloride is added at 15°C to a solution of 3.20 g (12.56 mmol) 2,5-dibromo-3-fluoro-pyridine in 30 mL dry THF and the mixture is stirred for 2 h at RT.
Then another 1 mL tert-butyl-ethynyl-dimethyl-silane is added and the mixture is stirred for 1 h at RT. The reaction mixture is evaporated down i. vac. and the residue taken up in EtOAc.
The organic phase is washed with semisaturated NaHC03 solution, 5% NH3 solution and water and dried over MgS04. After the desiccant and solvent have been eliminated the residue is purified by chromatography (silica gel, PE/DCM 9:1 ).
Yield: 1.62 g (41 % of theoretical) C~3H"BrFNSi (M= 314.269) Calc.: molpeak (M+H)+: 314/316 (Br) Found: molpeak (M+H) : 314/316 (Br) HPLC-MS: 7.85 Min (method B) 5c 2-[(tert-butyl-dimethyl-silanyl)-ethynyl]-5-(4-chloro-phenyl)-3-fluoro-pyridine mL MeOH, 10 mL 2 N NazC03 solution and 94 mg (0.13 mmol) PdCl2(dppf) are added to a 10 solution of 1.61 g (5.14 mmol) 5-bromo-2-[(tert-butyl-dimethyl-silanyl)-ethynyl]-3-fluoro-pyridine and 0.90 g (5.65 mmol) 4-chlorophenylboric acid in 30 mL 1,4-dioxane and the mixture is refluxed for15 min. The reaction mixture is evaporated down i. vac.
and diluted with EtOAc. The organic phase is washed with water and semisaturated NaHC03 solution and dried over Na2S04. After the desiccant and solvent have been eliminated the residue is purified by chromatography (silica gel, PE/DCM 1:1 ).
Yield: 1.25 g (70% of theoretical) C,9H2,CIFNSi (M= 345.913) Calc.: molpeak (M+H)': 346/348 (CI) Found: molpeak (M+H) : 346/348 (CI) HPLC-MS: 8.83 Min (method B) 5d 5-(4-chloro-phenyl)-2-ethynyl-3-fluoro-pyridine 1.14 g (3.61 mmol) TBAF are added at RT to a solution of 1.25 g (3.61 mmol) 2-[(tert-butyl-dimethyl-silanyl)-ethynyl]-5-(4-chloro-phenyl)-3-fluoro-pyridine in 30 mL DCM
and the mixture is stirred for 2 h. The organic phase is washed with water and dried over Na2S04. After the desiccant and solvent have been eliminated the residue is stirred with PE, the precipitate is filtered off, washed with PE and dried in the air.
Yield: 0.72 g (86% of theoretical) C,3H~CIFN (M= 231.653) Calc.: molpeak (M+H)+: 232/234 (CI) Found: molpeak (M+H) : 232/234 (CI) HPLC-MS: 5.81 Min (method B) 5e 2-(4-[5-(4-chloro-phenyl)-3-fluoro-pyridin-2-ylethynyl]-phenoxy}-ethanol Under an argon atmosphere 14.8 mg (0.08 mmol) Cul is added to a solution of 0.82 g (3.11 mmol) 2-(4-iodo-2-methyl-phenoxy)-ethanol, 0.72 g (2.11 mmol) 5-(4-chloro-phenyl)-2-ethynyl-3-fluoro-pyridine, 57 mg (0.078 mmol) PdCl2(dppf) and 0.86 mL (6.22 mmol) triethylamine in 20 mL THF and the mixture is stirred for 16 h at RT. The reaction mixture is combined with EtOAc, the precipitate is filtered off and washed with EtOAc.
The filtrate and the organic wash solutions are washed with 5% NH3 solution and water and dried over MgS04. After the desiccant and solvent have been eliminated the residue is purified by chromatography (silica gel, PE/EtOAc 1:1 ).
(silica gel, petroleum ether/EtOAc 1:1 ) Yield: 0.20 g (18% of theoretical) Cz~H,SCIFN02 (M= 367.800) Calc.: molpeak (M+H)': 368/370 (CI) Found: molpeak (M+H) : 368/370 (CI) HPLC-MS: 5.9 min (method B) 5f 2-{4-[5-(4-chloro-phenyl)-3-fluoro-pyridin-2-ylethynyl]-phenoxy}-ethyl methanesulphonate 63 NL (0.82 mmol) methanesulphonic acid chloride is added dropwise at 0 °C to a solution of 0.20 g (0.54 mmol) 2-{4-[5-(4-chloro-phenyl)-3-fluoro-pyridin-2-ylethynyl]-phenoxy}-ethanol and 0.11 mL (0.82 mmol) triethylamine in 10 mL DCM and the mixture is stirred for 16 h at RT. Another 0.11 mL (0.82 mmol) triethylamine and 63 NL (0.82 mmol) methanesulphonic acid chloride are added and the mixture is stirred for 8 h. The reaction mixture is diluted with DCM, the organic phase is washed with water and dilute NaHC03 solution, dried over MgS04 and evaporated down i. vac..
Yield: 0.24 g (99% of theoretical) CZZH,~CIFN04S (M= 445.892) Calc.: molpeak (M+H)+: 446/448 (CI) Found: molpeak (M+H) : 446/448 (CI) HPLC-MS: 6.2 min (method B) 5g (3R,4S)-1-(2-{4-[5-(4-chloro-phenyl)-3-fluoro-pyridin-2-ylethynyl]-phenoxy}-ethyl)-4-methyl-piperidine-3,4-diol The product is obtained analogously to Example 4f starting from 60 mg (0.135 mmol) methanesulphonate 2-{4-[5-(4-chloro-phenyl)-3-fluoro-pyridin-2-ylethynyl]-phenoxy}-ethyl and 35.3 mg (0.269 mmol) (3R,4S)-4-methyl-piperidine-3,4-diol (amine A3).
Yield: 47 mg (73% of theoretical) Cz~H26CIFN203 (M= 480.958) Calc.: molpeak (M+H)+: 481/483 (CI) Found: molpeak (M+H) : 481/483 (CI) HPLC-MS: 5.2 min (method A) The following compounds are prepared according to the process described in Example 5g:
ExampleStructure __ / c1 I

5.1 F \ \

off I
H / J
~N

.,.,. ~

~O I /

_ / CI
I

5.2 F \ \

OH N
HO

\

l I

~ /

CI
/I

5.3 F \ \

OH N
HO

N~ I /
O

CI
/

5.4 F \ \

OH I
F HO N

F ,..... \

F N~ I
O /

_ CI
/

5.5 F \ \

OH N
F HO

F \
F~~

N~ I
O /

/ CI

5.6 F \ \

OH OH / N

~N~

H O
Example 5.7 1-[(S)-1-(2-{4-[5-(4-chloro-phenyl)-3-fluoro-pyridin-2-ylethynyl]-phenoxy}-ethyl)-pyrrolidin-2-ylJ-cyclopropanol ~N~

HO~
The product is obtained analogously to Example 4f starting from 60 mg (0.135 mmol) 2-{4-[5-(4-chloro-phenyl)-3-fluoro-pyridin-2-ylethynyl]-phenoxy}-ethyl methanesulphonate and 34.2 mg (0.269 mmol) (S)-1-pyrrolidin-2-yl-cyclopropanol (amine A12).
Yield: 12 mg (19% of theoretical) C28H26CIFNZ02 (M= 476.969) Calc.: molpeak (M+H)+: 477/479 (CI) Found: molpeak (M+H) : 4771479 (CI) HPLC-MS: 5.6 min (method A) Example 6 1-[(S)-1-(2-{2-bromo-4-[5-(4-chloro-phenyl )-3-fl uoro-pyrid in-2-ylethynyl]-phenoxy}-ethyl )-pyrrolidin-2-yl]-cyclopropanol HO~
6a 2-(2-bromo-4-iodo-phenoxy)-ethanol The product is prepared analogously to Example 1a from 30.8 g (103 mmol) 2-bromo-4-iodo-phenol.
Yield: 18.5 g (52% of theoretical) C8H8Br102 (M= 342.956) Rf value: 0.18 (silica gel, PE/EtOAc 4:1 ) 6b 2-{2-bromo-4-[5-(4-chloro-phenyl)-3-fluoro-pyridin-2-ylethynyl]-phenoxy}-ethanol The product is prepared analogously to Example 5e starting from 1.5 g (4.37 mmol) 2-(2-bromo-4-iodo-phenoxy)-ethanol and 1.01 g (4.37 mmol) 5-(4-chloro-phenyl)-2-ethynyl-3-fluoro-pyridine.
Yield: 1.60 g (82% of theoretical) CZ,H,4BrCIFN02 (M= 446.697) Calc.: molpeak (M+H)+: 446/448/450 (BrCI) Found: molpeak (M+H) : 446/448/450 (BrCI) HPLC-MS: 6.4 min (method B) 6c 2-{2-bromo-4-[5-(4-chloro-phenyl)-3-fluoro-pyridin-2-ylethynyl]-phenoxy}-ethyl methanesulphonate The product is prepared analogously to Example 5f starting from 1.6 g (3.58 mmol) 2-(2-bromo-4-[5-(4-chloro-phenyl)-3- fluoro-pyridin-2-ylethynyl]-phenoxy}-ethanol.
Yield: 1.00 g (53% of theoretical) C22H,6BrCIFN04S (M= 524.788) Calc.: molpeak (M+H)+: 524/526/528 (BrCI) Found: molpeak (M+H)+: 524/526/528 (BrCI) HPLC-MS: 6.6 min (method B) 6d 1-[(S)-1-(2-{2-bromo-4-[5-(4-chloro-phenyl)-3-fluoro-pyridin-2-ylethynyl]-phenoxy}-ethyl)-pyrrolidin-2-yl]-cyclopropanol The product is obtained analogously to Example 4f starting from 60.0 mg (0.114 mmol) 2-{2-bromo-4-[5-(4-chloro-phenyl)-3-fluoro-pyridin-2-ylethynyl]-phenoxy}-ethyl methanesulphonate and 29.1 mg (0.229 mmol) (S)-1-pyrrolidin-2-yl-cyclopropanol (amine A12).
Yield: 11 mg (17% of theoretical) Cz8Hz5BrCIFN20z (M= 555.865) Calc.: molpeak (M+H)+: 555/557/559 (BrCI) Found: molpeak (M+H) : 555/557/559 (BrCI) HPLC-MS: 5.7 min (method A) The following compounds are prepared according to the process described in Example 6d:
ExampleStructure / c1 I

6.1 F ~ ~

HO QH ~ NJ
I

Br I

~N~ /
O

/ CI
I

6.2 F \ ~

OH N
HO

B

I /

/

6.3 F \ ~

OH N
H

Br ..,...

N~ I
O /

/ CI

6.4 F \ ~

OH N
HO

Br I/
O

- CI
/I

6.5 F ~

OH N

Br F

F 1~ I
O /

- / CI

6.6 F ~

OH N
F H~

Br F
~

F I
~N~O /
6.7 OH OH
E
~N~
H
Example 7 1-[(S)-1-(2-{4-[5-(4-chloro-phenyl)-3-fluoro-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-pyrrolidin-2-yl]-cyclopropanol HO~
7a 2-(4-iodo-2-methyl-phenoxy)-ethanol The product is prepared analogously to Example 1 a starting from 10 g (42.7 mmol) 4-iodo-2-methyl-phenol.
Yield: 11.4 g (96% of theoretical) CgH~~IO2 (M= 278.087) Rf value: 0.40 (silica gel, PE/EtOAc 3:2) 7b 2-{4-[5-(4-chloro-phenyl)-3-fluoro-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethanol The product is prepared analogously to Example 5e starting from 1.5 g (5.39 mmol) 2-(4-iodo 2-methyl-phenoxy)-ethanol and 1.25 g (5.39 mmol) 5-(4-chloro-phenyl)-2-ethynyl-3-fluoro-pyridine.
Yield: 1.40 g (68% of theoretical) CZZH»CIFNOZ (M= 381.827) Calc.: molpeak (M+H)+: 382/384 (CI) Found: molpeak (M+H) : 382/384 (CI) HPLC-MS: 6.3 min (method B) 7c 2-{4-[5-(4-chloro-phenyl)-3-fluoro-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl methanesulphonate The product is prepared analogously to Example 5f starting from 1.4 g (3.67 mmol) 2-{4-[5-(4-chloro-phenyl)-3-fluoro-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethanol.
Yield: 0.77 g (46% of theoretical) C23H,9CIFN04S (M= 459.918) Calc.: molpeak (M+H)+: 460/462 (CI) Found: molpeak (M+H) : 460/462 (CI) HPLC-MS: 6.5 min (method B) 7d 1-[(S)-1-(2-{4-[5-(4-chloro-phenyl)-3-fluoro-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-pyrrolidin-2-yl]-cyclopropanol The product is obtained analogously to Example 4f starting from 60.0 mg (0.130 mmol) 2-{4-[5-(4-chloro-phenyl)-3-fluoro-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl methanesulphonate and 33.2 mg (0.261 mmol) (S)-1-pyrrolidin-2-yl-cyclopropanol (amine A12).
Yield: 22 mg (34% of theoretical) C29H28CIFN20z (M= 490.996) Calc.: molpeak (M+H)+: 491/493 (CI) Found: molpeak (M+H) : 491/493 (CI) HPLC-MS: 5.8 min (method A) The following compounds are prepared according to the process described in Example 7d:
ExampleStructure c1 /

7.1 F
\
\
~

off J
HO

~N\~\
~
/
O

/
CI

7.2 F
\
~

off J
HO

.""~

~
~
/
O
a I

7.3 F \ \

OH I
HO N

\

"".. I

N~\ /
O

CI
/

7.4 F \ \

OH N
HO

Nw/\o /
I

/ CI

7.5 F \ \

OH I
F N
H J

F \
"...

F /
N~
I
O

/ CI

7.6 F \ \

OH N
F
HO

F \
~

N~ /
I
O

CI
/

7.7 F \ \

OH N
OH

~N~ ~
/

O
H

Example 8 (3R, 4S)-1-(( E)-3-{5-[5-(4-chloro-phenyl )-pyrid i n-2-ylethynyl]-pyrid in-2-yl}-a I lyl )-4-methyl-piperidine-3,4-diol .. , 8a (E)-3-(5-bromo-pyridin-2-yl)-prop-2-en-1-of A solution of 1.0 g (4.71 mmol) 3-(5-bromo-pyridin-2-yl)-prop-2-yn-1-of in 5 mL THF is added dropwise to a suspension of 4.7 mL (4.7 mmol, 1 M in THF) lithium aluminium hydride solution in 20 mL THF cooled to -5°C so that the temperature does not exceed 0°C. After the addition has ended the mixture is stirred for a further 2 h at 0°C. Excess lithium aluminium hydride is decomposed by the careful addition of 0.13 mL water, 0.13 mL 15% NaOH and 0.38 mL
water. The precipitate is filtered and the organic phase is dried over MgS04.
After the desiccant and solvent have been eliminated the residue is reacted further without purification.
Yield: 0.91 g (63% of theoretical) C8H8BrN0 (M= 214.059) Calc.: molpeak (M+H)+: 214/216 (Br) Found: molpeak (M+H) : 214/216 (Br) HPLC-MS: 4.2 min (method B) 8b (E)-3-(5-iodo-pyridin-2-yl)-prop-2-en-1-of Under an argon atmosphere 81 mg (0.43 mmol) Cul, 1.27 g (8.5 mmol) Nal and 90 NL N,N'-dimethylethylenediamine are added to a solution of 910 mg (4.25 mmol) (E)-3-(5-bromo-pyridin-2-yl)-prop-2-en-1-of in 4.5 mL 1,4-dioxane and the reaction mixture is refluxed overnight. After cooling it is combined with water, exhaustively extracted with EtOAc and the combined organic phases are dried over MgS04. After the desiccant and solvent have been eliminated the residue is reacted further without purification.
Yield: 870 mg (78% of theoretical) C8H81N0 (M= 261.060) Calc.: molpeak (M+H)+: 262 Found: molpeak (M+H) : 262 HPLC-MS: 4.2 min (method B) 8c (E)-3-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-pyridin-2-yl)-prop-2-en-1-of A solution of 870 mg (3.33 mmol) (E)-3-(5-iodo-pyridin-2-yl)-prop-2-en-1-ol, 712 mg (3.33 mmol) 5-(4-chloro-phenyl)-2-ethynyl-pyridine and 0.97 mL (7.0 mmol) triethylamine in 10 mL
dry acetonitrile is evacuated three times and then gassed with argon. Then 70 mg (0.37 mmol) Cul and 300 mg (0.37 mmol) PdCl2(dppf) are added. The reaction mixture is stirred overnight at RT. The precipitated product is filtered, washed with a little acetonitrile and dried in the circulating air dryer at 50°C until the weight remains constant.
Yield: 980 mg (85% of theoretical) C2,H~5CIN20 (M= 346.809) Calc.: molpeak (M+H)+: 347/349 (CI) Found: molpeak (M+H) : 347/349 (CI) HPLC-MS: 5.6 min (method B) 8d (E)-3-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-pyridin-2-yl}-allyl)-chloride A solution of 160 NL thionyl chloride in 5 mL DCM is added dropwise to a solution of 450 mg (1.30 mmol) (E)-3-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-pyridin-2-yl}-prop-2-en-1-of in 25 mL DCM cooled to -10°C. The reaction solution is stirred for a further 30 min at 0°C and stirred overnight at RT. The reaction mixture is combined with 50 mL
semisaturated NaHC03 solution, exhaustively extracted with DCM, the combined organic phases are washed twice with water and dried over MgS04. After the desiccant and solvent have been eliminated the residue is reacted further without purification.
Yield: 450 mg (95% of theoretical) C2~H,4CI2N2 (M= 365.255) Calc.: molpeak (M+H)+: 365/367/369 (2 CI) Found: molpeak (M+H) : 365/367/369 (2 CI) HPLC-MS: 6.8 min (method B) The following compounds are prepared according to the process described in Example 3g:
Exam Structure YieldMass HPLC

ple spectrumretention time (method) c1 40% 460/462 5.0 min 8 \ I [M+Hl+ (A) \

off ~ J
HO / N

~

N \
N

c1 13% 460/462 5.0 min 8.1 \ ~ I [M+H]+ (A) off ~ J
HO ~ N

..", \ N

CI

8.2 \

off ~ J
HO / ~N

\

.."..
~

J
\
a I

8.3 I \
\

OH N/
HO

N

- / CI

\
8.4 I a \

OH N/
F H

F "... \

F
N \ N

CI

8.5 \

OH I
F HO N/

F \
~~

F \ /
N N

CI

8.6 \

\

OH OH

/ N

HEN \ N

Example 9 (3S,4R)-1-(2-{4-[5-(4-chloro-phenyl)-pyrazin-2-ylethynyl]-phenoxy}-ethyl)-4-methyl-piperidine-3,4-diol 9a 5-(4-chloro-phenyl)-pyrazin-2-ylamine 50 mL 2 N NaZC03 solution and 1.16 g (1.00 mmol) Pd(PPh3)4 are added to a solution of 8.70 g (174 mmol) 5-bromo-pyrazin-2-ylamine and 7.98 g (156 mmol) 4-chlorophenylboric acid in 150 mL 1,4-dioxane and 50 mL MeOH and the reaction mixture is heated to 110°C for 2.5 h.
It is evaporated down i. vac., diluted with EtOAc, the organic phase is separated off, washed with water and dried over Na2S04. After the desiccant and solvent have been eliminated the residue is purified by chromatography (silica gel, gradient DCM to DCM/MeOH
20:1 ).
Yield: 8.30 g (81 % of theoretical) C,oH8CIN3 (M= 205.643) Calc.: molpeak (M+H)+: 206/208 (CI) Found: molpeak (M+H) : 206/208 (CI) HPLC-MS: 7.2 min (method A) 9b 2-(4-chloro-phenyl)-5-iodo-pyrazine In a flask protected from light, 4.90 mL (40.0 mmol) tert-butylnitrite and 7.61 g (30.0 mmol) iodine are added to a solution of 4.80 g (23.5 mmol) 5-(4-chloro-phenyl)-pyrazin-2-ylamine in 100 mL carbon tetrachloride and 50 mL DCM. The mixture is stirred overnight at RT and then combined with 100 mL water. The organic phase is separated off, washed twice with 50 mL of 10% sodium thiosulphate solution and 50 mL water and dried over MgS04. After filtration through activated charcoal and elimination of the solvent the residue is purified by column chromatography (silica gel, gradient PE to PE/EtOAc 8:2).
Yield: 3.40 g (46% of theoretical) C,oH6CIINz (M= 316.525) Calc.: molpeak (M+H)+: 317/319 (CI) Found: molpeak (M+H) : 317/319 (CI) Rf value: 0.55 (silica gel, PE/EtOAc 9:1 ) 9c 2-{4-[5-(4-chloro-phenyl)-pyrazin-2-ylethynyl]-phenoxy}-ethanol Under an argon atmosphere 49 mg (0.06 mmol) PdCl2(dppf) and 11 mg (0.06 mmol) Cul are added to a repeatedly degassed solution of 535 mg (3.30 mmol) 2-(4-chloro-phenyl)-5-iodo-pyrazine, 950 mg (3.30 mmol) 2-(4-ethynyl-phenoxy)-ethanol and 0.59 mL (6.00 mmol) piperidine in 50 mL THF and the mixture is stirred for 4 h at RT. The precipitate is suction filtered and washed with acetonitrile. The filtrate is concentrated, the precipitate formed is filtered off and washed with a little acetonitrile. The two precipitates are combined.
Yield: 700 mg (67% of theoretical) CZOH~SCINz02 (M= 350.798) Calc.: molpeak (M+H)+: 351/353 (CI) Found: molpeak (M+H) : 351/353 (CI) Rf value: 0.30 (silica gel, PE/EtOAc 1:1 ) 9d 2-{4-[5-(4-chloro-phenyl)-pyrazin-2-ylethynyl]-phenoxy}-ethyl methanesulphonate 0.62 mL (7.98 mmol) methanesulphonic acid chloride are added dropwise at RT to a solution of 700 mg (2.00 mmol) 2-{4-[5-(4-chloro-phenyl)-pyrazin-2-ylethynyl]-phenoxy}-ethanol and 0.65 mL (7.98 mmol) pyridine in 20 mL DCM and the mixture is then stirred overnight at RT.
After the addition of another 0.33 mL (3.99 mmol) pyridine and 0.32 mL (4.12 mmol) methanesulphonic acid chloride in the ultrasound bath the reaction mixture is stirred for a further 2 h at RT. The solution is diluted with 30 mL DCM, the organic phase is separated off, washed three times with 60 mL water and dried over MgS04. After the desiccant and solvent have been eliminated the residue is purified by chromatography (silica gel, DCM).
Yield: 600 mg (70% of theoretical) C2~H~~CIN204S (M= 428.889) Calc.: molpeak (M+H)+: 429/431 (CI) Found: molpeak (M+H) : 429/431 (CI) Rf value: 0.30 (silica gel, DCM/MeOH 9:1 ) 9e (3S,4R)-1-(2-{4-[5-(4-chloro-phenyl)-pyrazin-2-ylethynyl]-phenoxy}-ethyl)-4-methyl-piperidine-3,4-diol A solution of 64 mg (0.15 mmol) 2-{4-[5-(4-chloro-phenyl)-pyrazin-2-ylethynyl]-phenoxy}-ethyl methanesulphonate and 59 mg (0.45 mmol) (3S,4R)-4-methyl-piperidine-3,4-diol in 1.8 mL
DMF is shaken for 2 h at 60°C and then for 65 h at 30°C. The reaction mixture is purified by HPLC without any further working up. The fractions containing the product are combined and lyophilised.
Yield: 33 mg (47 % of theoretical) C26HZ6CIN3O3 (M= 463.956) Calc.: molpeak (M+H)+: 464/466 Found: molpeak (M+H)+: 464/466 HPLC-MS: 5.3 min (method E) Example 10 (3S,4R)-1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenyl}-ethyl)-4-methyl-piperidine-3,4-diol 10a 2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenyl}-ethanol Under an argon atmosphere 79 mg (0.10 mmol) PdCl2(dppf) and 18 mg (0.10 mmol) Cul are added to a repeatedly degassed solution of 2.0 g (8.06 mmol) 2-(4-iodo-phenyl)-ethanol, 1.74 g (8.06 mmol) 5-(4-chloro-phenyl)-2-ethynyl-pyridine and 2.6 mL triethylamine in 25 mL
acetonitrile and the mixture is stirred for 24 h at RT, during which time a precipitate forms.
This is filtered off and washed with a little acetonitrile. The filtrate is extracted with DCM, the organic phase is washed with water and added to the above precipitate. It is evaporated down i. vac. and the residue is purified by column chromatography (silica gel, gradient PE to DCM).
Yield: 1.80 g (67 % of theoretical) C2~H,6CIN0 (M= 333.811 ) Calc.: molpeak (M+H)+: 334/336 (CI) Found: molpeak (M+H)+: 334/336 (CI) HPLC-MS: 6.0 min (method B) 10b 2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenyl}-ethyl methanesulphonate 58 pL (0.75 mmol) methanesulphonic acid chloride are added dropwise at 0 °C to a solution of 167 mg (0.50 mmol) 2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenyl}-ethanol and 81 NL (1.00 mmol) pyridine in 5 mL DCM and the mixture is then stirred for 1 h at 0°C. This is again combined with pyridine (80 NL) and methanesulphonic acid chloride (58 NL) and stirred for 1 h at RT. Then 140 NL (1.00 mmol) triethylamine are added and after 20 min at RT the mixture is diluted with ice water. The organic phase is separated off, dried over MgS04, filtered and then the solvent is eliminated i. vac..
Yield: 185 mg (90% of theoretical) C22H,$CIN03S (M= 411.902) Calc.: molpeak (M+H)': 412/414 (CI) Found: molpeak (M+H) : 412/414 (CI) HPLC-MS: 6.3 min (method D) 10c (3S,4R)-1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenyl}-ethyl)-4-methyl-piperidine-3,4-diol A solution of 60 mg (0.15 mmol) 2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenyl}-ethyl methanesulphonate and 39 mg (0.30 mmol) (3S,4R)-4-methyl-piperidine-3,4-diol in 1 mL
DMF is heated to 50°C for 4 h, then combined with 69 mg (0.5 mmol) K2C03 and heated to 50°C for a further 2 h. The reaction mixture is poured onto water and the precipitate is filtered.
3o It is washed with a little water and purified by HPLC .
Yield: 24 mg (37 % of theoretical) C2,Hz~CIN202 (M= 446.968) Calc.: molpeak (M+H)+: 447/449 (CI) Found: molpeak (M+H)+: 447/449 (CI) HPLC-MS: 4.5 min (method B) Some test methods for determining an MCH-receptor antagonistic activity will now be described. In addition, other test methods known to the skilled man may be used, e.g. by inhibiting the MCH-receptor-mediated inhibition of cAMP production, as described by Hoogduijn M et al. in "Melanin-concentrating hormone and its receptor are expressed and functional in human skin", Biochem. Biophys. Res Commun. 296 (2002) 698-701 and by biosensory measurement of the binding of MCH to the MCH receptor in the presence of antagonistic substances by plasmon resonance, as described by Karlsson OP and Lofas S. in "Flow-Mediated On-Surface Reconstitution of G-Protein Coupled Receptors for Applications in Surface Plasmon Resonance Biosensors", Anal. Biochem. 300 (2002), 132-138.
Other methods of testing antagonistic activity to MCH receptors are contained in the references and patent documents mentioned hereinbefore, and the description of the test methods used is hereby incorporated in this application.
MCH-1 receptor binding test Method: MCH binding to hMCH-1 R transfected cells Species: Human Test cell: hMCH-1 R stably transfected into CHO/Galpha16 cells Results: IC50 values 2o Membranes from CHO/Galpha16 cells stably transfected with human hMCH-1 R
are resuspended using a syringe (needle 0.6 x 25 mm) and diluted in test buffer (50 mM HEPES, 10 mM MgClz, 2 mM EGTA, pH 7.00; 0.1 % bovine serum albumin (protease-free), 0.021 bacitracin, 1 Ng/ml aprotinin, 1 pg/ml leupeptin and 1 NM phosphoramidone) to a concentration of 5 to 15 pg/ml.
200 microlitres of this membrane fraction (contains 1 to 3 Ng of protein) are incubated for 60 minutes at ambient temperature with 100 pM of '251-tyrosyl melanin concentrating hormone ('251-MCH commercially obtainable from NEN) and increasing concentrations of the test compound in a final volume of 250 microlitres. After the incubation the reaction is filtered using a cell harvester through 0.5% PEI treated fibreglass filters (GF/B, Unifilter Packard).
The membrane-bound radioactivity retained on the filter is then determined after the addition of scintillator substance (Packard Microscint 20) in a measuring device (TopCount of Packard).
The non-specific binding is defined as bound radioactivity in the presence of 1 micromolar MCH during the incubation period.
The analysis of the concentration binding curve is carried out on the assumption of one receptor binding site.
Standard:
Non-labelled MCH competes with labelled '251-MCH for the receptor binding with an IC50 value of between 0.06 and 0.15 nM.
The KD value of the radioligand is 0.156 nM.
MCH-1 receptor-coupled Ca2+ mobilisation test Method: Calcium mobilisation test with human MCH (FLIPR38a) Species: Human Test cells: CHO/ Galpha 16 cells stably transfected with hMCH-R1 Results: 1 st measurement:: % stimulation of the reference (MCH 10~M) 2nd measurement: pKB value Reagents: HBSS (10x) (GIBCO) HEPES buffer (1 M) (GIBCO) Pluronic F-127 (Molecular Probes) Fluo-4 (Molecular Probes) Probenecid (Sigma) MCH (Bachem) bovine serum albumin (Serva) (protease-free) DMSO (Serva) Ham's F12 (BioWhittaker) FCS (BioWhittaker) L-Glutamine (GIBCO) Hygromycin B (GIBCO) PENStrep (BioWhittaker) Zeocin (Invitrogen) Clonal CHO/Galpha16 hMCH-R1 cells are cultivated in Ham's F12 cell culture medium (with L-glutamine; BioWhittaker; Cat.No.: BE12-615F). This contains per 500 ml 10%
FCS, 1%
PENStrep, 5 ml L-glutamine (200 mM stock solution), 3 ml hygromycin B (50 mg/ml in PBS) and 1.25 ml zeocin (100 pg/ml stock solution). One day before the experiment the cells are plated on a 384-well microtitre plate (black-walled with a transparent base, made by Costar) in a density of 2500 cells per cavity and cultivated in the above medium overnight at 37°C, 5% COz and 95% relative humidity. On the day of the experiment the cells are incubated with cell culture medium to which 2 mM Fluo-4 and 4.6 mM Probenicid have been added, at 37°C
for 45 minutes. After charging with fluorescent dye the cells are washed four times with Hanks buffer solution (1 x HBSS, 20 mM HEPES), which has been combined with 0.07%
Probenicid.
The test substances are diluted in Hanks buffer solution, combined with 2.5%
DMSO. The background fluorescence of non-stimulated cells is measured in the presence of substance in the 384-well microtitre plate five minutes after the last washing step in the FLIPR384 apparatus (Molecular Devices; excitation wavelength: 488 nm; emission wavelength:
bandpass 510 to 570 nm). To stimulate the cells MCH is diluted in Hanks buffer with 0.1 % BSA, pipetted into the 384-well cell culture plate 35 minutes after the last washing step and the MCH-stimulated fluorescence is then measured in the FLIPR384 apparatus.
Data analysis:
1 st measurement: The cellular Ca2+ mobilisation is measured as the peak of the relative fluorescence minus the background and is expressed as the percentage of the maximum signal of the reference (MCH 10~M). This measurement serves to identify any possible agonistic effect of a test substance.
2nd measurement: The cellular Ca2+ mobilisation is measured as the peak of the relative fluorescence minus the background and is expressed as the percentage of the maximum signal of the reference (MCH 10~M, signal is standardised to 100%). The EC50 values of the MCH dosage activity curve with and without test substance (defined concentration) are determined graphically by the GraphPad Prism 2.01 curve program. MCH
antagonists cause the MCH stimulation curve to shift to the right in the graph plotted.
The inhibition is expressed as a pKB value:
pKB=IOg(ECSO(testsubstance+MCH) / EC5o(MCH) -1 ) -IOg C(testsubstance) The compounds according to the invention, including their salts, exhibit an MCH-receptor antagonistic activity in the tests mentioned above. Using the MCH-1 receptor binding test described above an antagonistic activity is obtained in a dosage range from about 10-'° to 10-5 M, particularly from 10-9 to 10~ M.
The following IC50 values were determined using the MCH-1 receptor binding test described above:
compound compound name IC50 value according to Example No.
2.20 1-{[(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]- 13.8 nM
phenoxy}-ethyl)-(3-hydroxy-propyl)-amino]-methyl}-cyclopropanol 1.5 (3R,4S)-1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2- 10.9 nM
ylethynyl]-2-methy(-phenoxy}-ethyl)-3-methyl-piperidine-3,4-diol Some examples of formulations will be described hereinafter, wherein the term "active substance" denotes one or more compounds according to the invention, including their salts.
In the case of one of the combinations with one or more active substances described, the term "active substance" also includes the additional active substances.
Example A
Capsules for powder inhalation containing 1 ma active substance Composition:
1 capsule for powder inhalation contains:
active substance 1.0 mg lactose 20.0 mg hard gelatine capsules 50._ 0 ma 71.0 mg Method of preparation:
The active substance is ground to the particle size required for inhalation.
The ground active substance is homogeneously mixed with the lactose. The mixture is packed into hard gelatine capsules.
Example B
lnhalable solution for Respimat~ containing 1 mg active substance Composition:

1 spray contains:

active substance 1.0 mg benzalkonium chloride 0.002 mg 1o disodium edetate 0.0075 mg purified water ad 15.0 NI

Method of preparation:
The active substance and benzalkonium chloride are dissolved in water and packed into Respimat~ cartridges.
Example C
Inhalable solution for nebulisers containing 1 ma active substance Composition:

1 vial contains:

active substance 0.1 g sodium chloride 0.18 g benzalkonium chloride 0.002 g purified water ad 20.0 ml Method of preparation:
The active substance, sodium chloride and benzalkonium chloride are dissolved in water.
Example D
Pro~~ellant type metered dose aerosol containing 1 mg active substance Composition:
1 spray contains:
active substance 1.0 mg lecithin 0.1 propellant gas ad 50.0 NI
Method of preparation:
The micronised active substance is homogeneously suspended in the mixture of lecithin and propellant gas. The suspension is transferred into a pressurised container with a metering valve.
Example E
Nasal spray containing 1 mg_active substance Composition:

active substance 1.0 mg sodium chloride 0.9 mg benzalkonium chloride 0.025 mg disodium edetate 0.05 mg purified water ad 0.1 ml Method of preparation:
2o The active substance and the excipients are dissolved in water and transferred into a corresponding container.
Example F
Iniectable solution containing 5 ma of active substance per 5 ml Composition:

active substance 5 mg glucose 250 mg human serum albumin 10 mg glycofurol 250 mg water for injections ad 5 ml Preparation:
Glycofurol and glucose are dissolved in water for injections (Wfl); human serum albumin is added; active ingredient is dissolved with heating; made up to specified volume with Wfl;
transferred into ampoules under nitrogen gas.
Example G
Iniectable solution containing 100 ma of active substance per 20 ml Composition:
active substance 100 mg monopotassium dihydrogen phosphate = KH2P04 12 mg disodium hydrogen phosphate = Na2HP04~2H20 2 mg sodium chloride 180 mg human serum albumin 50 mg Polysorbate 80 20 mg water for injections ad 20 ml Preparation:
Polysorbate 80, sodium chloride, monopotassium dihydrogen phosphate and disodium hydrogen phosphate are dissolved in water for injections (Wfl); human serum albumin is added; active ingredient is dissolved with heating; made up to specified volume with Wfl;
transferred into ampoules.
Example H
L~iophilisate containing 10 m oq f active substance Composition:
Active substance 10 mg Mannitol 300 mg human serum albumin 20 mg Preparation:
3o Mannitol is dissolved in water for injections (Wfl); human serum albumin is added; active ingredient is dissolved with heating; made up to specified volume with Wfl;
transferred into vials; freeze-dried.
Solvent for lyophilisate:
Polysorbate 80 = Tween 80 20 mg mannitol 200 mg water for injections ad 10 ml Preparation:
Polysorbate 80 and mannitol are dissolved in water for injections (Wfl);
transferred into ampoules.
Example I
Tablets containing 20 m4 of active substance Composition:

active substance 20 mg lactose 120 mg maize starch 40 mg magnesium stearate2 mg Povidone K 25 1 8 mg Preparation:
Active substance, lactose and maize starch are homogeneously mixed; granulated with an aqueous solution of Povidone; mixed with magnesium stearate; compressed in a tablet press;
weight of tablet 200 mg.
Example J
Capsules containing 20 m_g active substance Composition:

active substance 20 mg maize starch 80 mg highly dispersed silica5 mg magnesium stearate 2.5 mg Preparation:
Active substance, maize starch and silica are homogeneously mixed; mixed with magnesium stearate; the mixture is packed into size 3 hard gelatine capsules in a capsule filling machine.
Example K
Suppositories containing 50 m4 of active substance Composition:
active substance 50 mg hard fat (Adeps solidus) q.s. ad 1700 mg Preparation:
Hard fat is melted at about 38°C; ground active substance is homogeneously dispersed in the molten hard fat; after cooling to about 35°C it is poured into chilled moulds.
Example L
Iniectable solution containing 10 mg of active substance per 1 ml Composition:
active substance 10 mg mannitol 50 mg human serum albumin 10 mg water for injections ad 1 ml Preparation:
Mannitol is dissolved in water for injections (Wfl); human serum albumin is added; active ingredient is dissolved with heating; made up to specified volume with Wfl;
transferred into ampoules under nitrogen gas.

Claims (28)

1. Alkyne compounds of general formula I
wherein R1 denotes C3-6-alkenyl, C3-6-alkynyl, (hydroxy-C3-7-cycloalkyl)-C1-3-alkyl, oxa-C4-7-cycloalkyl, dihydroxy-C3-7-alkyl, while the groups mentioned may be mono- or polysubstituted substituted by substituents which are selected independently of one another from the group consisting of halogen, hydroxy, cyano, C1-4-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-3-alkyl, C1-44-alkoxy-C1-4-alkyl, C1-4-alkoxy, C1-4-alkenyl, C1-4-alkynyl, amino, C1-4-alkyl-amino and di-(C1-4-alkyl)-amino, while the alkyl, alkoxy, cylcoalkyl groups may comprise one or more identical or different substituents selected from halogen and hydroxy; and R2 independently of R1 has one of the meanings given hereinbefore for R1 or R2 has a meaning from the group consisting of H, C1-8-alkyl, C3-7-cycloalkyl or a phenyl or pyridinyl group optionally mono- or polysubstituted by identical or different groups R20 and/or monosubstituted by nitro, while the alkyl or cycloalkyl group may be mono- or polysubstituted by identical or different groups R11, and a -CH2-group in position 3 or 4 of a 5-, 6- or 7-membered cycloalkyl group may be replaced by -O-, -S- or -NR13-, or the groups R1, R2 together with the N atom to which they are bound form a heterocyclic group which selected is from the meanings - dihydroxy-cyclo-C4-7-alkylene-imino, - (hydroxy-C1-4-alkyl)-hydroxy-cyclo-C3-7-alkylene-imino, - (hydroxy-C1-3-alkyl)-cyclo-C3-7-alkylene-imino, while in the last definition the C1-3-alkyl group is substituted by one or more identical or different C1-3-alkyl groups which may be joined together to form a C3-7-cyloalkyl group;

while the above-mentioned heterocyclic groups may be mono- or polysubstituted by substituents which are selected independently of one another from the group consisting of halogen, hydroxy, cyano, C1-4-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-3-alkyl, C1-4-alkoxy-C1-4-alkyl, C1-4-alkoxy, C1-4-alkenyl, C1-4-alkynyl, amino, C1-4-alkyl-amino and di-(C1-4-alkyl)-amino, while alkyl, alkoxy, cylcoalkyl groups may comprise one or more identical or different substituents selected from halogen and hydroxy;

X ~denotes a C1-4-alkylene bridge, while in the definition C2-4-alkylene one or two C atoms may be monosubstituted by R10, or a C3-4-alkylene bridge, wherein a -CH2-CH2- group not directly adjacent to the N atom of the R1R2N- group is replaced by -CH=CH-, -C.ident.C-, -CH2-O
,-CH2-S- or -CH2-NR4-, while the meanings given for X hereinbefore may comprise a substituent selected from C2-6-alkenyl, C2-6-alkynyl, C3-7-cycloalkyl and C3-7-cycloalkyl-C1-3-alkyl as well as independently one, two or three identical or different C1-4-alkyl substituents, while two alkyl groups may be joined together forming a 3 to 7-membered cyclic group or an alkyl and an alkenyl group may be joined together forming a 5 to 7-membered cyclic group, and W, Z independently of one another denote a single bond or a C1-2-alkylene bridge, while two adjacent C atoms may be joined together with an additional C1-4-alkylene bridge, and one or two C atoms independently of one another may be substituted by one or two identical or different C1-3-alkyl groups, while two alkyl groups may be joined together to form a carbocyclic ring, and Y, A ~are selected independently of one another from the group of the bivalent cyclic groups phenyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, naphthyl, tetrahydronaphthyl, indolyl, dihydroindolyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl, tetrahydro-isoquinolinyl, benzimidazolyl, benzoxazolyl, chromanyl, chromen-4-onyl, thienyl, furanyl, benzothienyl or benzofuranyl, while the above-mentioned cyclic groups may be mono- or polysubstituted at one or more C atoms by identical or different groups R20, and in the case of a phenyl ring may also additionally be monosubstituted by nitro, and/or one or more NH groups may be substituted by R21, B ~has one of the meanings given for Y, A or denotes C1-6-alkyl, C1-6-alkenyl, C1-6-alkynyl, C3-7-cycloalkyl, C5-7-cycloalkenyl, C3-cycloalkyl-C1-3-alkyl, C3-7-cycloalkenyl-C1-3-alkyl, C3-7-cycloalkyl-C1-3-alkenyl or C3-7-cycloalkyl-C1-3-alkynyl, wherein one or more C atoms may be mono- or polysubstituted independently of one another by halogen and/ or monosubstituted by hydroxy or cyano and/ or cyclic groups may be mono- or polysubstituted by identical or different groups R20, Cy ~denotes a carbo- or heterocyclic group selected from one of the following meanings - a saturated 3- to 7-membered carbocyclic group, - an unsaturated 4- to 7-membered carbocyclic group, - a phenyl group, - a saturated 4- to 7-membered or unsaturated 5- to 7-membered heterocyclic group with an N, O or S atom as heteroatom, - a saturated or unsaturated 5- to 7-membered heterocyclic group with two or more N atoms or with one or two N atoms and an O or S atom as heteroatoms, - an aromatic heterocyclic 5- or 6-membered group with one or more identical or different heteroatoms selected from N, O and/or S, while the above-mentioned saturated 6- or 7-membered groups may also be present as bridged ring systems with an imino, (C1-4-alkyl)-imino, methylene, (C1-4-alkyl)-methylene or di-(C1-4-alkyl)-methylene bridge, and the above-mentioned cyclic groups may be mono- or polysubstituted at one or more C atoms by identical or different groups R20, in the case of a phenyl group may also additionally be monosubstituted by nitro, and/or one or more NH groups may be substituted by R21, R4 denotes H, C1-4-alkyl, C3-7-cycloalkyl or C3-7-cycloalkyl-C1-3-alkyl, R10 denotes hydroxy, .omega.-hydroxy-C1-3-alkyl, C1-4-alkoxy or C1-4-alkoxy-C1-3-alkyl, R11 denotes halogen, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, R15-O-, R15-O-CO-, R15-CO-O-, cyano, R16R17N, R18R19N-CO- or Cy, while in the above-mentioned groups one or more C atoms may be mono- or polysubstituted independently of one another by substituents selected from halogen, OH, CN, CF3, C1-3-alkyl, hydroxy-C1-3-alkyl;
R13 has one of the meanings given for R17, R15 denotes H, C1-4-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-3-alkyl, phenyl, phenyl-C1-3-alkyl, pyridinyl or pyridinyl-C1-3-alkyl, R16 denotes H, C1-4-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-3-alkyl, C4-7-cycloalkenyl, C4-7-cycloalkenyl-C1-3-alkyl, .omega.-hydroxy-C2-3-alkyl, .omega.-(C1-4-alkoxy)-C2-3-alkyl, amino-C2-6-alkyl, C1-4-alkyl-amino-C2-6-alkyl, di-(C1-4-alkyl)-amino-C2-6-alkyl or cyclo-C3-6-alkyleneimino-C2-6-alkyl, R17 has one of the meanings given for R16 or denotes phenyl, phenyl-C1-3-alkyl, pyridinyl, C1-4-alkylcarbonyl, hydroxycarbonyl-C1-3-alkyl, C1-4-alkoxycarbonyl, C1-4-alkoxycarbonyl-C1-3-alkyl, C1-4-alkylcarbonylamino-C2-3-alkyl, N-(C1-4-alkylcarbonyl)-N-(C1-4-alkyl)-amino-C2-3-alkyl, C1-4-alkylsulphonyl, C1-4-alkylsulphonylamino-C2-3-alkyl or N-(C1-4-alkylsulphonyl)-N(-C1-4-alkyl)-amino-C2-3-alkyl;
R18, R19 independently of one another denote H or C1-6-alkyl, R20 denotes halogen, hydroxy, cyano, C1-4-alkyl, C2-6-alkenyl, C2-6-alkynyl, 7-cycloalkyl, C3-7-cycloalkyl-C1-3-alkyl, hydroxy-C1-3-alkyl, R22-C1-3-alkyl or has one of the meanings given for R22, R21 denotes C1-4-alkyl, .omega.-hydroxy-C2-6-alkyl, .omega.-C1-4-alkoxy-C2-6-alkyl, .omega.-C1-4-alkyl-amino-C2-6-alkyl, .omega.-di-(C1-4-alkyl)-amino-C2-6-alkyl, .omega.-cyclo-C3-6-alkyleneimino-C2-6-alkyl, phenyl, phenyl-C1-3-alkyl, C1-4-alkyl-carbonyl, C1-4-alkoxy-carbonyl, C1-4-alkylsulphonyl, aminosulphonyl, C1-4-alkylaminosulphonyl, di-C1-4-alkylaminosulphonyl or cyclo-C3-6-alkylene-imino-sulphonyl, R22 denotes pyridinyl, phenyl, phenyl-C1-3-alkoxy, cyclo-C3-6-alkyleneimino-C2-4-alkoxy, OHC-, HO-N=HC-, C1-4-alkoxy-N=HC-, C1-4-alkoxy, C1-4-alkylthio, carboxy, C1-4-alkylcarbonyl, C1-4-alkoxycarbonyl, aminocarbonyl, C1-4-alkylaminocarbonyl, di-(C1-4-alkyl)-aminocarbonyl, cyclo-C3-6-alkyl-amino-carbonyl, cyclo-C3-6-alkyleneimino-carbonyl, phenylaminocarbonyl, cyclo-C3-6-alkyleneimino-C2-4-alkyl-aminocarbonyl, C1-4-alkyl-sulphonyl, C1-4-alkyl-sulphinyl, C1-4-alkyl-sulphonylamino, amino, C1-4-alkylamino, di-(C1-4-alkyl)-amino, C1-4-alkyl-carbonyl-amino, cyclo-C3-6-alkyleneimino, phenyl-C1-3-alkylamino, N-(C1-4-alkyl)-phenyl-C1-3-alkylamino, acetylamino, propionylamino, phenylcarbonyl, phenylcarbonylamino, phenylcarbonylmethylamino, hydroxy-C2-3-alkylaminocarbonyl, (4-morpholinyl)carbonyl, (1-pyrrolidinyl)carbonyl, (1-piperidinyl)carbonyl, (hexahydro-1-azepinyl)carbonyl, (4-methyl-1-piperazinyl)carbonyl, methylenedioxy, aminocarbonylamino or C1-4-alkylaminocarbonylamino, while in the above-mentioned groups and radicals, particularly in W, X, Z, R4, R10, R13 and R15 to R22, in each case one or more C atoms may additionally be mono-or polysubstituted by F and/or in each case one or two C atoms independently of one another may additionally be monosubstituted by Cl or Br and/or in each case one or more phenyl rings may additionally comprise independently of one another one, two or three substituents selected from the group F, Cl, Br, I, cyano, C1-4-alkyl, alkoxy, difluoromethyl, trifluoromethyl, hydroxy, amino, C1-3-Aalkylamino, di-(C1-3-alkyl)-amino, acetylamino, aminocarbonyl, difluoromethoxy, trifluoromethoxy, amino-C1-3-alkyl, C1-3-alkylamino-C1-3-alkyl- and di-(C1-3-alkyl)-amino-C1-3-alkyl and/or may be monosubstituted by nitro, and the H atom of any carboxy group present or an H atom bound to an N atom may in each case be replaced by a group which can be cleaved in vivo, the tautomers, the diastereomers, the enantiomers, the mixtures thereof and the salts thereof, while the following compounds are not included:
(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-methyl-prop-2-ynyl-amine, (2-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-indol-1-yl}-ethyl)-cyclopropylmethyl-prop-2-ynyl-amine, {4-[6-(4-chloro-phenyl)-quinolin-2-ylethynyl]-benzyl}-methyl-(tetrahydro-pyran-4-yl)-amine, allyl-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-cyclopropylmethyl-amine, allyl-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-cyclopropylmethyl-amine, allyl-(2-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-indol-1-yl}-ethyl)-cyclopropylmethyl-amine.
2. Alkyne compounds according to claim 1, characterised in that R1 is selected from the group of meanings C3-6-alkenyl, C3-6-alkynyl, (hydroxy-C3-7-cycloalkyl)-C1-3-alkyl, oxa-C5-7-cycloalkyl, dihydroxy-C3-7-alkyl, while the groups mentioned may be mono-or polysubstituted by substituents which are selected independently of one another from the group consisting of halogen, hydroxy, cyano, C1-4-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-3-alkyl, C1-4-alkoxy-C1-4-alkyl, C1-4-alkoxy, C1-4-alkenyl, C1-4-alkynyl, amino, C1-4-alkyl-amino and di-(C1-4-alkyl)-amino, while alkyl, alkoxy, cylcoalkyl groups independently of one another may comprise one or more identical or different substituents selected from halogen and hydroxy, and R2 independently of R1 has one of the meanings given hereinbefore for R1 or H
denotes C1-6-alkyl, C3-5-alkenyl, C3-5-alkynyl, C3-7-cycloalkyl, hydroxy-C3-7-cycloalkyl, C3-7-cycloalkyl-C1-3-alkyl, (hydroxy-C3-7-cycloalkyl)-C1-3-alkyl, hydroxy-C2-4-alkyl, .omega.-NC-C2-3-alkyl, C1-4-alkoxy-C2-4-alkyl, hydroxy-C1-4-alkoxy-C2-4-alkyl, C1-4-alkoxy-carbonyl-C1-4-alkyl, carboxyl-C1-4-alkyl, amino-C2-4-alkyl, C1-4-alkyl-amino-C2-4-alkyl, di-(C1-4-alkyl)-amino-C2-4-alkyl, cyclo-C3-6-alkyleneimino-C2-4-alkyl, pyrrolidin-3-yl, N-(C1-4-alkyl)-pyrrolidin-3-yl, pyrrolidinyl-C1-3-alkyl, N-(C1-4-alkyl)-pyrrolidinyl-C1-3-alkyl, piperidin-3-yl, piperidin-4-yl, N-(C1-4-alkyl)-piperidin-3-yl, N-(C1-4-alkyl)-piperidin-4-yl, piperidinyl-C1-3-alkyl, N-(C1-4-alkyl)-piperidinyl-C1-3-alkyl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, phenyl, phenyl-C1-3-alkyl, pyridyl or pyridyl-C1-3-alkyl, while in the above-mentioned groups and radicals one or more C atoms may be mono- or polysubstituted independently of one another by F, C1-3-alkyl or hydroxy-C1-3-alkyl, and/or one or two C atoms independently of one another may be monosubstituted by Cl, Br, OH, CF3 or CN, and the phenyl or pyridyl group may be mono- or polysubstituted by identical or different groups R20 and/or monosubstituted by nitro, and the groups R20 and R21 are defined as in claim 1.
3. Alkyne compounds according to claim 1, characterised in that R1 and R2 together with the N atom to which they are bound form a heterocyclic group which is selected from the meanings 3,4-dihydroxypyrrolidinyl, 3,4-dihydroxypiperidinyl, 3,5-dihydroxypiperidinyl, (hydroxy-C1-3-alkyl)-hydroxypyrrolidinyl, (hydroxy-C1-3-alkyl)-hydroxy-piperidinyl, (hydroxy-C3-6-cycloalkyl)-hydroxypyrrolidinyl, (hydroxy-cycloalkyl)-hydroxy-piperidinyl, (C1-3-alkyl-hydroxy-methyl)-pyrrolidinyl, (C1-3-alkyl-hydroxy-methyl)-piperidinyl, (di-C1-3-alkyl-hydroxy-methyl)-pyrrolidinyl, (di-C1-3-alkyl-hydroxy-methyl)-piperidinyl, (1-hydroxy-C3-6-cycloalkyl)-pyrrolidinyl, (1-hydroxy-C3-6-cycloalkyl)-piperidinyl, while the above-mentioned heterocyclic groups may be mono-or polysubstituted by substituents which are selected independently of one another from the group consisting of halogen, hydroxy, cyano, C1-4-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-3-alkyl, C1-4-alkoxy-C1-4-alkyl, C1-4-alkoxy, C1-4-alkenyl, C1-4-alkynyl, amino, C1-4-alkyl-amino and di-(C1-4-alkyl)-amino, while alkyl, alkoxy, cylcoalkyl groups independently of one another may comprise one or more identical or different substituents selected from halogen and hydroxy.
4. Alkyne compounds according to one or more of the preceding claims, characterised in that X is selected from the meanings -CH2-, ethylene, propylene, -CH2-CH=CH-, -CH2-C.ident.C-, -CH2-CH2-O-, -CH2-CH2-S-, -CH2-CH2-NR4- as well as C2-4-alkylene, which has one or two identical or different substituents selected independently of one another from fluorine, chlorine, hydroxy and C1-3-alkyl and/or a C2-6-alkenyl or cyclopropyl substituent, while two alkyl substituents may be joined together forming a C3-6-cycloalkyl group or an alkyl and an alkenyl group may be joined together forming a C5-6-cycloalkenyl group, as well as -CH2-CH=CH-, -CH2-C.ident.C-, -CH2-CH2-O-, -CH2-CH2-S- or -CH2-CH2-NR4-, which have one or two identical or different substituents selected independently of one another from fluorine and C1-3-alkyl and/or a cyclopropyl substituent, while two alkyl groups may be joined together forming a C3-6-cycloalkyl group or if an alkyl group denotes the group R4, they may be joined together forming a pyrrolidine or piperidine group, while R4 has the meaning given in claim 1, preferably H or C1-3-alkyl.
5. Alkyne compounds according to one or more of the preceding claims, characterised in that Z denotes a single bond or ethylene and W denotes a single bond.
6. Alkyne compounds according to one or more of the preceding claims, characterised in that the group Y is selected from among the bivalent cyclic groups phenyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, tetrahydronaphthyl, indolyl, dihydroindolyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl, tetrahydro-isoquinolinyl, benzimidazolyl, benzoxazolyl, chromanyl, chromen-4-onyl, benzothienyl, or benzofuranyl, while the above-mentioned cyclic groups may be mono- or polysubstituted at one or more C atoms by identical or different groups R20, and in the case of a phenyl ring may also additionally be monosubstituted by nitro, and/or may be substituted by R21 at one or more N atoms, while R20 and R21 have the meanings given in claim 1.
7. Alkyne compounds according to one or more of the preceding claims, characterised in that the group A is selected from among the bivalent cyclic groups phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, which may be mono- or polysubstituted at one or more C atoms by identical or different groups R20, and in the case of a phenyl ring may also additionally be monosubstituted by nitro, and R20 has the meanings given in claim 1.
8. Alkyne compounds according to one or more of the preceding claims, characterised in that the group B is selected from among phenyl, cyclohexenyl, pyridyl, thienyl and furanyl, and the above-mentioned cyclic groups may be mono- or polysubstituted at one or more C atoms by identical or different groups R20, and in the case of a phenyl group may also additionally be monosubstituted by nitro, and R20 has the meanings given in claim 1.
9. Alkyne compounds according to one or more of the preceding claims, characterised in that Y has a meaning selected from A has a meaning selected from and B denotes phenyl, cyclohexenyl, pyridyl, thienyl and furanyl, preferably phenyl, while Y and A are unsubstituted or monosubstituted by R20, and B is unsubstituted or mono-, di- or trisubstituted independently of one another by R20, and in the case of a phenyl ring may also additionally be monosubstituted by nitro, and R20 has the meaning given in claim 1.
10. Alkyne compounds according to one or more of the preceding claims, characterised in that R20 denotes F, Cl, Br, I, OH, cyano, amino, methyl, difluoromethyl, trifluoromethyl, ethyl, n-propyl, iso-propyl, acetyl, methoxy, difluoromethoxy, trifluoromethoxy, ethoxy, n-propoxy or iso-propoxy, while substituents R20 that occur repeatedly may have identical or different meanings.
11. Physiologically acceptable salts of the alkyne compounds according to one or more of claims 1 to 10.
12. Composition, containing at least one alkyne compound according to one or more of claims 1 to 10 and/ or a salt according to claim 11, optionally together with one or more physiologically acceptable excipients.
13. Pharmaceutical compositions, containing at least one alkyne compound according to one or more of claims 1 to 10 and/ or a salt according to claim 11, optionally together with one or more inert carriers and/or diluents.
14. Use of at least one alkyne compound according to one or more of claims 1 to 10 and/ or a salt according to claim 11 for influencing the eating behaviour of a mammal.
15. Use of at least one amide compound according to one or more of claims 1 to and/or a salt according to claim 11, for reducing the body weight and/ or for preventing an increase in the body weight of a mammal.
16. Use of at least one alkyne compound according to one or more of claims 1 to 10 and/or a salt according to claim 11 for preparing a pharmaceutical composition with an MCH-receptor-antagonistic activity.
17. Use of at least one alkyne compound according to one or more of claims 1 to 10 and/or a salt according to claim 11 for preparing a pharmaceutical composition which is suitable for preventing and/or treating symptoms and/or diseases which are caused by MCH or are otherwise causally connected with MCH.
18. Use of at least one alkyne compound according to one or more of claims 1 to 10 and/or a salt according to claim 11 for preparing a pharmaceutical composition which is suitable for preventing and/or treating metabolic disorders and/or eating disorders, particularly obesity, bulimia, bulimia nervosa, cachexia, anorexia, anorexia nervosa and hyperphagia.
19. Use of at least one alkyne compound according to one or more of claims 1 to 10 and/or a salt according to claim 11 for preparing a pharmaceutical composition which is suitable for preventing and/or treating diseases and/or disorders associated with obesity, particularly diabetes, especially type II diabetes, complications of diabetes including diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, insulin resistance, pathological glucose tolerance, encephalorrhagia, cardiac insufficiency, cardiovascular diseases, particularly arteriosclerosis and high blood pressure, arthritis and gonitis.
20. Use of at least one alkyne compound according to one or more of claims 1 to 10 and/or a salt according to claim 11 for preparing a pharmaceutical composition which is suitable for preventing and/or treating hyperlipidaemia, cellulitis, fat accumulation, malignant mastocytosis, systemic mastocytosis, emotional disorders, affective disorders, depression, anxiety, sleep disorders, reproductive disorders, sexual disorders, memory disorders, epilepsy, forms of dementia and hormonal disorders.
21. Use of at least one alkyne compound according to one or more of claims 1 to 10 and/or a salt according to claim 11 for preparing a pharmaceutical composition which is suitable for preventing and/or treating micturition disorders, such as for example urinary incontinence, hyperactive urinary bladder, urgency, nycturia and enuresis.
22. Use of at least one alkyne compound according to one or more of claims 1 to 10 and/or a salt according to claim 11 for preparing a pharmaceutical composition which is suitable for preventing and/or treating dependencies and/or withdrawal symptoms.
23. Process for preparing a composition or a pharmaceutical composition according to one or more of claims 12, 13 and 16 to 22, characterised in that at least one alkyne compound according to one or more of claims 1 to 10 and/or a salt according to claim 11 is incorporated in one or more inert carriers and/or diluents by a non-chemical method.
24. Pharmaceutical composition, containing a first active substance which is selected from the alkyne compounds according to one or more of claims 1 to 10 and/or a salt according to claim 11, and a second active substance selected from the group consisting of active substances for the treatment of diabetes, active substances for the treatment of diabetic complications, active substances for the treatment of obesity, preferably other than MCH antagonists, active substances for the treatment of high blood pressure, active substances for the treatment of hyperlipidaemia, including arteriosclerosis, active substances for the treatment of arthritis, active substances for the treatment of anxiety states and active substances for the treatment of depression, optionally together with one or more inert carriers and/or diluents.
25. Process for preparing alkyne compounds of formula A.5 R1R2N-X-Y-C.ident.C-W-A-B (A.5) while in formulae A.1, A.2, A.3, A.4 and A.5 R1, R2, Y, X, W, A and B have one of the meanings given in claims 1 to 10, wherein a halogen compound of formula A.1 HO-X-Y-Hal (A.1) wherein Hal denotes chlorine, bromine or iodine, preferably bromine or iodine, is reacted with an alkyne compound of formula A.2 H-C.ident.C-W-A-B(A.2) in the presence of a suitable palladium catalyst, a suitable base and copper(I)iodide in a suitable solvent, and the compound of formula A.3 obtained HO-X-Y-C.ident.C-W-A-B (A.3) is reacted with methanesulphonic acid chloride (MsCl) to produce the methanesulphonate derivative A.4, MsO-X-Y-C.ident.C-W-A-B (A.4) which is further reacted with an amine of formula H-NR1R2 to form the end product A.5.
26. Process process for preparing alkyne compounds of formula B.5 R1R2N-X-Y-Z-C.ident.C-A-B (B.5) while in formulae B.1, B.2, B.3, B.4 and B.5 R1, R2, X, Y, Z, A and B have one of the meanings given in claims 1 to 10, wherein a halogen compound of formula B.1 Hal-A-B (B.1) wherein Hal denotes chlorine, bromine or iodine, preferably bromine or iodine, is reacted with an alkyne compound of formula B.2 HO-X-Y-Z-C.ident.C-H (B.2) in the presence of a suitable palladium catalyst, a suitable base and copper(I)iodide in a suitable solvent, and the resulting compound of formula B.3 HO-X-Y-Z-C.ident.C-A-B (B.3) is reacted with methanesulphonic acid chloride (MsCl) to form the methanesulphonate derivative B.4, MsO-X-Y-Z-C.ident.C-A-B (B.4) which is reacted further with an amine of formula H-NR1R2 to form the end product B.5.
27. Process for preparing alkyne compounds of formula C.3 R1R2N-X-Y-C.ident.C-W-A-B (C.3) while in formulae C.1, C.2 and C.3 R1, R2, X, Y, W, A and B have one of the meanings given in claims 1 to 10, wherein a halogen compound of formula C.1 R1R2N-X-Y-Hal (C.1) wherein Hal denotes chlorine, bromine or iodine, preferably bromine or iodine, is further reacted with an alkyne compound of formula C.2 H-C.ident.C-W-A-B (C.2) in the presence of a suitable palladium catalyst, a suitable base and copper(I)iodide in a suitable solvent to yield the end product C.3.
28. Process for preparing alkyne compounds of formula D.3 R1R2N-X-Y-Z-C.ident.C-A-B (D.3) while in formulae D.1, D.2 and D.3 R1, R2, X, Y, Z, A and B have one of the meanings given in claims 1 to 10, wherein a halogen compound of formula D.2 Hal-A-B (D.2) wherein Hal denotes chlorine, bromine or iodine, preferably bromine or iodine, is reacted with an alkyne compound of formula D.1 R1R2N-X-Y-Z-C.ident.C-H (D.1) in the presence of a suitable palladium catalyst, a suitable base and copper(I)iodide in a suitable solvent to form the end product D.3.
CA002559021A 2004-04-14 2005-04-08 Novel alkyne compounds with an mch-antagonistic action and medicaments containing said compounds Abandoned CA2559021A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004017935A DE102004017935A1 (en) 2004-04-14 2004-04-14 New alkyne compounds having MCH antagonist activity and medicaments containing these compounds
DE102004017935.2 2004-04-14
PCT/EP2005/003683 WO2005103031A1 (en) 2004-04-14 2005-04-08 Novel alkyne compounds with an mch-antagonistic action and medicaments containing said compounds

Publications (1)

Publication Number Publication Date
CA2559021A1 true CA2559021A1 (en) 2005-11-03

Family

ID=34982358

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002559021A Abandoned CA2559021A1 (en) 2004-04-14 2005-04-08 Novel alkyne compounds with an mch-antagonistic action and medicaments containing said compounds

Country Status (9)

Country Link
EP (1) EP1740572A1 (en)
JP (1) JP2007532593A (en)
AR (1) AR048692A1 (en)
CA (1) CA2559021A1 (en)
DE (1) DE102004017935A1 (en)
PE (1) PE20060333A1 (en)
TW (1) TW200602025A (en)
UY (1) UY28853A1 (en)
WO (1) WO2005103031A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8618132B2 (en) 2002-10-31 2013-12-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004017930A1 (en) * 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg New alkyne compounds having MCH antagonist activity and medicaments containing these compounds
DE102004017934A1 (en) * 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg New alkyne compounds having MCH antagonist activity and medicaments containing these compounds
EP2069327B1 (en) 2006-08-25 2013-10-16 Boehringer Ingelheim International GmbH New pyridone derivatives with mch antagonistic activity and medicaments comprising these compounds
CL2007003580A1 (en) 2006-12-11 2009-03-27 Boehringer Ingelheim Int Pyridazine derived compounds, mch antagonists; pharmaceutical composition comprising said compound; preparation procedure; and use of the compound in the treatment of metabolic disorders and / or eating disorders such as obesity, bulimia, anorexia, hyperphagia, diabetes.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856510A (en) * 1996-12-16 1999-01-05 Allelix Biopharmaceuticals Inc. 5-alkenyl and 5-alkynyl indole compounds
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
EP1218336A2 (en) * 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
DE10250708A1 (en) * 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg New alkyne compounds having MCH antagonist activity and medicaments containing these compounds
DE102004017930A1 (en) * 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg New alkyne compounds having MCH antagonist activity and medicaments containing these compounds
DE102004017934A1 (en) * 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg New alkyne compounds having MCH antagonist activity and medicaments containing these compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8618132B2 (en) 2002-10-31 2013-12-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

Also Published As

Publication number Publication date
EP1740572A1 (en) 2007-01-10
DE102004017935A1 (en) 2005-11-03
JP2007532593A (en) 2007-11-15
TW200602025A (en) 2006-01-16
UY28853A1 (en) 2005-11-30
PE20060333A1 (en) 2006-05-22
WO2005103031A1 (en) 2005-11-03
AR048692A1 (en) 2006-05-17

Similar Documents

Publication Publication Date Title
US8067590B2 (en) Pyridone derivates with MCH antagonistic activity and medicaments comprising these compounds
CA2558755A1 (en) Novel alkyne compounds having an mch-antagonistic effect, and medicaments containing said compounds
US20070111981A1 (en) New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds
US7592358B2 (en) Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
US8618132B2 (en) Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
US20100197908A1 (en) Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds
US20050245529A1 (en) Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
CA2559237A1 (en) Novel alkyne compounds having an mch-antagonistic effect and medicaments containing said compounds
US7605176B2 (en) β-ketoamide compounds with MCH antagonistic activity
CA2559021A1 (en) Novel alkyne compounds with an mch-antagonistic action and medicaments containing said compounds
CA2552907A1 (en) Beta-ketoamide compounds having an mch-antagonistic effect and medicaments containing said compounds
US20050267120A1 (en) Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
CA2559698A1 (en) Novel alkyne compounds exhibiting an mch antagonistic effect and drugs containing said compounds
US7524862B2 (en) Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
US20050239826A1 (en) Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

Legal Events

Date Code Title Description
FZDE Dead